

**STRATEGIC LEADERSHIP AND ARTIFICIAL INTELLIGENCE
INTEGRATION IN THE PHARMACEUTICAL INDUSTRY**

by

Charuta Dwivedi, Msc. IT

DISSERTATION

Presented to the Swiss School of Business and Management Geneva

In Partial Fulfilment

Of the Requirements

For the Degree

DOCTOR OF BUSINESS ADMINISTRATION

SWISS SCHOOL OF BUSINESS AND MANAGEMENT GENEVA

January 2026

STRATEGIC LEADERSHIP AND ARTIFICIAL INTELLIGENCE INTEGRATION IN THE
PHARMACEUTICAL INDUSTRY

by

Charuta Dwivedi

APPROVED BY

Iva Buljubic

Dissertation chair

RECEIVED/APPROVED BY:

Rense Goldstein Osmic

Admissions Director

Dedication

I dedicate this thesis to my parents and family, whose unwavering support, patience, and encouragement have been my greatest strength throughout this journey. I am equally indebted to my teachers and mentors, whose invaluable guidance and insights have shaped my academic path. This work is also dedicated to all the leaders, researchers, and professionals in the pharmaceutical industry whose commitment to innovation and integrity continues to inspire the integration of artificial intelligence with strategic leadership for the betterment of society.

Acknowledgements

I would like to express my deepest gratitude to my supervisor, Ljiljana Kukec, for her invaluable guidance, encouragement, and constructive feedback throughout the course of this research. Her expertise and patience have been instrumental in shaping this thesis and in helping me navigate the complexities of strategic leadership and artificial intelligence integration.

I am sincerely thankful to my SSBM and UpGrad for providing me with the academic foundation and resources that made this work possible.

Last but not least, I want to thank my family members for supporting me all along my journey. Without their support, it would not be possible for me to complete my work.

ABSTRACT

**STRATEGIC LEADERSHIP AND ARTIFICIAL INTELLIGENCE INTEGRATION IN
THE PHARMACEUTICAL INDUSTRY**

Charuta Dwivedi
January 2026

Purpose: The traditional leadership practice emphasises operational execution, yet strategic leadership offer long-term vision and adaptability. It is necessary to support the vision of this industry and enhance its expansion towards the global market. The key purpose of this research is to identify the effectiveness of strategic leadership to support the effective implication of AI technologies in pharmaceuticals. It creates a huge scope for this study to set a base for further research on similar topics. An AI system reinforces existing prejudices if the data is not representative of the population it serves.

Methodology: Mixed methods are used in this research, which involves both qualitative and quantitative information. The survey method is used to collect quantitative information from primary research practices. 200 participants are included in the present study, and these individuals are selected through purposive sampling, and the data are further analysed through Excel. Existing literatures are used to collect secondary qualitative information from authentic sources. The secondary data is further emphasised through the thematic analysis.

Findings: The findings of mixed data analysis illustrate that the healthcare provider must anticipate upcoming trends, carefully thought-out and manage changes to ensure long-term decisions and organisational targets contribute to the growth of the health sector. These leaders allow to lead organisations to handle unpredictable situations in markets, while sponsoring an environment where information, people and ideas are evaluated. The finding also emphasises that strategic

leadership is associated with responsibilities of engaging development for implementing ongoing change and building skills in accordance with a complex and competitive environment. This trend of changing different pharmaceutical organisations operates in collaboration with companies and institutions, incorporating AI in product development.

Conclusion: In conclusion, the study found that AI integration and strategic leadership are linked to the trend of digital transformation and the apparent emergence of leadership competency, with AI technology being implemented as digital advancements for maintaining competence among pharmaceutical industry. The findings of study revealed that leadership has a significant influence in the integrated adoption of AI within the pharmaceutical sector as a culture, as well as innovative integration into the organization's operations and workforce culture.

Keywords: AI, digital transformation, pharmaceutical industry, strategic leadership, development, competence.

Contents

Chapter I: INTRODUCTION	10
1.1 BACKGROUND	10
1.2 RESEARCH PROBLEM/PROBLEM STATEMENT	14
1.3 RESEARCH AIM AND OBJECTIVE	18
1.4 SIGNIFICANCE OF THE STUDY	19
1.5 SCOPE OF THE STUDY	20
1.6 RESEARCH QUESTIONS AND HYPOTHESIS	21
1.7 DEFINITION OF TERM	22
1.8 THESIS STRUCTURE	23
1.9 SUMMARY	24
 Chapter II: REVIEW OF LITERATURE.....	25
2.1 INTRODUCTION.....	25
2.2 FUNDAMENTAL CONCEPT AND COMPETENCIES OF STRATEGIC LEADERSHIP	25
2.3 ASSOCIATION BETWEEN DIGITAL INNOVATION AND STRATEGIC LEADERSHIP	28
2.4 TRENDS OF DIGITAL INNOVATION WITHIN THE PHARMACEUTICAL INDUSTRY	31
2.5 AI AS APPLICATIONS IN RELATION TO STRATEGIC LEADERSHIP	35
2.6 TECHNOLOGICAL COMPLEXITY AND INTEGRATION DURING AI APPLICATION.....	39
2.7 FUTURE INSIGHT INTO USING AI IN THE PHARMACEUTICAL FIELD	42
2.8 ETHICAL, LEGAL, AND REGULATORY CONSIDERATIONS OF AI IN STRATEGIC LEADERSHIP OF PHARMACEUTICAL SECTOR.....	44
2.9 THEORETICAL FRAMEWORK.....	47
2.10 LITERATURE GAP	52
2.11 CONCEPTUAL FRAMEWORK.....	52
FOUNDATIONS OF AI INTEGRATION	54
2.12 SUMMARY	57
 Chapter III: METHODOLOGY	58
3.1 INTRODUCTION.....	58
3.1 OVERVIEW OF THE RESEARCH PROBLEM	58
3.2 OPERATIONALISATION OF THEORETICAL CONSTRUCTS.....	59
3.3 RESEARCH PURPOSE AND QUESTIONS.....	61
3.4 RESEARCH DESIGN	63
3.5 POPULATION AND SAMPLE	65
3.6 PARTICIPANT SELECTION	66
3.7 INSTRUMENTATION.....	67
3.8 DATA COLLECTION PROCEDURES.....	68
3.9 DATA ANALYSIS.....	71

3.10 RESEARCH DESIGN LIMITATIONS	72
3.11 CONCLUSION	74
Chapter IV: RESULTS	75
4.1 INTRODUCTION.....	75
4.2 PRIMARY DATA ANALYSIS.....	76
4.2.1 RELIABILITY TEST.....	76
4.2.2 DEMOGRAPHIC STATISTICS.....	77
4.2.3 DV: AI INTEGRATION IN THE PHARMACEUTICAL INDUSTRY	81
4.2.4 IV1: STRATEGIC LEADERSHIP ORIENTATION.....	82
4.2.5 IV 2: LEADERSHIP COMPETENCE IN AI AND DIGITAL LEADERSHIP	85
4.2.6 IV 3: ORGANISATIONAL READINESS.....	89
4.3 SECONDARY DATA ANALYSIS.....	93
4.3.1 THEME 1: RECENT STATE OF INTEGRATION OF AI IN THE PHARMACEUTICAL SECTOR.....	93
4.3.2 THEME 2: GOVERNANCE MECHANISMS AND LEADERSHIP COMPETENCIES FOSTERING SCALABLE AI ADOPTION	96
4.3.3 <i>THEME 3: STRATEGIC ALIGNMENT PROCESSES ALIGNING AI ADOPTION WITH ORGANIZATIONAL VISION AND OPERATIONAL IMPERATIVES</i>	99
4.3.4 <i>THEME 4: ETHICAL LEADERSHIP AND RESPONSIBLE AI GOVERNANCE.....</i>	100
4.3.5 <i>THEME 5: INTEGRATIVE LEADERSHIP MODELS FOR AI IMPLEMENTATION</i>	102
4.4 SUMMARY OF FINDINGS	104
4.5 CONCLUSION.....	107
Chapter V: DISCUSSION	108
5.1 INTRODUCTION.....	108
5.2 DISCUSSION OF RESULTS.....	108
5.3 CONCLUSION.....	115
CHAPTER VI: SUMMARY, IMPLICATIONS, AND RECOMMENDATIONS.....	116
6.1 SUMMARY	116
6.2 IMPLICATIONS - LINKING FINDINGS TO RESEARCH OBJECTIVES	117
6.2.1 <i>LINKING WITH OBJECTIVE 1: UNDERSTANDING INDUSTRY TRENDS.....</i>	117
6.2.2 <i>LINKING WITH OBJECTIVE 2: SCALABLE LEADERSHIP COMPETENCIES.....</i>	118
6.2.3 <i>LINKING WITH OBJECTIVE 3: ALIGNMENT OF ORGANIZATIONAL VISION</i>	118
6.2.4 <i>LINKING WITH OBJECTIVE 4: ETHICAL AND GOVERNANCE FRAMEWORKS</i>	118
6.3 RECOMMENDATIONS FOR FUTURE RESEARCH.....	119
6.4 PRACTICAL RECOMMENDATIONS	121
6.5 CONCLUSION.....	122

References.....	123
Appendix A: Questionnaire.....	142

List of Figures

Figure 1.1.1: Adoption of adaptive leadership practices in the pharma industry	11
Figure 1.1.2: AI in analysing personalising treatment based on the patient data	12
Figure 1.1.3: Contribution of AI to drug research and development.....	13
Figure 1.2.1: Long-term trends of R&D investment of the pharmaceutical industry.....	16
Figure 1.2.2: Ethical considerations and challenges in implementing AI in health care.....	17
Figure 1.8.1: Thesis Structure	24
Figure 2.6.1: Fields of pharmaceutical sciences, AI can be applied.....	40
Figure 2.7.1: Future dynamics of AI use in the pharmaceutical industry.....	43
Figure 2.8.1: Challenges in implementing AI in the pharmaceutical sector.....	46
Figure 2.9.1: Dynamic Capabilities Framework	48
Figure 2.9.2: Upper Echelon Theory	49
Figure 2.9.3: UTAUT theory.....	51
Figure 2.11: Conceptual framework.....	56
Figure 3.8.1: Types of Primary and Secondary Data Collection Methods.....	69
Figure 4.2.2.1: Age	78
Figure 4.2.2.2: Gender.....	79
Figure 4.2.2.3: Job role/position.....	80
Figure 4.2.2.4: Years of Experience	81
Figure 4.2.4.1: Frequency analysis of question one based on IV1	82
Figure 4.2.4.2: Frequency analysis of question two based on IV1	83
Figure 4.2.4.3: Frequency analysis of question three based on IV1	84
Figure 4.2.4.4: Frequency analysis of question four based on IV1	84
Figure 4.2.10: Frequency analysis of question five based on IV1.....	85
Figure 4.2.6.1: Frequency analysis of question one based on IV 3	90

Figure 4.2.6.3: Frequency analysis of question three based on IV 2.....	91
Figure 4.2.6.5: Frequency analysis of question five based on IV 3.....	92
Figure 4.3.1.1: Applications of AI in Pharmaceutical industry.....	94
Figure 4.3.2.1: Novartis' AI governance framework	98
Figure 4.3.2.2: Lab in loop strategy by Roche	98
Figure 4.3.4.1: Proposed ethical framework for AI in healthcare	101
Figure 4.3.5.1: Multidimensional leadership framework for the transformation of AI.....	103

List of Tables

Table 1.8.1: Thesis structure	24
Table 4.2.1.1: Reliability Test	77
Table 4.2.3.1: Frequency analysis of the question based on DV	82
Table 4.2.5.1: Frequency analysis of question one based on IV 2	86
Table 4.2.5.2: Frequency analysis of question two based on IV 2	87
Table 4.2.5.3: Frequency analysis of question three based on IV 2	87
Table 4.2.5.4: Frequency analysis of question four based on IV 2	88
Table 4.2.5.1: Frequency analysis of question five based on IV 2	89
Table 4.2.6.2: Frequency analysis of question two based on IV 3	91
Table 4.2.6.4: Frequency analysis of question four based on IV 3	92

CHAPTER I:

INTRODUCTION

1.1 Background

The pharmaceutical industry is important for health innovations, helping in preventing diseases, managing difficult medical situations and improving expectancy of life. Nevertheless, this industry is influenced by fast development, powerful contenders, spiralling competition, changes in patient needs, and strict laws globally. Here, vision and continuous innovation are as important as scientific understanding. Recently, people believed that a pharmaceutical organisation's success depends on their strategic leadership (Patel, 2025). Any healthcare provider must anticipate the upcoming trends, ensure organisational targets, manage changes and make careful, thought-out, long-term decisions that contribute for society and the growth of the health sector. These leaders lead organisations while handling unpredictable situations in markets, while sponsoring an environment where people are adaptable, ideas are generated, and information is shared. The organisation directs its R&D programs for global healthcare objectives, that involve capabilities of new disease identification and pandemic readiness.

Organisational direction towards efficient program innovation needs a strategic leadership of pharmaceutical operations. The traditional leadership practice emphasises operational execution, yet strategic leadership presents long-term vision and adaptability together with a proactive decision-making of its primary elements (Stephen, 2025). For establish interdisciplinary partners who use cutting-edge manufacturing technologies for advancements in research, and lead in developing viral diseases and management of respiratory diseases, they must predict the trend of healthcare. Pharmaceutical programs' strategic leaders require abilities to foster cross-team work and manage the regulatory changes for protect process against risks. Since leaders must foresee possible issues of the healthcare industry, embrace digital technologies, navigate complicated regulations and guide people through concede uncertainty, strategic leadership is required. They must support fresh concepts, align the strategy of businesses and foster collaboration with the recent advancements in the marketplace and science. However, innovation management is important to exciting advancements and transforming innovative concepts into beneficial and profitable services and goods for patients.




Figure 1.1.1: Adoption of adaptive leadership practices in the pharma industry

(Source: Stephen, 2025)

Adoption of new technologies integrates with the global issues in healthcare and emerging requirements of medicine has transformed sector of pharmaceutical in a critical moment towards change the need to modify the management strategies of the program. The strategic leadership of the future require integrating innovative approaches for develop resilience and boost team working spectrum of upcoming pandemic alerts and health emergencies. Development of drug in long-term process are divided into target groups like clinical trials, preclinical stages, computational screening, target validation and selection (Kulkov, 2021). The pharmaceutical industry fosters AI as a solution of predictive analytics to boost decision-making ability in program management (Stephen, 2025). The primary difference between automated systems and AI is its ability to learn independently and recommend or make decisions for humans. The pharmaceutical sector generated demand in two groups of AI-based solutions. This system can provide scenarios with necessary resources and can also recommend best for a specific organisation.

AI can foster change in the sector through using predictive analytics, automation and optimisation in production. AI technologies, like intelligent manufacturing systems and predictive maintenance, allow in improving the quality of industrial operations, safety and productivity. Furthermore, AI can also allow in making organisational decisions towards management of resources and innovation

dynamics (Hu *et al.* 2024). The innovative work behaviour of an organisation can manage conditions of market conditions and foster its competitive advantage. Development of an environment which fosters innovations is important in industry to facilitate advances in processes and products, sustain growth and increase efficiency. AI techniques explore a large-scale of the biomedical data to emphasise existing drugs which have a therapeutic potential for diseases. Through repurposing the approved drugs towards new identification, AI accelerate the drug delivery process and can reduce costs. AI algorithms help users to find and analyse connections between processes and objects that are not available previously for analysis.




Figure 1.1.2: AI in analysing personalising treatment based on the patient data

(Source: Bhattamisra *et al.* 2023)

The solutions which is AI-based are identified, include platforms that can use different data types, viz., symptoms reported by biomarkers, patients, biometrics and imaging etc. With advancements in AI, for recognise potential illness leads to greater probability for prevention as a result of detection in the early stage (Bhattamisra *et al.* 2023). Physical robots are also being used in different healthcare segments, like nursing, rehabilitation, telemedicine, surgical, radiology, cleaning, etc. Leaders are also leveraging AI to enhance strategic planning. Hence, predictive analytics powered by AI allows to enable the leaders to explore potential risk, analyse customer behaviour and anticipate the shift in the market. Strategic leadership in this industry now need to integrate digital

capabilities into organisational core, which allows leveraging AI for employing digital platforms, predictive drug discovery, implementing blockchain in supply chain transparency and use of advanced analytics for clinical trial optimisation of a more personalised patient engagement.

The major pharma industry is aware about the need to use new technological capabilities. However, pharma companies also faced task of applying new technological opportunities and adapting their strategies. Digitisation of collected medical data from the pharmaceutical sector over subsequent of human analysis has not offered a significant rise in efficiency of the industry. AI also fosters a real-time processing of the patient data, candidate selection for clinical trials, through focuses to exchange information with doctor, patient, insurance company and providers (Kulkov, 2021). With the support of graphic analysis, voice recordings and text, AI can foster accurate and faster analysis. The pharmaceutical industry devotes resources for drug development, in this inadequate demand in the market for it.




Figure 1.1.3: Contribution of AI to drug research and development

(Source: Vora *et al.* 2023)

Major loopholes in the development and research of the pharma sector are predictability for the preclinical models. The dynamic of predictability assumption is based on chosen dynamic, and the same bid to complexity in the models. All the cases linked with the drug interactions with the membranes can be analysed through the use of a modelled environment, as shown in Figure 3. AI offer sophisticated technology for analysing these types of multilayer data (Vora *et al.* 2023). A systematically applied model for parameter evaluation on factors, like scoring, refinement, and simulation, in every research step for influencing best results. AI can also offer automated system implements all these functions for predicted refinement and guessing for consistent data improvement. For superior AI training in a biological environment, foster proper analysis of interaction with drug–biological is important, indicating the ' biology databases.

Industry 4.0 allows for a shift in the key issues for pharmaceutical manufacturers, starting from the controlling processes towards enabling understanding of human operations. For fostering human understanding and visualisation of digitised manufacturing operations, each segment can be divided into digital architectures. Different forms of architectures are proposed to address these challenges, like digital ecosystems for mapping key value drivers. For cost-effective intelligent systems that allow for the merging of customer demand and production systems with online data, it is important to further improve high-speed communications and develop powerful computing architectures in lower costs. While some specific tools developed for optimising the key value drivers vary on business models and core competencies of pharmaceutical firms, this leads to the development of a consistent and integrated system. Digital integration in IoT can produce disruptive pharmaceutical applications like real-time, on-demand, small-scale production systems and truly personalised biosensor diagnostics and dosage forms.

1.2 Research Problem/Problem Statement

The pharmaceutical industry holds a critical position in the healthcare ecosystem and global economy. It is not only an industry that focuses on profit, but it is also deeply tied to well-being and the survival of the human population. COVID-19 emphasises the pharmaceutical organisation centrality for safeguarding human health, managing supply chain, research and development (R&D) and critical drugs in unprecedented pressures. The problem lies, even after the promise of AI transformative influences on clinical trials, R&D, patient negotiation and manufacturing, their adoption in the pharmaceutical industry is uneven, and also fragmented through ethical, regulatory, cultural and leadership barriers. “The Global Health Drug R&D Centre opened up technical

platforms and R&D resources, of drug, like AI drug R&D and a big data sharing platform, for their scientific researchers” (Wang *et al.* 2021). This platform has super computing capabilities that can support screening of large-scale drug and their epidemiological research.

Along with the drug repurposing approach, AI is also helpful in the process of discovery of drug. This can also allow in deals with current treatments used in novel illness. Formulation, medication development and pharmacokinetics are influenced by medical circumstances and needs of patient. The databases availability with comprehensive information is a challenging dynamic to their full-scale application for development of AI in their delivery systems. This is necessary for the models and parameters to be evaluated objectively (Vora *et al.* 2023). AI uses existing knowledge to assist with future applications. AI tools can handle or digest a vast amount of data for a better approach to the product's rational design. Excellent self-supervised experimental outcomes can be obtained with a more rigorous codification in database of knowledge, which is related to appropriate parameter recording.

Similarly, pandemic acknowledged the fragility of existing system and innovative urgency. AI integration in the pharmaceutical industry and ability of strategic leadership is emerging as issues. The “WHO Commission on Intellectual Property Rights, Innovation and Public Health was appointed in 2003 and reported in 2006”, reviewed a mechanism designed range for spur the development of products for the concession influencing developing countries. This also involves delinking a medical R&D treaty for raising public funds towards an open approach development and pharmaceutical innovation of original technology freely (Legge and Kim, 2021). Pharmaceutical R&D is time-consuming and resource intensive. Regardless of this, the pharmaceutical sector is lagging behind industries like information technology, finance and retail in embracing AI at scale. This lag develops a problematic gap between organisational reality and technological potential, a gap that is shaped less by leadership challenges and technical barriers.




Figure 1.2.1: Long-term trends of R&D investment of the pharmaceutical industry

(Source: Stephen, 2025)

Recently developed pharmaceutical industry are characterised by lengthy and costly development cycles for new drugs and price pressures from states, patients and insurance companies. Typical cost for development of new medicine is valued at “USD 2.5 billion”, and it takes an average of about 10–15 years (Stephen, 2025). This cost begins through scan different components in the primary stages of R&D and end with an expensive clinical trial under poorly predictable outcomes. Despite proper and careful preparation, 12% of the clinical trials succeed. The entire pharmaceutical organisation looks for opportunities which allow them to increase efficiency in processes of business for development and discovery of new products, compliance with industry strict rules and achieving required financial parameters, among other things. However, disruptions in the supply chain of the pharmaceutical industry significantly ramifications potential profit, customer satisfaction and corporate reputation.

Adoption of technology is not totally technical; it is also managerial and strategic. As integration of AI in the pharmaceuticals sector needs leaders who can accelerate a clear vision which aligns with the changes in the organisation and manage resistance towards change. Hence, leaders in different pharmaceutical firms are bound, risk-averse and conservative with legal practices. Strategic leadership also emphasises the ability to empower others, maintain flexibility, envision and anticipate others for developing strategic change in navigating the adoption of AI. On the one

hand, the pharmaceutical sector is less likely to devote resources to the development of a drug if there is insufficient demand in the market for it. However, AI can select its best candidates for the clinical trials. Forming a profile for optimal candidates allowed for minimising the likelihood of failure at the stage of clinical trials, expensive in the pharmaceutical industry.




Figure 1.2.2: Ethical considerations and challenges in implementing AI in health care

(Source: Stasevych and Zvarych, 2023)

AI and Robotic systems need access to sensitive data of patient data, raises concerns about their data security and privacy. Ensuring that the information of patient is only used and protected for the intended purposes is vital. Similarly, accountability and liability in healthcare are complex challenges. Use of opaque AI-powered systems in clinical decision-making elevated concern about the allocation and accountability of responsibility and its legal liability. WHO also emphasises that the potential of AI in healthcare is realised if human rights and ethical considerations are central to its use, deployment and development. There are different legal and technical challenges as well with its informed consent. This involves the right to privacy, explanation when applying AI in diagnostic consultations of medical (Stasevych and Zvarych, 2023). Digital technologies are also tested and applied in innovative formats for informed consent. While use of AI in health care can also reduce human interaction, which is often an important aspect of care, that influences the relationship of the patient–provider.

When using AI and robotic technologies in healthcare, bias and fairness are important considerations. Data, human judgment and computational biases are some of the sources of bias in AI systems. An AI system might also reinforce existing prejudices, for example, if the data used to train it is not representative of the population it serves. One way to think of fairness is its ethical value. Fairness requires more than merely distribution and absence of discrimination and biases; it also needs that healthcare machine learning algorithms treat people as unique individuals and as persons. In the ethics of AI, joint statements of “Canada, Europe, and North America, doctors played the role of the guardian of the machine, serving as an active operator rather than a passive user” (Jiang *et al.* 2021). Retraining and development of skill, awareness and education, career legislative measures and counselling and support are encompassing things, such as job placement services, unemployment insurance and other types of support, to prepare the workforce for adaptive changes in the job displacement dynamic.

Affordability and accessibility are critical factors to consider when integrating robotic technologies in healthcare. Work could change for everyone thanks to automation technology like physical robots, machine learning algorithms, and process automation bots. To guarantee its safety, effectiveness, and moral use, robotic technology in healthcare must be properly regulated. The leaders of the healthcare industry are demonstrating the growing commitment towards AI, as 37% of them have outlined plans to focus on AI investments in the coming three years (Stasevych and Zvarych, 2023). The global pandemic situation, like COVID-19, expedited the transition towards remote care, as nearly 42% of the healthcare leaders are focused on sustaining this trend. Moreover, some significant AI advancements are exemplified by breakthroughs like “AlphaFold and Rosetta Fold” for revolutionising the discovery of drugs through multiplying opportunities to analyse new drugs. These trends foster a transformative health care phase that emphasises a pivotal role for shaping AI in the future patient care, healthcare operations and medical research.

1.3 Research Aim and Objective

Aim

The aim of the research is to emphasise the importance of strategic leadership and AI integration in the pharmaceutical sector.

Objectives

- To analyse the recent state of integration of AI in the pharmaceutical sector, which assists for exploring effective strategies, implementation pitfalls and success patterns.
- To observe governance mechanisms and leadership competencies that foster scalable AI adoption involving case examples like AstraZeneca's governance model along with AI upskilling initiatives
- To analyse strategic alignment processes that align AI adoption with organizational vision and operational imperatives including change management approaches as articulated in recent frameworks
- To evaluate ethical considerations like data privacy, algorithmic bias, and transparency related to leadership framework that honours high stakes and regulatory sensitivity of pharmaceutical applications
- To identify a relevant practical leadership model that can balance technical, strategic, governance and cultural dimensions of AI implementation in a large-scale, regulated pharmaceutical industry.

1.4 Significance of the Study

Technological innovation is most necessary for pharmaceutical industry as demand for pharmaceutical products has increased. Strategic leadership helps to implement effective AI technology that enhances quality and service of this industry (MAHABUB *et al.* 2025). AI emerged as an effective tool that can revolutionise drug discovery and support this industry to achieve ultimate success. In managing supply chain (SC) in critical situations and enhancing clinical trials for essential medicines, AI plays a crucial role (Ogbuagu *et al.* 2023). Implication of advanced technologies require skilled leaders and knowledgeable team management. This study helps to identify current level of AI application in pharmaceutical sector. It can be effective to analyse exact impact of AI and be able to measure progress of pharmaceutical companies.

Leaders who can take transformative steps and inspire team members to handle technology, able to transform organisational practices. Understanding ethical implications of AI has become necessary in this digital era to improve trust of buyers on pharmaceutical sector (Odumbo, 2025). This study

is significant for several reasons as it has academic contribution and practical relevance. It provides a base to pharmaceutical research involving AI incorporation. Pharmaceutical companies experience huge pressure due to innovation and rapid changes of patient safety protocols (Mensah *et al.* 2024). This study suggests strategic leadership as a differentiator of successful AI adoption and costly failures. This research helps to provide a roadmap for leaders to implement advanced technology in an effective manner.

Strategic leadership is essential for implementing AI related policies in pharmaceutical industry. This study provides information regarding governments and regulatory bodies that are involved in shaping future of AI in healthcare. In understanding leadership dynamics behind AI integration and effective approaches that can support innovation while safeguarding public interest. This study is important to suggest global health impact due to integration of automation. AI has potential to accelerate drug development and improve access to treatments throughout the world (Nishan, 2025) Strategic leadership ensures that these technologies are involved responsibly and equitably. This study highlights pivotal role of leadership in unlocking potential of advanced technologies in pharmaceutical industry. Such practices make an impactful contribution to both theory and practice.

1.5 Scope of the study

This study has huge scope in different parameters as this research focuses on strategic leadership practices, it enables successful integration of AI in pharmaceutical organisations. It is industry focused research involving biotechnology firms, drug manufacturers and medicine related research organizations. Analysing importance of AI involvement in these organisations helps to provide more opportunities to whole pharmaceutical sector (Kulkov, 2021). This study highlights global trends that reduce geographical barriers and provide information about the global pharmaceutical market. Emphasis on leading pharmaceutical markets like US, Europe and others helps to show increasing AI involvement. This study is significant for researchers and readers to provide important information about this demanding industry.

Technological scope of this study needs to be highlighted to highlight its importance for further research. This study examines AI applications involving machine learning (ML), natural language processing (NLP), robotic process automation and predictive analytics. Special focus on drug discovery and clinical trials make it extremely important for pharmaceutical research. Other than that, leadership strategies that are involved in this research helps to define activities of leaders that

can influence organizational direction. In fostering innovation and managing change an effective leadership approach is necessary in pharmaceutical organisations (Patel, 2025). It explores leadership styles, its decision-making processes and culture of organizations for integrating AI technology. In discussing temporal scope of present research its forward-looking perspective on emerging trends and future implications can be discussed.

Implementing appropriate methods enhance importance of this research and its ability to guide further studies in similar topics. Involving industry data increases its scope to be accepted among readers in an effective manner. Excluded from scope are non-pharmaceutical healthcare sectors involving hospitals are considered as purely technical AI development. It is also a fact that without leadership context and regions with minimal AI activity in pharma technological development is not possible (Suri *et al.* 2024). Providing a clear delineation of its scope helps this study to ensure a focused and relevant exploration of strategies for strategic leadership that can drive AI integration in a complex industry.

1.6 Research Questions and Hypothesis

Research questions

- How to analyse the recent state of integration of AI in the pharmaceutical sector, which assists for exploring effective strategies, implementation pitfalls and success patterns?
- What are the governance mechanisms and leadership competencies that foster scalable AI adoption involving case examples like AstraZeneca's governance model along with AI upskilling initiatives?
- How to analyse strategic alignment processes that align AI adoption with organizational vision and operational imperatives including change management approaches as articulated in recent frameworks?
- What are ethical considerations like data privacy, algorithmic bias, and transparency related to leadership framework that honours high stakes and regulatory sensitivity of pharmaceutical applications?

- How to identify a relevant practical leadership model that can balance technical, strategic, governance and cultural dimensions of AI implementation in a large-scale, regulated pharmaceutical industry?

Hypothesis

H0: Strategic leadership orientation, leadership competence in AI and digital innovation, and organisational readiness have a negative impact on implementing AI in the pharmaceutical industry.

H1: Strategic leadership orientation positively influences the implementation of AI in the pharmaceutical industry.

H2: Leadership competence in AI and digital innovation has a positive impact on the implementation of AI in the pharmaceutical industry.

H3: Organisational readiness significantly has a positive effect on the implementation of AI in the pharmaceutical industry.

1.7 Definition of Term

- **AI:** It is an emerging technology that enables machines to perform tasks that require human intelligence (Ilyas, 2022). In learning about market, analysing recent trends and solving issues this technology creates a huge impact. AI involves ML, deep learning and NLP that support pharmaceutical organizations to expand its implications.
- **Strategic leadership:** It represents ability of individuals in leadership positions to influence organizational decisions and foster innovation. Taking strategies to manage organisational practices and long-term goals, strategic leadership is important (Cortes and Herrmann, 2021). It involves resource allocation, setting vision and ensuring stakeholder engagement.
- **Pharmaceutical industry:** A sector that involves research, development and production related activities to develop drugs can be considered as pharmaceutical industry (Hole *et al.* 2021). It involves biotechnology firms, generic drug manufacturers and private pharmaceutical corporations.

- **Operational efficiency:** Capability of individuals to deliver products and services in an effective manner is referred to as operational efficiency (Hole *et al.* 2021). AI can enhance efficiency in this digital era through implementation automation in tasks and optimizing resource use.
- **Innovation:** Implementation of new ideas and technologies to improve organisational outcomes is known as innovation (Santos *et al.* 2022). In pharmaceutical industry innovation often refers to essential drug development and improves outcome of patients. In improving clinical trial methodologies and offering personalized treatment, innovation is necessary.
- **Patient outcomes:** Patient outcome refers to end results of healthcare interventions, including improvements in health status (Connor *et al.* 2023). It promotes quality of life and enhances satisfaction level of patients as well. AI has a significant contribution in providing better outcomes through personalized medicine.

1.8 Thesis Structure

Chapters	Contents
CHAPTER I: INTRODUCTION	Outlines research background, objectives, significance, scope and key questions. It provides an overview of the study through defining terms and presenting thesis structure.
CHAPTER II: REVIEW OF LITERATURE	Involve existing research on strategic leadership, AI in pharmaceuticals and patient outcome. It analyses gaps of existing thesis and builds theoretical foundation for present study.
CHAPTER III: METHODOLOGY	Describes research strategy and data collection methods. It involves a structured method that is used to achieve desired results.
CHAPTER IV: RESULTS	Presents results including qualitative insights and quantitative data analysis. This section interprets findings in relation to objectives of research.
CHAPTER V: DISCUSSION	This section includes implications of findings for strategic leadership and AI integration in pharmaceutical sector. It also compares results with existing literature and explores theoretical information.

CHAPTER VI: SUMMARY, IMPLICATIONS, AND RECOMMENDATIONS	Summarizes findings of this study and highlights its key contributions through offering recommendations.
--	--

Table 1.8.1: Thesis structure




Figure 1.8.1: Thesis Structure

1.9 Summary

This section provides detailed exploration of strategic leadership and involvement of advanced technologies in pharmaceutical industry. It starts with background of this research involving information about focus of this study. Detailed information about aim like impact of strategic leadership on essential implication of AI technologies in pharmaceutical organisations are involved in this section. Practical application of this study in real life and policy implications in healthcare firms is also involved in this part. Other than that, it also involved definition of important terminologies like AI, operational efficiency and many more.

CHAPTER II:

REVIEW OF LITERATURE

2.1 Introduction

The chapter focuses on presenting a review of existing literature and developing a comprehensive idea on the subjects that are being explored in the study. The implication of this focused on addressing the understanding and capacity of building a comprehensibility of different subjects associated with the topic of the study as well as understanding the possible components that are associated with the same. Existing research literature has been explored and reviewed in the purpose of understanding concepts such as strategic leadership and digitalisation AI integrations as under the context of pharmaceutical industries. The following chapter presents itself to you so contribute to gaining an insightful understanding on the theoretical underpinnings that are associated with the study subject.

2.2 Fundamental concept and competencies of Strategic Leadership

Organisational and industrial development imply the understanding of success in the face of advance in changes and development happening within the industries scenario to be associated and evaluated in focus to leadership changes and dynamics such as strategic leadership. This initiates the understanding of conceptualization of strategic leadership as a leadership concept divided into two elements of strategy and leadership. As opined by Ojogiwa (2021) in research, the resolve of strategy success, that is noted to have been reached through creating objectives and making astute adoptions to grasp those objectives, and leadership is important to the growth and application of tactics.

Thereby, strategic leadership refers to a leader's aptitude for enabling, envisioning, foresight, and flexibility maintenance, and instigating collectively to bring about fundamental strategic change. This leadership doesn't essential component into the development and surface of organisation and for dieting a long-time sustainability within the organisational action plans. As per the study by Tao *et al.* (2021), strategic leadership has become essential for businesses to advance their growth,

preserve their competitive edge, and look for new prospects. According to the research, leadership holds the capability of providing the individuals the potential of foresight and imagination, maintaining adaptability, induced strategic thinking, integrated collaboration with others as a way of implementing the changes, and building sustainable futures for organisations.

In many ways, strategic leadership enhances organizational learning, fosters organizational transformation, and improves organizational performance. Strategic leadership is indispensable for the success of an organization alongside guiding a long-term, sustainable plan of action for a specific organization. In the study by Carvalho *et al.* (2021), under the case of educational sector, strategic leadership was defined as that focuses on Strategies and behaviours that are associated to the entire procedure of commencement, expansion, operation, monitoring, and appraisal of strategic actions, while taking into account all diverse past present and future contexts, with maintaining accessibility for financial, human, and physical resources.

Strategic leaders plan for the future and define organizational goals. Under the study by Willis *et al.* (2022), strategic leadership facilitated development of organizational goals by bringing strategic leaders' future ambitions. Their power grows as they understand and confront important aspects of their surroundings. The study also found that there are variances between the principles of leadership and strategic leadership. Leadership, as principle, is applicable to all firm executives, irrespective of level in management, meanwhile strategic leadership denotes to highest levels of leaders at the organizations. Consequently, it is noted that top level executives of an organization face diverse responsibilities than the ones at intermediate level of organisation. Strategic leadership is defined as a set of distinct qualities that include encouraging staff, envisioning, remaining flexible, thinking strategically, and predicting for the production of innovative ideas that contribute to high performance.

As is observed in existing literature, strategic leadership does not exist as a new concept, but rather as a strategic element of the greater leadership paradigm. As mentioned by Maharani *et al.* (2024), the study noted that efficient strategic leadership is focused on the concept of progressive practices that are integrated by organisations and is essential for the purpose of contributing towards the driving competitive business environment of times. This form of leadership is noted to expand over the prospects of strategic division is alongside in compassing a major range of high ranking administrative and supervisory responsibilities alongside operational, innovation and engagement

associated duties. The research noted studies that define the concept by stressing on intrinsic qualities of strategic leaders, such as adaptability, discerning wisdom and keenness for transformative change. Strategic leadership is essentially considered as a judicious combination involving essential functional capacities within the organisation environment alongside high-ranking positional authorities through the emphasis of multifunctional rules that the strategic leaders of an implement it is essential for securing holistic organisation results.

The capability of a leader to contribute towards adjusting, empowerment, and foresight on others to execute strategic change as needed is recognized as strategic leadership. Under the research by Sazly *et al.* (2024), studies show that there are five elemental skills of strategic leaders that comprise strategic competency development, strategic orientation, strategic implementation, and strategic adjustment. Due to their importance in companies that wish to quickly adapt to change, strategic leaders face several challenges, one of which is the requirement to make wise decisions. The research also points out that it is well-established that leadership includes all employees in the organization that occupy leadership roles, irrespective of their level of management expertise. Additionally, this leadership enhances and fortifies the business. Since they are necessary to maintain long-term performance, strategic leaders must give top priority to critical resources, competencies, and abilities.

There are different competencies to strategic leadership, often scaling to visionary thinking, strategic agility, innovation leadership culture and ethical responsibility. The study by Whitehead *et al.* (2025) mentioned that, in case of visionary thinking, since visionary thinking entails predicting future trends in "Industry 5.0" and making the organization to familiarize and flourish in a socially responsible and sustainable manner. This necessitates the leaders to learn to adapt to a long-term perspective by giving higher preference two sustainability and social responsibility over short term profit. The study also noted that strategic leaders must be excellent at making ethical decisions that take into account the wider social implications of deployment of technology. Inclusivity is also considered as a necessary prospect that is needed to ensure the employees involved during the organisation of transition through digitalisation and maintained incorporation of diversity into the strategic planning processes.

In addition to that, strategic agility is also a beneficial competency of strategic agility with shifts in industry. As observed in the study by Kuzmanov (2025), by facilitating strategic agility, that is

essential for the survival and development of an organization, cognitive competence improves leadership. This ability enables leaders to quickly switch between many mental models, adjust to unanticipated setbacks, and combine seemingly unrelated facts into a cohesive whole. To demonstrate the idea that leaders with high cognitive proficiency successfully modified their operational models, embraced new technologies, and reimagined team dynamics, while those without this agility found it difficult to sustain productivity and employee morale, the study used the example of remote working during the COVID-19 pandemic.

According to studies, innovation is institutionalized and promoted as a component of strategic planning, which enhances competitive advantage and digital maturity. As opined by Kazmi (2025), in case of innovation leadership as an outcome to innovation culture, advantages of digital integration were greater for companies that promoted a culture of ongoing innovation. Sustainable innovations were fostered by leaders who promoted experimentation, iterative thinking, and a willingness to fail. Innovation was spread among teams in these firms, from marketing to operations, rather than being limited to R&D departments. These companies' strategic executives established internal innovation hubs, digital sandboxes, and cross-functional teams to investigate how trailblazing technologies like blockchain, AI, and IoT could improve supply chains or reshape customer experiences.

2.3 Association between Digital Innovation and Strategic Leadership

In context to strategic leadership, leveraging and using digital technologies could provide a competitive edge to leaders and organisations according to studies. The research by Schlosser *et al.* (2023) mentions through a theoretic case of dynamic strategic leadership is the consideration of environmental and social issues in company operations. With the intention of increasing financial and social influences, the strategic leader is needed to focus on implementing digital technologies. For the purpose of identifying emerging trends and be prepared to take advantage of any opportunity, the strategic leader is needed to seek for enhancing change and risk quality during this sensing of new technologies.

In today's economic environment, digital innovation has emerged as a crucial concern for major corporations. Following global economic crises, supply chain disruptions, changing markets, the future of work, and the fifth industrial revolution, business organizations must deal with several challenging challenges. As observed in research by Gachugu (2023), strategic leadership has been

noticed ever growing into an increasingly crucial leadership form due to businesses becoming exponentially innovative on a digital level. The study noted an important factor in association to digital Innovation and performance being influenced within major businesses to be in connection to transformational leadership under the context of strategic leadership for Institution of digital innovation within organisation. The study had additionally pointed out that organisations hold the capacity of promoting a work culture for boosting opportunities of risk management and teamwork through integration of such leadership modes as a vital element for efficiency in digital innovations.

Strategic leadership in its significance has been identified to be increasingly apparent in the modern business environment that is characterised through the instability of the international environment and constant shift in technical advancements. Under the research by Kazmi (2025) it has been noticed that revolutionary technology such as AI, big data, cloud computing and IoT, have controlled the transformation of organisational leadership approaches throughout multiple sectors by observing the intersection between strategic decision making and digital innovations. The study head however also noted that despite its contribution towards development of wealth creation that digital instruments and integrations have contributed towards certain challenges including higher competition, cybersecurity risks, data privacy concerns, and moral conundrums. Strategic leadership is identified to have a critical role in this circumstance because of its scope in embracing and implementing technology alongside integrating such innovations into the corporate strategy Foundation with the guidance concept of sustainability within it. The importance of leaders in having digital fluency is identified as a capacity for the incorporation of technology focused thinking formed into strategic decision-making capacities and have been noted as an increasingly necessary development by leadership academics and corporate strategies.

In the context of digital innovation, it has been noted that strategic leadership who has a vital part in the procedure of cultivating innovation culture within organisation behaviours and climate holds the capacity of enabling creativity and adaptation as well as enhancing the potential for risk taking capacities of the organisation. As opined by Davis (2024), organisations are capable of nurturing innovation culture within their structure through the benefit of efficient strategic leadership. This culture of innovation is often under strategic leadership channelised through the perspective of visionary leadership that can contribute towards the operation of innovation objectives. The innovation objectives operate through maintaining and alignment with the objectives and for the

don employee empowerment for exploring novel solutions and concepts for organisation success is also a prospective competency.

The study emphasized how important corporate culture, contextual factors, and leadership styles are in determining the results of innovation. Additionally, studies connote that organizations need to use digital leadership for developing innovation and maintaining competitiveness within a time of fast digital transition. As per the study by Tunaboyle and Cerasi (2025), digital leadership comprises a portfolio of business, digital, market, and strategic leadership skills that encompass interpersonal and intrapersonal competences to drive activities, strategic mindset, and decision-making to drive digital transformation within organisations.

As per studies, in order to harness innovation for institutional advancement, visionary leadership is required because the rapid expansion of digital technology has drastically changed the landscape of several companies and sectors. It is mentioned under the research of Nancy *et al.* (2025), strategic leadership encourages innovation, backs efforts for digital transformation, and synchronizes the use of technology with educational objectives. The significance of collaborative decision-making, flexible leadership approaches, and faculty and staff involvement in digital competencies are emphasized. The report emphasizes how good leadership tackles issues like organizational inertia, digital equity, and change aversion in addition to facilitating the adoption of cutting-edge technology like data analytics, and virtual learning environment in addition to application of AI.

Studies also connote that digital transformation is an “ecosystem challenge”, the adoption of innovative business models and tactics by incumbent firms, that is made possible by a plethora of new information technological applications, is a potent source of “value creation” as mentioned by Reuter and Floyd (2024). The study also mentioned that it is crucial to conduct study on strategic leadership for “business ecosystems”. The importance of the ecosystem leader's "vision" was highlighted by the newly developed cognitive viewpoint on ecosystem leadership in the study. Incumbent companies frequently build an ecosystem strategy to generate and capture value in the digital transformation. Instead of finding and occupying a strong competitive position, this type of endogenous strategic action aims to mould the competitive environment so that businesses can develop, leverage, and expand their position.

Strategic leadership is essential in promoting digital transformation across businesses, especially in telecoms, in the quickly changing digital landscape of today. It is observed by Alruwaili and Ali

(2025), digital platforms are becoming the main way that companies communicate with their customers in a variety of industries, including telecoms. In contemporary sectors, digital transformation has emerged as a potent force that is changing how businesses function, engage with clients, and provide services. The growing dependence on digital solutions emphasizes how crucial strong leadership is to direct these transformation initiatives. Making sure that digital efforts are in line with organizational objectives, encouraging innovation, improving employee competencies, and—above all—maximizing the quality of e-services are all made possible by strategic leadership.

2.4 Trends of Digital innovation within the pharmaceutical industry

Healthcare sector inclusive of pharmaceutical industry is undergoing a paradigm shift due to digital revolution, moving away from traditional stereotypes and toward creative and integrative methods. As observed by Lee. and Kim (2024), pharmaceuticals in addition to governmental organizations, research institutes, and insurance firms are all taking part in digital healthcare projects. The speed of digital transformation is being accelerated by the convergence of several players in the healthcare sector. According to the study, AI integrations such as generative AI is foretold to increase productivity within the pharmaceutical and medical product sectors by a range of 3% to 5% of global sales, or \$600 billion to \$1.1 trillion. Generative AI is already a top goal for most the world's largest pharmaceutical businesses.

As a result of digital transformation pharmaceutical industries are being noted undergoing a trend of change that is redefining how businesses interact with patients and “healthcare professionals (HCPs)” (Anthuvan *et al.* 2025). The combination of big data analytics, omnichannel strategies, and AI has created new opportunities for data-driven, personalized communication. In the study by Anthuvan *et al* (2025) it is mentioned that, to improve the caliber and scope of interactions with HCPs, pharmaceutical companies are progressively implementing digital marketing tactics. For instance, firms are now utilizing Virtual Reality (VR) to provide HCPs with immersive simulations of molecular biology, replacing traditional pamphlets with high-impact visual education. With the help of advancements in content formats and delivery channels, focused, impactful messaging is being delivered through personalized and technologically enabled techniques. These techniques have been identified to involve the consistency of SEO optimisation alongside features such as interactive platforms, instructional video campaigns and AI-driven chatbots that provide 24/7 support for patients managing complex specialty medications.

Studies implies that pharmaceutical sectors have presented a strong capacity of making adaptations and changes in time with challenges and advancements. The rapid process and approach of digital transformation include reinvention of the industry has been essential for implementations of supply chain destructions and the development of remote labour alongside contributing towards aim message change in consumer behaviours. Almeman (2024) mentioned in research that, the market development of the pharmaceutical business before to the pandemic was marked by revolutionary changes that laid the foundation for the industry's ability to respond to later global issues. Innovations within medication development, digital health, collaborative collaborations, regulatory frameworks, market access strategies, and sustainability initiatives collectively transformed the landscape of the sector. A key example is the use of "Digital Twins" in manufacturing, where virtual replicas of production lines allow companies to predict equipment failure and simulate efficiency gains without pausing real-world operations.

The pharmaceutical industry has been observed to be going through a major transformation of digital change. This has been an ongoing trend under the influence of constantly developed technology innovations within industry in the form of a response to maintain competence. Transformative impact of digitalisation upon the global pharmaceutical industry has been noted in a study by Shoukat *et al.* (2023). The study notes that in person interactions and paper-based processes are most prominently the fundamental focus of pharmacy services. The inclination for instigating healthcare to be transparent, efficient and patient centric is also unignorable evidence for the expansion of digital transformation within the industry being at a constant demand. The healthcare industry has been transforming according to the study as an outcome of digital innovations that include cloud computing and mobile communications as well as interpretation of enhanced analytics and IoT. Specifically, Decentralized Clinical Trials (DCTs) are now using mobile health (mHealth) apps to allow patients to participate in drug trials from home, significantly increasing the diversity and reach of clinical research. The study noted different sectors within the industry such as retail, media and banking that these innovations contributed to the strong advancement of service delivery and patient care.

The expansion of domestic internet accessibility observed by studies to have contributed to a speech endorsement of pharmaceutical businesses undergoing a transformative progress alongside medium policy development for digital integrations to become up to date. As opined by Klimanov *et al.* (2021), AI companies have only recently made their way into the pharmaceutical sector. Data

breaches have always been a possible concern in digital transformation, as the study shown via the lens of the EU pharmaceutical industry's digital evolution. The core of the transition is the creation and use of data yet concerns about pharmaceutical data security and privacy are never easy to resolve. The privacy of data given by pharmaceutical companies and consumers has always been a critical topic in the context of digital transformation.

The pharmaceutical sector has embraced digital revolution through various trends. In a study by Henstock (2021) trends such as, blockchain and cybersecurity are becoming evident in the industry. Every step of the production and circulation of pharmaceuticals is significantly impacted by the adoption of blockchain technology. A practical application is the use of "Smart Packaging," where IoT sensors track medication adherence and sync data with provider dashboards to ensure patient safety. Due to the sensitive nature of their data, the stakeholders in the pharmaceutical sector are generally discreet. The use of subpar and counterfeit medications that penetrate the pharmaceutical supply chain and kill thousands of people annually has been investigated using blockchain technology. This is currently being utilized for "Cold Chain Integrity," providing an unalterable digital log of temperature variables for sensitive biologics during transit. The study pointed out that cybersecurity is desperately needed in the pharmaceutical sector, which is a source of the most sensitive data. It raises the prospect of increased data leaks, which can come from a variety of sources and formats. The pharmaceutical business will inevitably encounter security threats due to the seemingly endless developments in technology.

In addition to this, Dharma Moorthy *et al.* (2022) notes that, the potential advantages of utilizing AI alongside its diversity of subfields, including advanced analytics, data science, deep learning, and machine learning, have been recognized by pharmaceutical R&D in recent years. This shift is manifesting in AI-powered drug discovery, where companies screen billions of chemical compounds virtually to identify candidates for rare diseases, reducing the initial research phase from year's to month's. Only a few years ago, AI techniques were causing a stir in a variety of industries. Pharmaceutical businesses were trying to develop ways of employing this into their industrial concerns. AI is being rapidly used by IT/informatics and innovation teams as a result of corporate digital changes. Specifically, Generative AI is now being used to automate the drafting of complex regulatory filings, such as Clinical Study Reports, ensuring they are processed with higher speed and accuracy. The report also noted that assembling these new teams has become more difficult as the number of AI practitioners in the pharmaceutical industry has grown. Due to

the nature of the work, AI specialists in the pharmaceutical and life sciences sectors require subject area experience in addition to computer science scripting and math/statistics abilities for machine learning. This expertise is critical for the advancement of Precision Medicine, where digital platforms integrate genomic sequencing data to develop medications tailored to a patient’s specific genetic profile, and for the harvesting of Real-World Evidence (RWE) to analyse how drugs perform in everyday settings compared to controlled clinical environments.

Summary of digital transformation/technology enablement in pharmaceutical industry:

Focus Area	Core Concept / Study	Real-World Examples & Applications
Productivity & Economics	Generative AI is predicted to increase productivity by 3% to 5% of global sales (\$600B–\$1.1T). (Lee & Kim, 2024)	Regulatory Automation: Using GenAI to draft complex Clinical Study Reports and regulatory filings to speed up FDA/EMA submissions.
HCP Engagement	Redefining interactions with Healthcare Professionals through omnichannel and digital marketing. (Anthuvan et al., 2025)	Virtual Reality (VR) Education: Immersive simulations of molecular interactions used by sales reps to educate doctors on drug efficacy.
Patient Support	Moving toward patient-centric, personalized communication and technologically enabled techniques.	AI-Driven Chatbots: Providing 24/7 assistance to patients on specialty medications to manage side effects and adherence.
Manufacturing & Supply Chain	Reinventing operations to handle disruptions and improve resilience. (Almeman, 2024)	Digital Twins: Creating virtual replicas of production lines to simulate runs and predict equipment failure before it happens.

Clinical Research	Shifting from paper-based, in-person processes to transparent, efficient digital systems. (Shoukat et al., 2023)	Decentralized Clinical Trials (DCTs): Using mHealth apps and remote monitoring to allow patients to participate in trials from their homes.
Security & Integrity	Addressing data privacy concerns and the threat of counterfeit drugs. (Henstock, 2021)	Blockchain for Cold Chain: Maintaining an unalterable log of temperature data for sensitive biologics during global transit.
Medication Safety	Utilizing IoT and internet accessibility to improve patient outcomes. (Klimanov et al., 2021)	Smart Packaging: IoT-enabled pill bottles that track when medication is taken and alert providers if doses are missed.
Drug Discovery (R&D)	Leveraging deep learning and advanced analytics to shorten development cycles. (Dharma Moorthy et al., 2022)	Virtual Screening: Using AI to screen billions of chemical compounds in months rather than years to find leads for rare diseases.
Personalized Medicine	The need for AI specialists with subject-matter expertise to drive innovation.	Precision Medicine: Integrating genomic sequencing data to create "niche-buster" drugs tailored to a patient's specific DNA.
Performance Tracking	Transitioning toward data-driven evidence and real-time analytics.	Real-World Evidence (RWE): Analyzing electronic health records and wearable data to see how drugs perform outside of trials.

2.5 AI as applications in relation to Strategic Leadership

The responsibilities of a strategic leader in the era of artificial intelligence (AI) cannot be adequately described by merely stating a vision, thereby making the scope of AI applications into strategic leadership and consequent leadership dilemmas. In the study by Türkgenç *et al.* (2025), it is noted that improving strategic leadership abilities was once a conventional task, but it has become increasingly difficult, especially in light of the complexity brought about by the age of AI and technological development. The conventional practice of outlying a vision is not entirely sufficient for full feeling of the implementation of strategic leadership within the age of AI technology that necessitates integration of a diversity of responsibilities. This research has also confirmed that strategic leadership can be challenging in terms of acquisition and application. The progress and implementation of strategic leadership capacity have become a more challenging prospect in the prospect of new challenges and opportunities that are presented by the AI period. Significant technology innovations include big data and AI and are recognised as impactful integrations on proper application for supporting strategic leadership abilities within the organisational environment.

Because of the revolution in information, communications, and technology, as well as the speed at which they are being updated, the contemporary era is seeing many rapid and multiple advances and changes. As per the research by Almanie (2025), strategic leadership is highly associated to responsibilities of engaging development that call for them to build skills and implement ongoing change in accordance with the dynamic and complex environment as well as the competitive environment. This calls for leadership that has a strategic vision and the capacity to allocate knowledge in a way that advances organizational objectives. According to the research, leaders in the modern corporate world are finding AI to be more and more significant. The study noted that prosperous leaders are recognizing the necessity of implementing a strategy that prioritizes both people and technology. In this regard, leaders' operational and strategic decision-making processes can benefit greatly from the use of AI technologies.

According to studies, there are benefits and challenges to using AI-driven business models. While AI increases efficiency, reduces costs, and speeds up innovation, it also raises questions about algorithmic bias, data security, ethical decision-making, and the evolving role of human leadership. The research MAHABUB *et al.* (2025) mentioned that, adopting new technology is only one aspect of strategic leadership in the AI era; other aspects include ethical behaviour, workforce adaption, and corporate culture stewardship. The ability of AI-driven leadership to promote long-term,

sustainable growth is a key characteristic. AI streamlines supply chains, reduces waste, and fosters innovation to improve short-term corporate performance and develop resilient, sustainable business models. Businesses that use AI to strategic decision-making may be better able to anticipate shifts in the market, adapt to changing consumer demands, and position themselves as leaders in an increasingly digital economy.

Existing research literature also supports that the use of machine learning into the strategic leadership has greater impact because it will continue to advance in quality. According to the research by Priyanka et al. (2025), integration of predictive analytics as a form of digital injection into the operations of strategic leadership has the perspective of contributing towards the endorsement of a constantly enhancing and innovative work culture. Implementation of smart systems and empirical data contributes to lettering leaders to have the initiative for building motivation of organisational change through functioning as a major transition facilitator. Adopting such digital transforming innovations are notice every contributing towards causing and shift in cultures of organisation influences be ratings of the administration for presenting a strong likely to be involved with project adaptations to digital innovation integration full study had positive that leaders are needed to pledge for contributing in investments in generous manner for strong infrastructure development and narration data literacy within organisation was alongside addressing ethical issues such as transparency and responsibility alongside fairness that are essential for AI integration.

According to studies, AI technologies are becoming essential tools that improve decision-making, operational effectiveness, and employee engagement as companies negotiate the complexity of the modern workplace. According to Elbadaoui (2025), by enabling data-driven insights and individualized employee experiences, the use of AI in strategic leadership is changing established paradigms. There is a direct correlation between AI integration and improved employee outcomes, as evidenced by research showing that companies using AI-driven performance management systems can see productivity gains of up to 40%. The incorporation of strategic leadership methods augmented by AI has important ramifications for influencing workforce performance. Leaders must balance the advantages of AI with the moral and interpersonal components of good management as they adjust to these advancements. In order to ensure that workers feel appreciated and empowered in their positions, leaders must balance the demands of utilizing data-driven insights with upholding a human-centric approach to leadership as firms continue to use AI technologies.

Through increased productivity and creativity, the use of AI in strategic leadership and executive decision-making has completely changed organizational dynamics. AI is a general-purpose technology that is developing quickly, requiring interdisciplinary approaches to address ethical, social, and policy concerns. As per the research by Alami and Al-Masaeid (2025), AI has revolutionized strategic leadership by changing leadership interactions and decision-making processes. AI's explosive growth is changing how organizations make strategic decisions and exercise leadership. This change is being driven by AI's capacity to process vast amounts of data, provide predictive insights, and automate intricate procedures, all of which enhance executive abilities and strategic agility. AI uses predictive analytics and data-driven insights to improve organizational performance and the spread of knowledge. Leaders with this capacity are more equipped to make strategic choices that boost productivity and competitiveness. As a component of strategic leadership, AI calls for new skills and abilities. AI's impact goes beyond supporting strategic planning and foresight; it can also identify consumer behaviour patterns and market trends, giving executives the information they need to make proactive decisions.

In particular interest to the pharmaceutical industry, studies present the implications of AI into strategic leadership. As observed by Stephen (2025), the pharmaceutical industry plays a vital role in tackling global health challenges. Strategic leadership in pharmaceutical program management is now crucial. Pharmaceutical companies can manage complex regulatory requirements by forming multidirectional partnerships and doing cutting-edge Under strategic leadership, pharmaceutical program management employs innovative approaches that include risk prevention strategies, cross-team collaboration, and visionary decisions. Pharmaceutical program management involves increasing AI-driven innovation.

Strategic leadership in the age of AI is the art of combining human intuition with machine intelligence. Leaders who treat AI as a mere productivity tool will be outpaced by those who treat it as a Strategic Co-Pilot. In this new era, the competitive advantage lies not in having the most data, but in having the most effective 'Human-AI feedback loop' at the executive level. For a leader to be effective in this new digital era, they must master three distinct domains where AI intersects with leadership:

1. Data-Driven Foresight - Diagnostic AI for real-time KPI visualization and reporting. AI dashboards tracking real-time sales performance and HCP engagement metrics is a great example of data drive foresight.

2. Algorithmic Governance - This involves ensuring that the algorithms driving pricing, hiring, or supply chain moves are free from bias and are transparent.

3. Human-Centric Orchestration - As AI takes over the "cognitive heavy lifting," the strategic leader's role shifts toward **EQ (Emotional Intelligence)**. The goal is to keep the workforce engaged and purpose-driven while AI manages the operational complexity.

2.6 Technological Complexity and Integration during AI application

In the pharmaceutical dynamic, different types of AI models are employed for different purposes, each of them offers different applications and capabilities. Models of ML, like supervised learning, is one of the fundamental concepts of this field. Involvement of supervised learning in training models uses labelled datasets during decisions and predictions. Techniques such as “regression models”, “support vector machines” (SVM), and “decision trees” are commonly adopted (Mottaghi-Dastjerdi and Soltany-Rezaee-Rad, 2024). For example, SVMs are classify drug compounds based on their chemical properties for aiding the discovery of drugs. However, regression models are used to predict pharmacokinetic properties and drug efficacy, while decision trees help in optimising the formulation of the drug and predicting responses of patient.

“Real-world data” (RWD) from wearable devices and electronic health records are adopted to offer AI algorithm insights that algorithms of AI can explore for personalising regimens during treatment, stratifying the population of patients and predicting adverse events (Kandhare *et al.* 2025



Figure 2.6.1: Fields of pharmaceutical sciences, AI can be applied

(Source: Mottaghi-Dastjerdi and Soltany-Rezaee-Rad, 2024)

Multifaceted roles played by AI play a comprehensive role in the pharmaceutical industry. As per to Emersion Insights research, “start-ups through implement AI in the development of drugs raised about \$2.1 billion in the first half of 2021” (Qureshi *et al.* 2023). This author also states that AI is already used by different biopharmaceutical organisations at different drug discovery stages. For instance, “Pfizer use IBM Watson, a machine learning-based system, to search for immuno-oncology drugs”. “Roche Gentech use GNS Healthcare from Cambridge”, “Novartis adopt Microsoft image and cell segmentation research”, and “AstraZeneca are associated with BenovalentAI for commercialising and developing Jenssen's novel clinical stage candidates”. This vital notion in AI implementation can help in resolving this cost through using their expertise to simulate human specialist cognition (Sarkar *et al.* 2024). Emphasising these criteria that govern the product valuation can help follow its production.

AI integration in systems, mainly in optimisation and design systems, led to advancements. AI methods, like neural networks, genetic algorithms and machine learning algorithms, used in

automating the processes of complex design, solve problems and optimise system performance, are intractable with traditional approaches (Adeyeye and Akanbi, 2024). “The global AI market of pharmaceutical industry is expected to reach \$1.24 billion in 2022 at a growth rate of 32.3%”. However, the pharmaceutical organisations are also invested in AI companies or develop joint ventures for better medical devices and drug products (Jiang *et al.* 2022). AI applications have already improved the process of decision-making and efficiency in clinical trials for offering benefits to regulators, patients, insurers and physicians. This trend is changing different pharmaceutical companies operating dynamically through collaborating with companies and institutions, incorporating AI during the development of a product.

The integration of Artificial Intelligence (AI) into the pharmaceutical sector is not a simple "plug-and-play" scenario but rather a journey through high-dimensional technological complexity. This complexity arises from the necessity to harmonize disparate data silos with emerging algorithmic architectures. As observed by Lee and Kim (2024), the convergence of pharmaceutical entities, research institutes, and insurance firms has accelerated the digital shift, yet it has also introduced significant integration challenges.

1. Data Heterogeneity and Algorithmic Synthesis

The primary technical hurdle in AI application is the "Data Silo" problem. Dharma Moorthy et al. (2022) note that for AI subfields—such as deep learning—to be effective, they require massive, high-quality datasets that are often trapped in legacy, paper-based systems or incompatible digital formats. The complexity is compounded when integrating Real-World Evidence (RWE) with controlled clinical trial data. This necessitates what Raisch and Krakowski (2021) call the "augmentation paradox," where leaders must manage the complexity of automated data processing while maintaining human oversight over the results.

2. Security, Blockchain, and Infrastructure Complexity

Technological integration also brings significant risks to data integrity. Klimanov et al. (2021) highlight that as the EU pharmaceutical industry evolves, data breaches become a critical concern. To mitigate these risks, the integration of Blockchain technology has been proposed as a solution for supply chain and cold chain integrity (Henstock, 2021). However, the complexity of layering

blockchain on top of existing Internet of Things (IoT) sensors requires a robust digital infrastructure that many firms are still struggling to develop (Stephen, 2025).

3. The Shift toward Agentic Workflows

Recent research by Alami and Al-Masaeid (2025) suggests that the latest phase of integration involves Agentic Workflows, where AI agents do not just analyze data but perform sequential tasks across the drug discovery lifecycle. This level of complexity requires a shift in leadership from managing people to orchestrating "Human-AI teams." The strategic framework illustrates this transition, showing that integration reaches its peak at Level 3 (Cognitive Orchestration), where AI is integrated into the very fabric of strategic decision-making and ethical stewardship.

4. Regulatory and Ethical Integration

Finally, technological complexity is not just technical but also regulatory. As noted by Stephen (2025), pharmaceutical program management must now account for AI-driven innovation while complying with evolving global health regulations. The integration of Generative AI for regulatory filings—while increasing productivity by up to 5% of global sales (Lee and Kim, 2024)—adds a layer of complexity regarding the transparency and "explainability" of the algorithms used.

2.7 Future insight into using AI in the pharmaceutical field

Future AI integration in pharmaceutical fields fosters innovation, personalised and efficiency in medicine. Capabilities of AI in simulating biological processes and analysing large datasets can make drug discovery and development more cost-effective and efficient, potentially reducing timelines by half and costs by 40% by 2030 (Mottaghi-Dastjerdi and Soltany-Rezaee-Rad, 2024). This technology is also expected to foster highly personalised treatment plans, minimise side effects and optimise therapeutic outcomes, with widespread adoption anticipated in the coming decade. However, despite of the several advancements, some challenges are still there which require to be addressed, offering opportunities for ample further data-driven AI innovations dynamic (Tripathi *et al.* 2021). Through exploring large medical literature and data of patients, AI systems may assist the healthcare professionals in making informed decisions, predicting outcomes of patients and

identifying patterns resulting in better outcomes of health and patient care (Visan and Negut, 2024). The field of AI in medicine has rapidly expanded and is already focusing on taking an influence in areas including monitoring remote patients, drug discovery and virtual health assistants.



Figure 2.7.1: Future dynamics of AI use in the pharmaceutical industry

(Source: Mottaghi-Dastjerdi and Soltany-Rezaee-Rad, 2024)

Adaptation and utilisation of AI-driven tools can enhance medical diagnoses, get treatment outcomes faster than general and prevention of disease, which leads to an efficient and patient-centred healthcare system. Developing a new drug is a long and costly process with a relatively low success rate. For example, the average investment in research and development for a new drug is about \$1.3 billion, with the median development time ranging from 5.9 to 7.2 years for non-oncology drugs and 13.1 years for oncology drugs. Only around 13.8% of all drug development programs result in approved drugs (Kolluri *et al.* 2022). Acknowledging these challenges, AI and machine learning techniques are becoming appealing to the pharmaceutical industry due to their automated nature, predictive abilities, and the expected increase in efficiency. However, the effective application of AI in medicine requires a combination of skills across various disciplines (Ahmad *et al.* 2021). Despite recent promising biomedical and biomarker discoveries, individually

tailored care is still far from being a reality, and therapies developed in preclinical trials are rarely translated into evaluations for their diagnostic and therapeutic potential.

AI is often used in the development of digital computers or computer-controlled robots that can perform cognitive and intellectual tasks similar to humans. These tasks include learning, reasoning, problem-solving, perception, and language understanding (Raza *et al.* 2022). The AI in use today is referred to as narrow AI or weak AI because it is designed for specific tasks like internet searching, facial and voice recognition, controlling and driving cars, and others. However, the long-term goal of the AI community is to create machines that can outperform humans in all cognitive tasks. The AI that involves machines capable of performing all human cognitive tasks is called strong AI or general AI. AI could predict new uses of existing drugs, which could accelerate the process of drug development and costs for cut down (Han *et al.* 2023). This ability is necessary to tackle the urgent needs of medicine, as repurposing of the existing drugs may skip the expensive and lengthy process for safety assessments and preclinical testing.

2.8 Ethical, Legal, and Regulatory Considerations of AI in Strategic Leadership of Pharmaceutical Sector

In this era where AI technologies are dominant, ethical leadership can foster the implementation and development of AI in a manner which aligns with societal norms and ethical values. Leaders must foster a culture of transparency, accountability and fairness, while leveraging AI can enhance the processes of decision-making as well (Ucheagwu-Okoye, 2025). AI technologies evolve; there are different challenges which are continuously arising. However, issues like potential job displacement, data privacy and informed consent must be addressed with a proactive ethical approach. While, Suljic (2025) states that the AI and Governance Report indicates that organisations with a robust framework under AI governance can lower reputational risks by 30% while enhancing accountability and transparency. For example, ethical leaders must ensure that compliance with the law of data protection, including GDPR, is maintained to protect individual privacy rights. Transparency in the AI-driven process of decision-making is crucial, as it enables stakeholders to emphasise how decisions foster trust in AI systems.

Pressing issues are the risk of privacy and data breaches for the centralised AI system. Previous AI models also need a large dataset for training and need consideration of the healthcare supply chain across several sources. These dynamic poses security threats, as a cyberattack on this repository may compromise proprietary pharmaceutical data, patient records and drug supply information

(Odumbo, 2025). Addressing this risk is vital for fostering trust in AI-powered solutions in supply chains while focusing on compliance with regulations of data protection like GDPR and the “Health Insurance Portability and Accountability Act” (HIPAA). Under several regulatory compliance, AI is still one of the significant contributions to medical imaging. The AI-powered stream can also analyse diagnostic predictions like MRI, CT scan and X-ray for analysing anomalies. While AI-powered focus towards solutions to evaluating medical dimensions, ethical considerations are limiting their ability to autonomously control instruments or make intraoperative judgments (Deivayanai *et al.* 2025). Through emphasising a large volume of medical data to recommend suitable measures and find trends, AI can lessen these challenges.

Confidentiality among patients is a fundamental ethical principle of healthcare that safeguards patient information privacy. With AI technologies in healthcare entrepreneurship, there is a concern about the confidentiality and security of data of patient. An AI system also need access to a large volume of health data, which is sensitive to generate insights and train the algorithm (Familoni, 2024). Hence, maintaining the confidentiality of patients is paramount for preventing unauthorised breaches, suits and access to information of sensitive health data. The entrepreneurs of healthcare must foster robust security dynamics like data anonymisation, access control and encryption to protect the confidentiality of patients and comply with privacy regulations in healthcare like HIPAA. Law and regulation of data protection allow in government to store, process and collect personal data, like information as health to ensure the privacy rights of individuals are also taken care.




Figure 2.8.1: Challenges in implementing AI in the pharmaceutical sector

(Source: Allam, 2025)

The implementation of AI in pharmacy has different challenges which must be addressed. The primary barriers are standardisation of data, mitigating biases in the AI models and seamless integration of the existing system of healthcare. Regulatory compliance is another challenge, as AI applications must adhere to evolving and complex regulations in healthcare to ensure data privacy and the safety of patients (Allam, 2025). Skilled workforce needs and high infrastructure of costs pose logical challenges. However, ethical considerations like fairness, accountability, and transparency in decision-making through AI are also complicating the process of adoption. Overcoming this barrier needs a strategic investment, interdisciplinary collaboration and robust validation framework for integrating AI technology in pharmaceutical practices. However, medical negligence also arises when the doctors are relying on an AI system or fail to critically analyse an AI recommendation (Mensah *et al.* 2024). Hence, doctors need to be trained properly, which allows them to analyse the limitations and capabilities of the AI stream and use them as a tool for supporting decisions.

Different types of concerns are raised on precipitous consumption of AI, like safety and security, accountability, ethical considerations, adoption and trust, global competitiveness, environmental harm and economic disruption. Regulations help with aspects like (Pantanowitz *et al.* 2024):

- mitigate different risks,
- ensure that AI-ML is implemented and developed fairly, respectfully and transparently for human rights,
- promote appropriate standards and guidelines,
- assure technology tools are employed, reliable, responsible and safe,
- ensure that AI benefits are shared globally, and
- advocate sustainable practices through AI.

Digital adoption improves occupational safety and has provided opportunities for fostered community engagement. Governance includes establishing policies for data management, ethical use and in integration of technologies. Integrating these ESG metrics in performance evaluation and reporting systems aligns digital transformation goals with sustainability objectives (Ullagaddi, 2024). However, the recent regulatory dynamic is ill-equipped to address challenges posed by AI in clinical pharmacology (Rubinic *et al.* 2024). The existing regulation analyses the issues related to AI, like the misuse of data of patients' needs a proper regulatory insight. It needs the development of a framework that addresses principles of safety, accountability and transparency. In addition to the regulatory measures, there may also be concerted efforts to promote standards and ethical norms in AI and communities of clinical pharmacology.

2.9 Theoretical Framework

2.9.1 Dynamic Capabilities Framework




Figure 2.9.1: Dynamic Capabilities Framework

(Source: Developed based on Jemmy *et al.* 2025)

The research indicates implications of theoretical frameworks as a dynamic measure of understanding the changes with organizational leadership and potentially implications of such changes on both the industry and the leader respectively. The dynamic capabilities framework presents itself through a range of factors and procedures. Dynamic Capabilities Framework includes the three organisation processes as critical components through sensing, seizing, and reconfiguring (Jemmy *et al.* 2025). The first organisation processes that involve identifying the problems and threats cost to the patient and expense. The dynamic capabilities framework implementation that focuses on real structure and assets as a way of adapting to the engine environment. Dynamic capability is identified as an essential development into maintaining organisation competence with changing market circumstances as in implementing the consistent issues of improvement, combination and rearrangement of external and internal affairs. Dynamic capability Framework is identified as a fundamental principle to include the fact that a competitive advantage over the long term requires negotiating business to be developed and utilised on a strategic basis with the implementation of core capacities with the market challenge (Zhang et al. 2025).

Dynamic capabilities Framework is identified through impact on influencing firms to have better achievement and sustenance towards competitive management in the pharmaceutical industry. Dynamic capability theory has been noted to be contributing towards assisting organisation leaderships to identify problem and development as a way of interacting between (Chatzifoti et al. 2024). The theory is noted to integrate information technology and employee engagement through its operation and is identifiably a major enabler of enhancing the firms' capacities in this activity. Implementation of this theory hence is potentially applicable in relation to real situations. The theoretical model emphasizes the importance of leadership for maintaining organisation development capability in a dynamic environment that maintains competition among workers as a way of earning better. The research presented itself as identifying potential implications and positive development into the organisation. It is essential for understanding improvement of data collection and communication processes for the purpose of safety.

2.9.2 Upper Echelon Theory




Figure 2.9.2: Upper Echelon Theory

(Source: Developed based on Dhir *et al.* 2023; Mardjono *et al.* 2025; Tetteh *et al.* 2024)

This theory is identified to be most specifically focused on development and strategies and underline the implication top management members are often focused on providing development associated with strategic choices. The theory focuses on including cognitive structures and value preferences of the organisation top management teams and high-level managers alongside CEOs

that contribute towards creating and influence on strategic choices are identified as the upper echelons (Dhir *et al.* 2023). It is noted that strategic choices are associated with behavioural components that reflect the difference and distinctness of decision makers. This theory implicates the role of the cognitive base of top managers including information awareness regarding future events and accessible alternative options alongside the probability of consequences of each strategic choice.

The theory focuses on expanding on the fact that organisation outcomes are associated with the executive management levels. The theory implies that the results of organisation decisions that includes financial performance and strategic decisions are often contributed to be developed by the top executive that is often subjected to the personalities, values and experience of these executive members (Mardjono *et al.* 2025). It is to be noted that theory presents us as decision makers interpreting situations through their native experience and perspective that make it essentially that their corporate behaviour comprehends are given by psychological and demographic attributes. As per theory it is to be noted that components of values, cognitive styles and experience as a senior manager are understood to have an important impact on the capacity of making strategic decisions and the potential organisation success that is attested in context to pharmaceutical industries.

In association to this, it has been noted that the theory contributes to the comprehension of the pharmaceutical industry being capable of implementing industry 4.0 related integrations for the purpose of company success and sustainability (Tetteh *et al.* 2024). In the context to the study that is being conducted as of presently this implies the connectivity of the organisational structure of the top management and high-level leadership members having an influence on the organisational objectives. The theory focuses on developing a link between the demographic characteristics of senior executives being positive as predictor of organisational outcomes and contributes towards the comprehension of individual managerial cognitions in organisation level consequences. This theory exists that senior executives built their in-challenge interpretation upon the basis of personalities, values and experience that contribute to interpretation upon the decision-making process and strategy assessment.

2.9.3 UTAUT theory




Figure 2.9.3: UTAUT theory

(Source: Developed based on Ratta *et al.* 2025; Adebo *et al.* 2025)

The UTAUT model is focused on contributing towards an assessment on the adaptation and implementation of AI Technology within the pharmaceutical industry adapted by the senior management and top executive members of pharmaceutical industries as a theory focusing on providing an understanding towards adoption of technology advancement. It is to be noted that the theoretical model is applied in the interest of the technology adoption field and presents itself to have to main aspects that involve facilitating conditions and behaviour intention impacting adaptation behaviour among individuals with behavioural intention being determined by performance expectancy, effort expectancy and social influence (Ratta *et al.* 2025). The performance expectancy focuses on the level of individual belief towards application of the technology contributing towards enabling better job performance profits while expectancy implies the perceived is a fuse for the technology system while social influence implies the pressure and competitiveness influencing people for adoption of technology.

This theoretical model is identified to imply that adoption of digital innovation such as AI technology within the pharmaceutical industry. Components such as the facilitating conditions present the level of belief among organisation and technical infrastructure to support the system

(Adebo *et al.* 2025). In the context of the pharmaceutical industry and AI integration in the prospect of strategic leadership, this theory employs the influence of technological innovation and the appeal of features of AI integration and its advancement in the industry. By convincing the top executive level and higher-level management to consider the adoption of such innovative technology, successful implication of strategic leadership is also secured in purpose of guiding leadership through strategic decision making of integrating advancements in change of organisational structure and operation practices through implementation of AI into the organisation.

2.10 Literature Gap

Literature gap analysis is necessary to understand areas that are not discussed in previous studies based on chosen phenomena. There are several literatures based on strategic leadership and digital transformation in recent years (Porfirio *et al.* 2021; Türk, 2023). However, critical gaps can be identified from these literatures regarding AI integration in pharmaceutical industry. A major gap is lack of aligning strategic leadership practices to measure implication of effective AI in pharmaceutical sector. Most studies involve leadership competencies without involving evidence about strategic approaches. Existing literature provides generalized information regarding AI adoption involving technology firms that are not enough for explaining technological adaptation in other organisations.

There is another unexplored area in existing literature like ethical governance of AI in leadership research. Involving empirical evidence is necessary to explore strategies that leaders follow to utilize AI technology (Hu *et al.* 2024). Role of organizational culture on the other side, explained as a mediating factor between leadership and digital transformation outcomes that is acknowledged but not investigated in detail. Understanding approaches to implement strategic leadership that influence culture to foster digital readiness and agility. In previous literature most theoretical models that are applied to strategic leadership in digital contexts lack adaptation to dynamic regulatory environments (Ali, 2023; Patel, 2025). It suggests customized frameworks involving regulatory navigation, ethical considerations and technology adoption are needed to provide practical guidance.

2.11 Conceptual framework

Drawing upon the framework of digital transformation identified by Raisch and Krakowski (2021), this study proposes the **Strategic Leadership framework**. This framework suggests that leadership efficacy in the digital era is not merely a product of technological adoption, but a result

of a maturational shift from passive automation to cognitive orchestration (Iansiti & Lakhani, 2020). By integrating AI as a 'co-pilot' in decision-making, strategic leaders can mitigate the cognitive biases identified by Shrestha et al. (2019), thereby achieving a higher state of organizational resilience and foresight.

Synthesizing the theoretical analysis of Raisch and Krakowski (2021) and the decision-making frameworks of Shrestha et al. (2019), this paper proposes a **Strategic Leadership framework**.

Levels	Pharma Leadership Focus	Sector-Specific AI Application	Examples of Strategic Outcome (ROI/Impact)
Foundational/Analytical To solve legacy inefficiencies	Operational Efficiency	Using LLMs for basic email drafting and internal medical writing summaries.	Administrative Relief: Reduced burnout in medical affairs teams.
	Data-Informed Insights	AI dashboards tracking real-time sales performance and HCP engagement metrics.	Transparency: Clearer visibility into "omnichannel" marketing effectiveness.
Augmented/Integrated Predictive analysis	Predictive R&D	AI-driven "What-If" simulations for clinical trial site selection and patient enrollment.	Risk Mitigation: 20% reduction in trial delays by predicting high-attrition sites.
	Orchestrated Discovery	Managing "Human + AI" labs where AI proposes molecules and humans validate therapeutic logic.	Agility: Shortened "Hit-to-Lead" times; faster response to emerging viral threats.

Cognitive	Visionary Stewardship	AI as a Co-Pilot for ethical drug pricing models and long-term genomic strategy (AI manages immense data complexity of genomic sequencing and real-world evidence (RWE))	Sustainable Alpha: Leaders focus on high-level bioethics and global health equity.
------------------	-----------------------	--	--

Foundations of AI Integration

The following analysis outlines the conceptual framework of this research, which serves to map the intricate relationships between foundational theories, strategic leadership variables, and the eventual integration of technology within the pharmaceutical sector. This research is anchored by three primary academic frameworks that explain the "why" and "how" of organizational change:

1. The Theoretical Foundation

- **Dynamic Capabilities Framework:** This theory provides the foundation for understanding how pharmaceutical firms reconfigure their internal resources and expertise to adapt to the digital revolution.
- **Upper Echelon Theory:** This perspective posits that the strategic choices and AI integration successes of a firm are a direct reflection of the values, cognitive biases, and background of its top-level leaders.
- **UTAUT Theory (Unified Theory of Acceptance and Use of Technology):** This model is utilized to explain the factors influencing a leader's or organization's intention to adopt complex digital innovations, such as blockchain or AI.

2. Independent Variables (The Drivers of Change)

The framework identifies three core variables that act as catalysts for transformation:

- **Strategic Leadership Orientation:** Strategic leadership in the AI era requires more than just a vision; it necessitates the integration of diverse responsibilities to navigate technological complexity.
- **Leadership Competence in AI and Digital Innovation:** Successful digital change requires leaders to possess a specialized blend of subject-matter expertise, computer science proficiency, and statistical literacy.
- **Organizational Readiness (Culture, Infrastructure, and Resources):** Leadership must pledge generous investments in infrastructure and data literacy to ensure the organizational culture is prepared for digital transformation.

3. Dependent Variable (The Strategic Outcome)

- **AI Integration in the Pharmaceutical Industry:** The ultimate focus is the successful implementation of AI to redefine interactions with patients and healthcare professionals, streamline R&D, and secure supply chains.




Figure 2.11: Conceptual framework

As illustrated in the diagram, the relationship is multidirectional and symbiotic:

1. The Dynamic Capabilities Framework and Upper Echelon Theory directly shape the Strategic Leadership Orientation and Competence levels within the firm.
2. There is a strong, direct correlation between Leadership Competence and the effectiveness of AI Integration, with research suggesting that AI-driven performance systems can yield productivity gains.
3. Successful AI Integration does not just rely on Organizational Readiness; it actively contributes to it by fostering a more innovative work culture and enhancing the empirical data available to leaders.

2.12 Summary

This sector involves existing literature on AI integration and role of strategic leadership. Pharmaceutical industry required advanced technologies to improve health outcomes of individuals and enhance satisfaction level. Digital innovation in pharmaceutical industry is also discussed in this section. Theoretical frameworks that explain implication of AI involving “theory of reasoned action (TRA)”, “human society theory (HST)” and “UTAUT theory” are discussed here. While the literature identifies the potential of AI (Lee & Kim, 2024) and the risks of digital transformation (Klimanov et al., 2021), it fails to provide a sector-specific evolutionary path for leadership. This research addresses this void by introducing the **Strategic leadership framework**, moving beyond theoretical productivity to a structured framework for strategic orchestration. In identifying key gaps in leadership-focused research previous literature are reviewed. This chapter highlighted need for a deeper understanding of the way strategic leadership enables AI adoption. These frameworks will serve as foundation for methodology of this present study.

CHAPTER III: METHODOLOGY

3.1 Introduction

This section involves research methodology that is appropriate to investigate relationship between strategic leadership and integration of AI in pharmaceutical sector. Research design, operationalization of constructs, purpose of this research work and data collection method are incorporated in this chapter. This study follows a mixed-methods approach involving pharmaceutical professionals to align findings with research aims. This dual approach ensures a comprehensive understanding of both strategic and operational dimensions of technological adoption in pharma. The methodology is designed to validate conceptual framework introduced in above section and answer research questions with scientific rigor. This chapter is crucial to provide structure for research design and make it effective research. In addressing research gaps and increasing acceptance of this research, selecting relevant methods are extremely important.

A sample section process is involved here that guides to identify relevant participants. Data analysis processes and ethical considerations are also mentioned that are necessary to manage the credibility of research. Methodological framework focuses on ensuring objectivity, validity and reliability in findings. Through adopting analytical and descriptive approaches, the study focuses on balancing the theoretical inquiry of the thesis with its practical evidence. This helps in conducting a systematic evaluation of organisational factors and leadership variables influencing the integration of AI while ensuring a robust vision in the pharmaceutical industry paradigm.

3.1 Overview of the Research Problem

Digital transformation revolutionises pharmaceutical industry through enhancing its efficiency in clinical trials and production of generic medicines. Advanced technology like AI plays a pivotal role in drug discovery and patient engagement. Human intelligence has a significant impact on implementing effective AI on pharmaceutical sector and achieving success (Kulkov, 2021). In this scenario, strategic leadership has become important to enhance capacity of an organization in promoting technological development. Strategic leadership is one of the major factors for ensuring growth of technology in organisations and it is necessary to invest a significant amount in skilled

individuals (Cortes and Herrmann, 2021). Leaders must navigate regulatory complexities and foster an innovative culture to realize potential of innovation in this digital era.

Integration of AI can be monitored through metrics regarding its adoption scope and improving organisational operation after involving AI. Acceptance of advanced technologies are quite high in pharma due to enhancing demand for clinical trials (Chopra *et al.* 2023). Technology can accelerate drug development processes that are necessary for improving health outcomes across the globe. AI is not only effective for enhancing drug production, but it is also effective for managing supply chains (SC). These practices can reduce SC disruption and ensure timely delivery of resources required for medicine production. Strategic leadership maintains this process and contributes to achieve organisational goals. In investigating requirements of people and creating infrastructure to fulfil consumer demand regarding pharmaceutical industry, AI is essential (Allam, 2025). Usage of AI is optimised through skilled leaders as they have knowledge about effective implication.

Organizational performance may be elevated through using objective and subjective indicators. Perceptions of leaders, employees regarding technological usage are considered as subjective measures. Measuring timeline of production and drug delivery can be viewed as objective. Strategic leadership can promote ethical practices in incorporating AI technology to develop essential drugs (Patel, 2025). Other than that, mediating variables like data governance, regulatory compliance and talent availability are also considered as effective factors for effective technological incorporation. It is necessary for leaders to develop such skills to promote technologies to get desired outcomes.

3.2 Operationalisation of Theoretical Constructs

Investigating effectiveness of strategic leadership in AI integration among pharmaceutical organisations theoretical framework are important. Present research draws upon three foundational theories like TRA, HST and UTAUT. These frameworks guide operationalisation of key constructs and helps to inform design of survey instruments and thematic analysis. TRA suggests individual behaviour and stated behavioural intentions of leaders are shaped through attitudes along with subjective norms (Fan and Ukaegbu, 2024). In promoting innovation, managing change and fostering AI adoption, strategic leadership approaches play an important role. Attitudes of leaders towards AI helps to measure capability of pharmaceutical organisations to achieve its goals. This

theory is appropriate to suggest role of leaders and guide organizations in right direction to experience success.

UTAUT can be used to examine AI integration in enhancing organisational performance. It describes performance expectancy, social influence, and facilitating conditions as these are crucial determinants of technological adoption (Marto *et al.* 2023). This research revolves around impact of strategic leadership in enhancing involvement of AI among Pharma. In understanding application of AI in organisations and its effectiveness to improve organisational operation UTAUT model plays a crucial role. This study involves certain theories that are related to strategic leadership practices in enhancing overall performance of firms. Real-life implications of leadership approaches can be described through using appropriate frameworks. Technological transition can create issues for pharmaceutical organisations and models like UTAUT support organizations in such situations.

There is another model like HST involved in this study to highlight different activities of leaders to contribute to technological development. AI can be used for different purposes, and it is necessary to ensure its ethical application. This theory shows values of leaders during adapting advanced technologies and suggests necessary behaviour of individuals (Senturk, 2023). These aspects needed to be discussed for developing better understanding regarding strategic leadership. Such operational constructs provide multidimensional analysis that improve approaches of leaders regarding AI implementation. It can improve methodology designs and involve approaches that can support aims of the present research work.

Digital transformation in pharma is no longer an optional efficiency gain; it is a structural revolution affecting everything from drug discovery to patient engagement. However, the successful implementation of AI is inextricably linked to human intelligence and strategic vision. Leaders must act as architects of an innovative culture while navigating the dense regulatory thickets of global health. In this context, AI is not merely a tool for production but a critical infrastructure for managing complex supply chains and fulfilling surging consumer demands.

The pharmaceutical industry is currently navigating a structural paradigm shift, where digital transformation is no longer a peripheral advantage but a core requirement for survival. This research identifies the challenge as the "**Leadership Competence Gap**"—the disconnect between

the vast potential of AI and the strategic capacity of leadership to integrate these tools effectively within a highly regulated environment.

Digital transformation is revolutionizing the pharmaceutical sector by fundamentally enhancing efficiency in clinical trials and the production of generic medicines. Advanced technologies, specifically Artificial Intelligence (AI), play a pivotal role in drug discovery and patient engagement. However, the success of these integrations is not purely technical; research confirms that **Human Intelligence** remains the decisive factor in implementing effective AI strategies and achieving long-term success (Kulkov, 2021).

In this landscape, AI serves as an essential engine for:

- **Accelerating Drug Development:** Speeding up processes necessary for improving global health outcomes.
- **Supply Chain (SC) Resilience:** Reducing disruptions and ensuring the timely delivery of resources required for medicine production through predictive analytics (Allam, 2025).
- **Market Responsiveness:** Creating the infrastructure required to fulfill complex consumer demands in the modern pharmaceutical industry.

Strategic leadership has emerged as the primary variable for enhancing an organization's capacity to promote technological development. It is one of the major factors ensuring the growth of technology, requiring significant investment in skilled individuals and infrastructure (Cortes and Herrmann, 2021). Within the AI era, leaders must navigate two primary challenges:

1. **Regulatory Complexity:** Ensuring AI adoption adheres to the rigid legal frameworks of the pharma sector.
2. **Cultural Stewardship:** Fostering an innovative organizational culture that allows for the full realization of AI's potential.

3.3 Research Purpose and Questions

Purpose of the research

Essentially, the primary research objective is to define the transition from foundational '**Passive Automation**' (Level 1) to advanced '**Cognitive Orchestration**' (Level 3), utilizing the Strategic Leadership Framework as the evaluative benchmark.

Primary Purpose: To evaluate leadership competencies that foster scalable AI adoption while honoring regulatory sensitivity.

Central idea: These focus on the state of AI integration, governance mechanisms, strategic alignment, and the ethical management of algorithmic bias in high-stakes pharmaceutical applications.

This study is dedicated to exploring importance of effective AI integration in pharmaceutical sector through adopting a strategic leadership approach. Analysis of effective leadership practices to enhance effectiveness of technologies and expand ability of pharma to fulfil customer requirements. Investigating approaches of leaders to ensure successful adaptation and utilisation of AI technology are focus of this research. Evaluation of challenges that leaders experienced during AI implication is an aim of this study that helps to suggest potential recommendations.

Questions

- How to analyse the recent state of integration of AI in the pharmaceutical sector, which assists for exploring effective strategies, implementation pitfalls and success patterns?
- What are the governance mechanisms and leadership competencies that foster scalable AI adoption involving case examples like AstraZeneca's governance model along with AI upskilling initiatives?
- How to analyse strategic alignment processes that align AI adoption with organizational vision and operational imperatives including change management approaches as articulated in recent frameworks?
- What are ethical considerations like data privacy, algorithmic bias, and transparency related to leadership framework that honours high stakes and regulatory sensitivity of pharmaceutical applications?

- How to identify a relevant practical leadership model that can balance technical, strategic, governance and cultural dimensions of AI implementation in a large-scale, regulated pharmaceutical industry?

3.4 Research Design

A mixed method is used in this research for collecting data and relevant approaches have taken to design this research. *Pragmatism research philosophy* is followed to structure this study as it allows to combine qualitative and quantitative approaches in addressing research questions. This method is effective to find solutions to real-world issues and ensure practical applications (Ormerod, 2021). In providing contextual understanding this research philosophy plays an important role.

Pragmatist philosophy emphasises that the actions of humans cannot be separated from experiences of the past and from beliefs that originated from the past experiences. Human thoughts are also intrinsically linked with the action. People are taking actions based on actions possible consequences and use action outcomes for forecast similar action consequences in future. One of the main contentions of pragmatist philosophy is that meaning of human beliefs and actions is found in its consequences. The external forces do not emphasise humans; they are also capable to shape their experience by their intelligence and actions. Pragmatists accept that reality is not based on static, it transforms at each turn of events. Pragmatism is obtained from pluralistic mixed methods research (Elgeddawy and Abouraia, 2024). Pragmatists also value both the quantitative worldview of objectivity and the subjective experience of stakeholders. They locate a research problem in a specific context.

Pragmatism emphasises three types of widely shared ideas of pragmatism, which emphasise that pragmatists are focused on the experience of nature, far from other philosophies which underscore nature of reality. First, “actions cannot be separated from the situations and contexts in which they occur”. Second, “actions are linked to consequences in ways that are open to change”, indicates that, if action situations change, their consequences also change, regardless of actions being same. Finally, “actions depend on worldviews that are socially shared sets of beliefs”. Pragmatists maintain that no individual has identical experiences, so their views are also not identical. However, as per Hampson and McKinley, (2023), pragmatists provide a “research is what works” type of

argument. Pragmatist philosophy understood that the individual is free to believe anything they want.

Deductive research approach is utilized in this study due to its ability in describing complex phenomena. Choosing methods in a careful manner is necessary to maintain the needs of research and fulfil its demand. Deductive approach starts with theory that is necessary to provide detailed information about research problems. This approach provides a chance to test hypotheses and ensure logical flow of ideas (Chen and Chen, 2024). This study needs a structure design that should involve a descriptive research design method. It assists in providing both descriptive and numerical data that may satisfy demand for present research. This process is effective to involve empirical evidence and enhance quality of findings. Appropriate methodology uplifts this study and makes it useful for providing information regarding usefulness of strategic leadership in maintaining AI. Other than that, it guides data collection process and research design in the right path. Research design and other chosen strategies help to generalise conclusions.

Five steps in the deductive research process are (Kumar and Ujire, 2024):

1. *Hypothesis Formulation*: First step in the deductive research develops a hypothesis and estimate how variables are related. Mostly, a hypothesis is developed on research or theories that are already done.
2. *Research Design*: The second step is to design a research study for testing the hypothesis. This indicates choosing a research method that allows for determining what require to be measured and figuring out how to look at and collect the data.
3. *Collecting Data*: Once the research design is set, different methods, like surveys, observational or experimental studies, are adopted to collect data. Basically, a standard protocol used to collect data to ensure it is consistent and correct.
4. *Data Analysis*: In the fourth step, the data collected was analysed to see if it disproves or supports the hypothesis. The goal is to explore if data refutes or supports the hypothesis of the thesis, through statistical methods to analyse the patterns and links among variables of the study.

5. Concluding: The final step concludes the dynamic of data analysis. If the hypothesis is supported, it can also be used to construct generalisations about the population. However, if the hypothesis is wrong, the process must be started again by the researcher.

Five steps of the deductive research are repeated, and researchers can return to the early steps if they find new ways or new information by looking at things. In contrast to an inductive research, deductive research focuses on testing hypotheses or theories that are already made.

Present research work depends on the methodology design as it supports precipitation selection process as well. This method provides a holistic understanding about present research problem. Structuring a study and developing research work in a systematic manner needs supportive design. Mixed method helps to generalise findings of research that can provide important insight regarding research (Nagpal *et al.* 2021). Quantitative component on the other side involves a structured survey to collect authentic information. This survey captures data on leadership practices, usage of AI in pharma and organizational outcomes. Based on research design further steps are completed involving identification of population and sampling.

3.5 Population and Sample

Target population for the present research comprises professionals from pharmaceutical industry. Participants involving executives, managers and other staff members can provide exact internal information about AI implication. Selecting a significant number of participants is necessary to get authentic information (Taherdoost, 2021). In this present research 200 participants are involved in a quantitative survey that is collected through primary data collection. Secondary data collection process involved previous literatures published in reputed journals. Selecting participants from a huge population helps to provide desired information regarding chosen research problems. Participants are only chosen from pharmaceutical industry to get important data about strategic leadership and AI outcomes.

In this study ***purposive sampling*** is used to select participants from a particular sector. Purposive sampling ensures that data is collected from respondents who are most knowledgeable in the subject area (Tajik *et al.* 2024). This sampling is followed in research that involve specific industry and research questions regarding a particular sector. It also aligns with mix-method and supports data

collection process in an effective manner. In selecting subgroups from a large population this process can be quite effective. Present research requires this sampling process to ensure credibility of research that makes it acceptable among readers. Participant selection is an important process to shape an entire study in a scientific way.

3.6 Participant Selection

Selection criteria involve certain aspects like job role, industry and experience of employees. In this research employees from different departments tried to be included to get detailed data. These practices can capture cross-functional perspectives of employees. Experienced employees can suggest evolution of leadership due to digital transformations. These criteria are strictly followed throughout this study for achieving required results. Such process is followed to involve participants who can represent a whole population.

Participant selection is guided by the requirement to obtain representative, reliable, and relevant insights on the pharmaceutical industry based on AI integration and strategic leadership. The targeted population are professional active executives, senior and middle managers, technical staff and team leaders with experience with from less than 1 year to 20 years and above. A purposive sampling method was adopted in mixed methods research as it can provide rich and context-specific insights (Tajik *et al.* 2024). This sampling enables the researchers to focus on population characteristics that are of interest and yield detailed insights. The author Tajik *et al.* (2024) also mentioned in this study that “the justification [for purposive sampling] is that selecting participants from the population is reasonably decided by researchers who are familiar with the population”. Therefore, for accumulating relevant specific information, the purpose method of data sampling has been chosen for this thesis.

The inclusion and exclusion criteria of the study are as follows:

Primary Data Collection

Inclusion Criteria

- Employees from the pharmaceutical sector
- Participant who has experience of at least 1 year in their current role

- Informed Consent

Exclusion Criteria

- Employees from non-pharmaceutical industries
- Participants with less than 1 year of experience in their current role
- Decline to provide informed consent.

Secondary Data Collection

Inclusion Criteria

- Publications after 2021, to ensure recent and relevant insights.
- Publications available in English.
- Full-text articles must be accessed and reviewed in detail.

Exclusion Criteria

- Publications before 2018, to avoid outdated technologies or practices.
- Articles not available in English can hamper detailed analysis.
- Publications with inaccessible full text cannot offer a thorough evaluation of the study outcome.

Ethical considerations are also strictly followed, like voluntary participation, informed consent and confidentiality. Through select participants based on role, experience and department, the study focuses on the data collected correctly indicates AI integration results, organisational practices, and leadership effectiveness, for enhancing the applicability, credibility and validity of findings of the research.

3.7 Instrumentation

The present research implements a primary and secondary data collection and evaluation methodology that would include processing the information hence accumulated into finding through integration of prospective research instruments. The research follows a mixed method for accumulation of data and evaluating the information into comprehensible findings in association to the research topic. The study focuses on choosing participants from the pharmaceutical industry for the purpose of sampling a population of 200 participants that will then be needed to profile insights through the implementation of a research survey. Instruments of primary data accumulation involve surveys and questionnaires that included sample surveys (Mazhar *et al.* 2021). The research will be implementing a questionnaire format for the purpose of accumulating answers through the responses of the participants from the service that will be conducted for the purpose of quantifiably accumulating the answers in a structured manner. Doing so follows developing a constructed structure of questions laid out and provided to the respondents as an instrument of gathering information from different people.

This is focused on being a primary data research instrumentation that has been identified as the quantitative segment of the waste method approach that has been applied for the purpose of this research study. In particular context to the secondary qualitative data collection aspect of the mixed methodology research that the study implemented for the purpose of accumulating data. Qualitative research focuses on expanding integration of analytical methods for understanding research in a descriptive manner. The selected qualitative and secondary data collection instrument has been identified to be thematic analysis. It is noted that qualitative researchers include a common understanding of thematic analysis being associated with the identification of recurring patterns that has been presented by researchers (Lochmiller, 2021). They implement thematic analysis as a means for identifying the different things of research in association to the research objectives and concepts better associated to AI integrations in the pharmaceutical industry and implementation of strategic leadership.

3.8 Data Collection Procedures

The study employs a mixed-method approach for collecting data by using both primary and secondary methods to offer a comprehensive dynamic of integrating AI in pharmaceutical and strategic leadership roles to facilitate this method. The strategy for data collection is designed to

balance the empirical insight from professionals' understanding of the industry with the published research.




Figure 3.8.1: Types of Primary and Secondary Data Collection Methods

(Source: Taherdoost, 2021)

Primary Data Collection

The primary data is collected through a structured survey questionnaire distributed among 200 employees from the pharmaceutical sector. The participants are purposely selected to ensure professional exposure for AI-related processes, digital transformation and strategic leadership in their organisation. Questions are developed using a five-point Likert scale ranging from “strongly disagree” to “strongly agree” for capturing nuanced perceptions of the study domain. A

questionnaire is the main dominant way for collecting primary quantitative data, and making the data collection process standardised (Taherdoost, 2022). Thus, it also ensures an accurate and faster process of data collection and enables data processing. The questionnaire is divided into different key sections. The first detention involves demographic variables, including gender, age, role in organisation and year of experience, to explore possible variation in different groups. The second section emphasises strategic leadership competence and orientation, focusing on capabilities of digital innovation, adaptability, decision-making and vision. The third section emphasises organisational readiness, like resource allocation, cultural openness and infrastructure support for AI initiatives.

For conducting in large-scale data collection process, this survey is distributed through email to different pharmaceutical sectors that use AI and conduct strategic leadership approaches in their organisations. Participants are assured of confidentiality and anonymity, which can allow them to minimise risk for socially desirable answers. The final dataset is then prepared for statistical analysis through the use of appropriate software, enabling correlation identification between AI adoption, organisational readiness, and leadership, and hypothesis testing. As per Mazhar *et al.* (2021), the features of the Good Questionnaire are

- Questions must be small and to the point
- Questions may be in sequence
- Questions must proceed in logical sequence
- Technical terms are not allowed in questionnaires
- Questions should be multiple-choice, dichotomous or open-ended
- Questions that can affect respondents' answers must be avoided
- Questions should involve all aspects of the challenges related to the topic

Secondary Data Collection

Secondary data collected through using different existing literature from websites, Sage Pub, Google Scholar, journals, Scopus, articles, etc. The search was limited to publications from 2021 onwards for analysis of the recent evolving trends in the pharmaceutical sector. Academic scholarly articles and journals are some of the good sources for the secondary data analysis process. Secondary data is important for research that allows for getting information from the past studies as a basis for implementing the required background and research information (Taherdoost, 2021).

It also allows for designing a study and offers a baseline that helps in comparing the primary outcomes.

The mixed-method data collection design offers a holistic understanding of quantitative survey and qualitative existing data analysis uncovers the underlying paradigm which shapes those patterns in the data collection phase.

3.9 Data Analysis

Analysis of collected data is assembled around a mixed-methods design of research, a combination of quantitative survey data that is analysed through using excel and qualitative thematic analyses through existing studies and reports.

Primary Data Analysis

Quantitative dataset drawn from responses of 200 respondents is analysed by Excel software for measuring relations and correlation and identifying trends on the impact of strategic leadership on integration of AI. Excel has quality of digging deeper into the analyst's data and making it an efficient instrument than other available standard multi-dimensional, spreadsheets and databases tools (Al Marufet *al.* 2022). Results of the quantitative analysis provide evidence of measurable influences on organisational structures and leadership practices of AI adoption, contributing to findings based on objectives that can further allow to inform practical recommendations. This analysis involves the statistical evaluation to be carried out through frequency analysis and reliability analysis.

Secondary Data Analysis

The secondary dataset, which involves academic articles, regulatory publications and industry reports, is analysed by using thematic analysis to emphasise sights, identify concepts and patterns beyond numerical results. Thematic analysis is a popular choice for analysing secondary qualitative data as it helps readers by emphasising the study goals along with analysing data. Thematic analysis provides a tremendous flexibility in conducting research, which helps researchers with a wide range of disciplinary perspectives and theories. Apart from that, conducting thematic analysis allows for sorting the overall dataset that identifies the practices, phrases and relationships in the previous study. Thematic analysis is a conceptualisation of qualitative research that holds that “qualitative researchers study things in their natural settings, attempting to make sense of, or to interpret,

phenomena in terms of the meanings people bring to them” (Lochmiller, 2021). Thematic statements rely on the development of robust categories for produce themes.

However, the final stage includes integrating qualitative and quantitative findings to ensure triangulation. While the survey offered statistical evidence of relationship between AI adoption and leadership, thematic analysis reinforces these findings in a contextual depth.

3.10 Research Design Limitations

While this study employs a rigorous **Deductive-Pragmatist** methodology, certain inherent limitations must be acknowledged to provide a transparent and balanced interpretation of the findings. Recognizing these constraints ensures that the recommendations for the pharmaceutical industry are applied with the necessary contextual caution.

1. Sampling and Generalizability Constraints

The study utilizes **purposive sampling** to target professionals with specific expertise in AI and strategic leadership. While this ensures "information-rich" data from experts, it introduces a potential **selection bias**. Furthermore, the sample size of 200 participants, while statistically significant for the scope of this research, may not fully capture the diverse operational challenges found in small-scale biotech startups versus large-scale multinational pharmaceutical corporations (MNCs).

2. Subjectivity and Response Bias

The reliance on primary survey data introduces the risk of **social desirability bias**. Respondents may overstate the digital maturity of their organization or the efficacy of their own leadership orientation to align with industry "best practices." Additionally, the **subjective indicators** of performance—based on the perceptions of employees and leaders—may vary based on individual experience levels and departmental cultures.

3. Temporal and Technological Velocity

The rapid pace of AI evolution (particularly Generative AI and Agentic Workflows) presents a temporal limitation. The "recent state" of integration analyzed in this study (2024–2026) is based

on a snapshot in time. As technologies evolve, the specific leadership competencies required for Level 3 (Cognitive Orchestration) may shift, potentially impacting the long-term applicability of the findings.

4. Secondary Data and Publication Bias

The **thematic analysis** of secondary data is restricted to published literature and industry reports from 2021 onwards. This approach is susceptible to publication bias, where success stories of AI integration are more frequently documented than implementation failures or "pitfalls." This may skew the qualitative findings toward a more optimistic view of AI's current readiness in the sector.

Mitigation Strategies

Regardless of this limitation, the study design focuses on incorporating **triangulation** among secondary and primary data, focuses on mitigating the limitation and offers an actionable, balanced and credible understanding of strategic leadership framework, which influences on integration of AI in the pharmaceutical sector.

This method ensures that findings are balanced and reliable. Triangulation involves examining the research problem from multiple perspectives—specifically by combining the quantitative data from the professional survey with the qualitative insights from the secondary literature review.

The primary goal of this approach is to cross-verify the results. By comparing the statistical trends gathered from the 200 pharmaceutical professionals against the documented trends in recent industry reports (2021–2026), the study can confirm whether the survey responses align with broader industry patterns.

Using a triangulation strategy provides several key advantages for this study:

- **Validation of Data:** It strengthens the credibility of the research by showing that the conclusions are supported by more than one type of evidence.
- **Reduction of Bias:** Relying on a single data source can lead to skewed results. Comparing survey data with published industry case studies helps to minimize potential respondent bias and provides a more objective view.

- **Comprehensive Insight:** While the quantitative survey identifies "what" is happening regarding AI adoption, the qualitative thematic analysis helps explain "why" these trends are occurring, offering a deeper understanding of the leadership challenges involved.

In summary, this method ensures that the results are not only statistically relevant but also contextually accurate within the current pharmaceutical landscape.

3.11 Conclusion

The methodology established in this chapter provides a structured and comprehensive framework for investigating the critical link between strategic leadership and AI integration within the pharmaceutical sector. By adopting a **mixed-methods research design**, the study achieves a multidimensional understanding of the problem, balancing empirical breadth with contextual depth.

The research leverages two primary data streams to ensure a robust analysis:

- **Primary Quantitative Data:** A structured survey of 200 pharmaceutical professionals provides the first-hand data necessary to identify measurable relationships and statistical patterns in AI adoption.
- **Secondary Qualitative Data:** A systematic thematic analysis of existing literature and industry reports offers valuable insights into the broader opportunities, challenges, and cultural considerations affecting the industry.

The central focus of this methodology is the evaluation of leadership practices and their role in enhancing technology effectiveness. By investigating the specific approaches leaders take to ensure the successful adaptation of AI, this research can identify where current strategies succeed or fail. Furthermore, the analysis of the challenges faced by leaders allows the study to move beyond theory and propose practical, evidence-based recommendations. The quantitative data focuses on measuring relationships and patterns, whereas qualitative data focuses on patterns, opportunities, challenges and considerations based on the adoption of AI.

In summary, this methodology chapter provides a rigorous pathway for analyzing how strategic leadership influences the AI-driven pharmaceutical landscape. The structured research design

ensures that the resulting findings will be capable of informing future organizational policies, technological investments, and leadership development strategies in this highly competitive and innovation-driven industry.

CHAPTER IV:

RESULTS

4.1 Introduction

The following chapter focuses on presenting the primary and secondary data that have been accumulated in the study that has been evaluated in the focus of a mixed method of research

integration for understanding both quantifiable and qualitative inside on the subject. The chapter focuses on presenting the primary data that had been collected through the survey instrument to be presented in the form of a quantitative research data evaluation that has been presented through frequency analysis of the hen made by the responding sample population of studies. The finding set is then presented through the frequency data analysis by understanding the quantifiable assessment of the finding hence presented.

The following chapter has also focused on presenting the qualitative data that had been equal what's the inheritance, defining that presented themselves in the progressive layout of exploring the objectives' themes. The qualitative data that is accumulated through secondary data collection procedures to include research articles and case narrative from websites as a means of exploring the research objectives as a geometric analysis. It is to be noted that the findings of the research is presented through an implication of developing and understanding for the research objectives in association to be presented in alignment to the research objectives in the partnership of exploring the qualitative data that has been collected through the secondary data collection procedures to understand the thematic patterns identified the research objectives selected. The findings present itself for the purpose of expanding the opportunity for AI integrations within pharmaceutical industries being understood.

4.2 Primary Data Analysis

4.2.1 Reliability test

Before performing the primary data analysis, it was essential to evaluate the internal consistency of the survey instrument. Reliability testing ensures that the questionnaire items are consistent and that the measurement tool would yield the same results if the study were repeated under similar conditions.

The standard statistical tool used for this purpose is Cronbach's Alpha. This coefficient measures the inter-correlation between the 20 items in the questionnaire to determine if they collectively measure the same underlying construct—namely, the impact of strategic leadership on AI integration.

Reliability Statistics	
Cronbach's Alpha	N of Items
.950	20

Table 4.2.1.1: Reliability Test

As shown in Table 4.2.1.1, the reliability test yielded a Cronbach's Alpha value of **0.950**. According to academic standards (Izah et al., 2023), the interpretation of Alpha values is generally categorized as follows:

- **alpha value > 0.9:** Excellent Reliability
- **0.8 > alpha value > 0.9:** Good Reliability
- **0.7 > alpha value > 0.8:** Acceptable Reliability

The reliability test for the purpose of evaluating the validity and inter relation that has been applied, and it has been acknowledged that the Cronbach's Alpha value present itself to be 0.950 there by indicating that for the implementation of the questionnaire has presented that the data is highly reliable in the context of primary findings. This exceptionally high value indicates that the 20 items are highly interrelated and that the primary data collected from the 200 pharmaceutical professionals is very reliable. This high level of reliability provides a strong foundation for the subsequent stages of analysis, such as correlation and regression, as it confirms that the measurement instrument was both stable and precise in capturing the respondents' perceptions. To ensure the research findings are accurate and meaningful, the survey instrument was subjected to a rigorous validity assessment. Validity refers to the extent to which an instrument measures what it claims to measure. For this study, two primary forms of validity were established: Content Validity and Construct Validity.

4.2.2 Demographic Statistics




Figure 4.2.2.1: Age

(Source: author)

The age distribution reveals a diverse participant base, which enriches the validity of the findings. Most respondents are between 25–30 years (35.5%) and below 25 years (33.5%). This shows that younger professionals dominate the segment of the pharmaceutical workforce surveyed, likely reflecting the industry’s reliance on early-career employees who are more adaptable to technological innovations like AI. The 31–35 (10.5%), 36–40 (8%), and 40 and above (12.5%) categories collectively represent the experienced employees. Their presence can help ensure that perspectives from mid-career and senior professionals are captured, balancing youthful enthusiasm with seasoned judgment. However, the data highlights a workforce skewed toward younger professionals, potentially signalling strong readiness for AI-driven transformation.




Figure 4.2.2.2: Gender

(Source: author)

The gender profile shows a predominance of male respondents (58%), followed by female participants (39%), with a small representation of others (3%). While the pharmaceutical sector often underscores diversity, the sample mirrors the common gender gap, as in other science-driven industries, where mainly men are occupying a larger proportion of roles in technical and leadership domains. However, the 39% presence of females also offers a notable dynamic highlight growing sector of inclusivity. The inclusion of a small percentage exploring as “Other” shows increasing awareness of gender diversity beyond binary, which adds to study's representativeness.




Figure 4.2.2.3: Job role/position

(Source: author)

The job role distribution indicates that most respondents are staff (39.5%) and team lead (30.5%). This concentration of operational and mid-tier employees is significant because they are the ones who directly engage with workflows and technologies, making their views on AI adoption particularly valuable. In addition, executives (9.5%), middle management (9.5%), and senior management (7%) bring leadership perspectives that are crucial to the study's focus on strategic leadership. The 4% "Other" category further adds diverse roles that may not neatly fall into standard hierarchies. Thus, Figure 4.2.3 demonstrates a sample that provides insights across hierarchical levels, enabling the study to draw connections between leadership strategies and workforce acceptance of AI.




Figure 4.2.2.4: Years of Experience

(Source: author)

The distribution of industry experience shows that 40.5% of respondents have less than one year in the pharmaceutical sector, followed by 36.5% with 1–5 years. This indicates that a majority are relatively new to the industry, making up 77% of the sample. Such a profile reflects a workforce in its formative professional stages, where openness to technological transformation like AI tends to be high. However, experienced voices are also present: 6–10 years (10%), 11–20 years (6%), and more than 20 years (7%). Their inclusion provides critical insights into long-term strategic perspectives and institutional memory.

4.2.3 DV: AI Integration in the Pharmaceutical Industry

Q: Artificial intelligence in pharmaceutical sector significantly improved research productivity, enhanced regulatory compliance, reduced development timelines and strengthened overall strategic competitiveness		
	“Frequency”	“Percent”
“Strongly Disagree”	11	5.5

“Disagree”	17	8.5
“Neutral”	10	5
“Agree”	52	26
“Strongly Agree”	110	55
“Total”	200	100

Table 4.2.3.1: Frequency analysis of the question based on DV

The data presented above, through Table 4.2.3.1 on AI integration, highlights overwhelmingly positive perceptions within the pharmaceutical sector. A combined 81% of respondents (Agree 26% + Strongly Agree 55%) believe that AI significantly improves research productivity, enhances regulatory compliance, reduces development timelines, and strengthens strategic competitiveness. Only 14% (Strongly Disagree 5.5% + Disagree 8.5%) expressed reservations, while a small fraction (5%) remained neutral. This distribution emphasises strong confidence in the transformative potential of AI, indicating that both employees and leaders recognise its value across multiple dimensions of the industry.

4.2.4 IV1: Strategic Leadership Orientation




Figure 4.2.4.1: Frequency analysis of question one based on IV1

(Source: author)

The findings of the above, through the Table and Figure, reveal strong support for leadership's role in articulating a vision for AI adoption. Nearly 80% (Agree 32% + Strongly Agree 48%) believe leaders successfully align AI initiatives with long-term organisational goals. Only 12.5% expressed disagreement, while 7.5% remained neutral. This shows that leadership vision is widely recognised as a guiding force in integrating AI into the pharmaceutical sector.




Figure 4.2.4.2: Frequency analysis of question two based on IV1

(Source: author)

The data shows that leadership commitment to AI integration is strongly acknowledged. A large proportion of respondents (81.5%) agreed or strongly agreed that senior leaders prioritise resources, strategic discussions, and budgets for AI. Only 11.5% disagreed, while 7% remained neutral. This underscores leadership's readiness to invest in AI as a strategic asset




Figure 4.2.4.3: Frequency analysis of question three based on IV1

(Source: author)

The results of Table 4 and Figure 4.2.8 illustrate a clear consensus that top management fosters a culture of innovation. About 83% (Agree 30.5% + Strongly Agree 52.5%) affirmed AI adoption is embedded as a strategic planning priority. A small minority (11.5%) expressed disagreement, while 5.5% remained neutral. This exhibits that leadership is actively shaping organisational culture to embrace AI.




Figure 4.2.4.4: Frequency analysis of question four based on IV1

(Source: author)

The above table and figure emphasise leadership’s role in consistently communicating AI’s importance. A strong majority (81.5%) agreed or strongly agreed that leaders build confidence, awareness, and alignment through effective communication. Only 12.5% disagreed, with 6% neutral. This shows leadership’s success in bridging strategic vision with employee understanding.




Figure 4.2.10: Frequency analysis of question five based on IV1

(Source: author)

The data from the above figure and table indicate a strong perception of accountability among executive leadership. About 83.5% (Agree 32% + Strongly Agree 51.5%) recognised leaders’ responsibility in linking AI outcomes to organisational performance indicators and competitiveness. Only 11% disagreed, and 5.5% were neutral. This indicates leadership is seen as owning the success of AI adoption, ensuring it aligns with broader objectives instead of functioning as isolated projects.

4.2.5 IV 2: Leadership competence in AI and Digital leadership

Q: Leaders possess strong knowledge of AI applications, enabling informed decisions which enhance research, compliance, development and performance of the overall pharmaceutical industry.

	“Frequency”	“Percent”
“Strongly Disagree”	10	5
“Disagree”	11	5.5
“Neutral”	14	7
“Agree”	64	32
“Strongly Agree”	101	50.5
“Total”	200	100

Table 4.2.5.1: Frequency analysis of question one based on IV 2

The above findings presented that a percentage of participants 50.5% had presented their strong agreement to the fact that leaders hold a strong knowledge of AI application and capable of enabling informed decisions that can be achieved through enhanced research complaints and performance and development for the overall pharmaceutical industry. The findings presented through this that apart from the message number of participants that has strongly agreed in motion to the statement it has been presented that 32% of the participants had agreed to the fact that leader process knowledge of AI applications being a constant necessity for the development purposes of the organisation is integrated. This is followed by the fact that there is a marginal level of participants that had noted to have soul disagreement and neutral responses.

Q: Leadership illustrates the capability to emphasise AI solutions, selecting processes and tools that align with organisational objectives and pharmaceutical innovation.		
	“Frequency”	“Percent”
“Strongly Disagree”	10	5
“Disagree”	16	8
“Neutral”	8	4
“Agree”	58	29
“Strongly Agree”	108	54
“Total”	200	100

Table 4.2.5.2: Frequency analysis of question two based on IV 2

Findings presented the data that most of the participants standing at 54% had strong affinity towards the statement that leadership possesses the capacity for emphasizing AI solutions in alignment with organisational objectives and pharmaceutical innovations. The findings presented as per the table and figure illustrated that 29% of the participants have agreed to the statement that pressed on the matter that the capacity for emphasizing AI solutions selection processes and tools in alignment to organisational objectives and pharmaceutical innovation of a portrait by the leadership of the organisation. The finding shows that a small fragment of participants shows a range of disagreement regarding the same statement. This implies participants most strongly agree up on the fact that leadership has the capacity of emphasizing AI solutions and integration as falling in place with organisational objectives.

Q: Leaders are actively engaged in continuous learning about trends of AI, staying updated with the emerging digital innovations relevant to pharmaceutical operations and research.		
	“Frequency”	“Percent”
“Strongly Disagree”	12	6
“Disagree”	10	5
“Neutral”	12	6
“Agree”	66	33
“Strongly Agree”	100	50
“Total”	200	100

Table 4.2.5.3: Frequency analysis of question three based on IV 2

Table 4.2.5.3 and the following Figure 4.2.5.3 had presented that most participants standing at 50% and 33% respectively show that they strongly agree and are in agreement to the statement of question 3 related to the IV 2. The findings presented in this conversation show that participants have agreed upon the fact that leaders show an active engagement in maintaining the continuous

learning trend of AI as a way of building up to date maintenance of the organisation with emerging digital innovations that are relevant to pharmaceutical operations and research. 6% of participants showed strong disagreement to the statement while 5% of them had not agreed.

Q: Decision-making through leadership emphasises high digital competence, integrating AI insights in strategic planning, regulatory compliance frameworks and operational improvements.		
	“Frequency”	“Percent”
“Strongly Disagree”	11	5.5
“Disagree”	13	6.5
“Neutral”	9	4.5
“Agree”	65	32.5
“Strongly Agree”	102	51
“Total”	200	100

Table 4.2.5.4: Frequency analysis of question four based on IV 2

The following table and graphical illustration had presented a major percentage of participants that included as a total of 83.5% that comprises 51% of participants in strong agreement and 32.5% of participants in agreement. Only a total of 16.5% comprising 5.5% of participants in strong disagreement, 6.5% and disagreement and 4.5% neutral responses had been recorded. Most of the participants had noted their belief on the fact that leadership conducted decision making is capable of emphasizing high digital competency alongside AI insight integration for strategic planning with maintenance of operational improvements and regulatory compliance frameworks.

Q: Leadership encourages confidence in AI initiatives through demonstrating technical expertise, supporting successful implementation and guiding cross-functional teams across pharmaceutical processes.		
	“Frequency”	“Percent”
“Strongly Disagree”	11	5.5

“Disagree”	13	6.5
“Neutral”	11	5.5
“Agree”	60	30
“Strongly Agree”	105	52.5
“Total”	200	100

Table 4.2.5.1: Frequency analysis of question five based on IV 2

The findings in this graphical illustration and tabular representation of the frequency analysis done at presented is a strong positive response in association to the statement related to encouragement of confidence in an initiative being a part of leadership. The findings had supported Hate Story 2.5% in strong agreement and 30% in agreement that leadership is indeed capable of motivating confidence in AI initiative through providing implementation support and cross functional team guidance alongside technical expertise demonstrated throughout the pharmaceutical procedures. Only a small margin of participants collectively should agree to the statement there by indicating that this prospect is quite positively admitted and identified to be valid.

4.2.6 IV 3: Organisational Readiness




Figure 4.2.6.1: Frequency analysis of question one based on IV 3

(Source: author)

Under table 4.2.6.1 it has been observed that a vast majority of the participants comprising almost 53% strongly supported the fact that organisational culture is capable of motivating adoption of AI and fostering collaboration. In addition to this 28.5% of them also admitted to the same in addition to the fact that employee participation information is also encouraged through collaboration and adoption of AI within organisation culture. The finding showed however only 7.5% of the participants had disagreed while 4% of the participant head strongly disagreed to the same statement.

Q: Data infrastructure within the organisation is developed, ensuring quality standards, reliable access, and integration for effective AI implementation.		
	“Frequency”	“Percent”
“Strongly Disagree”	9	4.5
“Disagree”	12	6
“Neutral”	9	4.5
“Agree”	55	27.5
“Strongly Agree”	115	57.5

“Total”	200	100
---------	-----	-----

Table 4.2.6.2: Frequency analysis of question two based on IV 3

The primary data finding indicated that 57.5% of the participants at phone are in strong support of the fact that data infrastructure within an organisation is considered as developed and securing quality standards alongside maintaining reliable access and integration of efficiency in implementation of AI. The findings at present at 27.5% of the sample population had also agreed on the. This is followed by the fact that a very small margin of participants had shown their disagreement to this concept.




Figure 4.2.6.3: Frequency analysis of question three based on IV 2

(Source: author)

49% participants as per table 4.2.6.3 and figure 4.2.6.3 had presented strong agreement to the fact that had been stated in the third question to IV 3 that had stated that sufficient financial and human resources have been constantly allotted and has been done through maintaining successful adoption being enabled alongside management or sustainability and scalability of initiative of AI within pharmaceutical industry. Followed by 33% of participants occurring upon the same it is to be observed that a large segment of participants so their strong agreement and support to the conception that financial and human resources required to be sufficient for successful AI integration and scalability.

Q: Cross-functional collaborations are actively supported, creating synergies in departments which can foster readiness for AI integration and change management in the organisation.		
	“Frequency”	“Percent”
“Strongly Disagree”	7	3.5
“Disagree”	16	8
“Neutral”	13	6.5
“Agree”	58	29
“Strongly Agree”	106	53
“Total”	200	100

Table 4.2.6.4: Frequency analysis of question four based on IV 3

53% strongly agree and 29% agree regarding the questions statement presented under table 4.2.6.4 that cross functional collaborations have an active support in creating synergies within departments that can contribute towards strong readiness for AI integration and change management within the organisation. The outcomes of the primary data evaluation and presented participants from a marginal segment in terms of disagreement among participants regarding the same.




Figure 4.2.6.5: Frequency analysis of question five based on IV 3 (Source: author)

Per the table 4.2.6.5 figure 4.2.6.5 the findings had presented that there is a strong agreement among most participants amount into 55% of the participant population and 27% in agreement to the same that employee training programs and change management initiative through their implementation

are capable of enabling organisation readiness and staff preparedness for adopting AI for digital innovation. Only 5.5% of the sample population had shown strong disagreement to the same.

4.3 Secondary Data Analysis

4.3.1 Theme 1: Recent state of integration of AI in the pharmaceutical sector

The use of AI in the pharmaceutical industry has changed drastically over the last few decades, that has evidently made it one of the most prominent globally leading sector and industries. AI applications in drug development during the 1980s and 1990s were mostly limited to simple computational models used for molecular modelling and chemical structure prediction (Garg *et al.* 2025). However, studies present that technological developments made it possible to optimize pharmaceutical formulations and make better predictions about chemical interactions in the early 2000s with the rise of machine learning algorithms. And since the 2010s, the widespread use of AI in the pharmaceutical industry has been made more accessible by recent developments in Big Data, deep learning, and large datasets accessibility, according to the studies.




Figure 4.3.1.1: Applications of AI in Pharmaceutical industry

(Source: Garg *et al.* 2025)

AI can entirely renovate the pharmaceutical industry by quickly recognizing patterns in complex data streams that are undetectable to humans. Since the major use case is to improve real-time decision support, process modifications make use of embedded domain knowledge rather than depending just on operator expertise and traditional tribal knowledge (Tetteh-Caesar *et al.* 2024). In order to optimize cycle parameters, “Bayesian learning algorithms”, were noted in the studies, in particular, to enable the combination of historical datasets with incoming sensor signals from IoT-enabled equipment for continuously updated risk estimations. Automated warnings are triggered in advance if measurements diverged in ways that would eventually result in a failed microbial limit test, drastically reducing acceptable batches. The research further supports the idea that reinforcement learning algorithms will further enhance the usefulness of AI through digital twin simulations, and that natural language generation enables such AI to explain the underlying causes contributing most to its predicted quality estimates.

A pillar of the global healthcare system, the pharmaceutical sector faces numerous obstacles, including exorbitant costs, complex regulations, the intricacies of drug pricing, intellectual property protection, and the constant threat of new health issues. AI technological advancements have completely changed the pharmaceutical sector (Suri *et al.* 2024). the revolutionary role of AI in the pharmaceutical industry, revealing its multifaceted impact across critical domains. These critical domains ranged from transforming drug development and discovery to optimizing clinical trials. This had also been improving manufacturing and quality control, allowing personalized medicine, guaranteeing “pharmacovigilance”, streamlining supply chain management, and even influencing drug marketing and sales. The integration of AI offers many advantages, such as improved clinical trials through better data analysis, faster and more cost-effective drug discovery, and enhanced precision in personalized medicine.

An important development in pharmaceutical manufacturing is the combination of AI and the IoTs. For increased overall efficiency, the production process and quality control have been improved. Through this connection, real-time analysis, predictive maintenance, automation, and continuous monitoring of critical manufacturing parameters are made possible by machine learning and deep

learning (Kodumuru *et al.* 2025). This study had, with the aim of outlining the future of autonomous pharmaceutical manufacturing, also addressed the current trends, such as blockchain for data traceability and AI on drug discovery. This thereby presented the innovation in pharmaceutical manufacturing and efficiently bridges the gap between digital and physical worlds of the industry.

From medication discovery to post-market surveillance, AI has become a game-changer in the pharmaceutical product life cycle. With the ability to forecast possible medication candidates, find hidden patterns in data, and improve clinical trial designs, AI offers a singular chance to enhance human capabilities. AI has made a significant contribution to drug development by speeding up the process of identifying possible therapeutic candidates (Sampene and Nyirenda, 2024). AI is capable of presenting the opportunity to evaluate enormous datasets, such as genetic data and chemical attributes, by utilizing machine learning algorithms to forecast the potential interactions and behaviours of various molecules. AI can promptly identify possible negative reactions and new safety issues by examining vast amounts of data, such as social media and electronic medical records.

The era of predictive maintenance in pharmaceutical manufacturing has been brought about by AI. AI can forecast maintenance needs by evaluating sensor data from equipment, reducing downtime and averting expensive malfunctions. This predictive method boosts overall manufacturing efficiency and maximizes resource use. AI has drastically changed the pharmaceutical product manufacturing industry, transforming every step of the process from R&D to production and quality assurance (Tade *et al.* 2024). AI's capacity to swiftly analyse enormous volumes of data and offer previously unattainable insights is at the forefront of these interventions, speeding up the creation of new drugs. When AI is used in computational drug design, it effectively models and forecasts molecular interactions, allowing for the more accurate identification of possible drug candidates and cutting down on the time and expense associated with hit-to-lead optimization.

However, over these trends and benefiting applications, AI does have certain challenges to its application in the pharmaceutical industry. Significant ethical and data privacy issues are raised by the integration of AI into the pharmaceutical industry. AI systems frequently handle sensitive patient data, including genetic information and electronic health records, which calls for strong data anonymization, encryption, and de-identification techniques to ensure privacy (Mosisa *et al.* 2024).

The pharmaceutical industry faces significant obstacles to collaboration and data sharing due to the lack of standardization in data formats and the limited interoperability between AI systems. Pharmaceutical data comes from a variety of sources, such as clinical trials, electronic health records, and real-world evidence, but is frequently stored in heterogeneous formats, which makes it difficult to integrate AI systems seamlessly and hinders collaboration.

4.3.2 Theme 2: Governance mechanisms and leadership competencies fostering scalable AI adoption

In community pharmacies, hospital pharmacies, and pharmaceutical business contexts, the use of digital integrations such as AI and its important subset, machine learning, has greatly improved pharmaceutical procedures within the last five years. Studies such as of Simpson and Qasim (2025) note that, since deploying AI technology, community pharmacies have experienced a 40% improvement in drug adherence and a 55% reduction in missed prescription refills, demonstrating quantifiable progressions in the use of AI in healthcare delivery.

This can be observed through a few cases in the globally operating pharmaceutical organizations that have integrated AI as an instrument of governance mechanism and development.

Case 1: AstraZeneca

The pharmaceutical company had focused on integrating AI technology and data implementation for the purpose of building sustainability within their governance framework and upskilling program. The company has focused on building a constant integration of principals of ethics compliance by focusing on “AI Governance Framework” implementation and integrating “Risk Framework and Playbook” for assisting AI developers into expanding regulation and public expectations of maintaining data and ethics within their focus of building stronger improved “Global Health” outcomes through AI application (AstraZeneca, 2025). They are organizational structures to work around the benefits of AI integration within governance and operations as a way of maintaining ethical and data-based development for the organisation.

The company has also implemented a generated AI accreditation program by integrating AI governance and collaborating with IT and HR, business and corporate communication departments. Thus, collaboration has been focusing on providing opportunities for the workers and workforce to utilise generative AI tools for practicing on a self-development basis (AstraZeneca, 2025). The

organisation had integrated AI into their learning and development activities for the purpose of simplifying working ways and innovative organisation capacity and talent.

Case 2: Pfizer

The organisation has commented on the fact that pharmaceutical companies are often extremely focused on developing faster and smarter clinical drug development. The company had presented that it is essential for pharmaceutical companies to be focused on developing faster innovations for the purpose of building better opportunities for the organisation to maintain proper clinical drug development capacities. The organisation had agreed upon the fact that AI is capable of automating the production of a large number of reports and regulator documentations (Pfizer, 2025).

The organisation supports that integration of AI is capable of alleviating the chance of maintaining and scanning and fast documents for the purpose of clinical drug development. The organisation has particularly focused on association to Regulation and Governance of AI to maintain the AI governance mechanism and model to be a patient regulatory approach as supported (Pfizer, 2025). The findings present at the organisation has focused on maintaining a reliability regarding risk based dedicate and stilling innovation in the form of scheduling data and privacy protection appropriation for patients.

Case 3: Novartis



Figure 4.3.2.1: Novartis' AI governance framework

(Source: Novartis, 2025)

The organisation focuses on making and maintaining the framework that is built upon ethical principles of AI that includes following an AI risk and compliance management framework alongside maintaining an ethical use of data and technology policy followed by maintaining a code of ethics (Novartis, 2025). The company focuses on implementation of the risk and compliance management framework as a means for supporting the employees and business functionality for innovative and motivating innovation developments in time with risk mitigation arising from, I use cases. The company focuses on maintaining a global collaborative effort and risk-based approach that includes risk assessment on a functional level and maintaining a continuity within assessment programs that evolve the framework and procedures in accordance with it. The governance framework most particularly focused on maintaining motivation for risk management and governance through management of transparency explain ability and human oversight control of risk.

Case 4: Roche




Figure 4.3.2.2: Lab in loop strategy by Roche

(Source: Roche, 2025)

The company had integrated AI as a solution for revolutionising drug discovery and data analysis prediction capabilities for the organisation to reduce the probability of high failure rate within the complex and resource intensive procedure. The company had focused on building a “lab in a loop” solution, with AI and machine learning mechanisms for utilising generating AI to drug discovery and development for training models to make algorithm waste predictions on drug targets (Roche, 2025). This has been identified as a framework model to enhance capacity of streamlining traditional trial and error approach to improve drug discovery capacity and reduce the potential of high failure rate through streamlining the discovery procedure by applying algorithmic and data driven prediction.

4.3.3 Theme 3: Strategic alignment processes aligning AI adoption with organizational vision and operational imperatives

In the pharmaceutical industry, strategic leadership aids in directing and promoting novel concepts, adjustments, and long-term advancement such as AI adoption for organisational structure and operational efficiency. Pharmaceutical companies may manage the difficulties in the global healthcare sector and continue to produce useful medications if their leaders set clear objectives and permit significant adjustments (Graham, 2024). Complexities within innovations necessitate pharmaceutical companies to utilise structured procedures such as pharmaceutical innovation management framework integrating AI application for different procedures and stages including ideation and discovery alongside intuition of AI in collaboration and celebrity management and compliance with agility features.

the transformative capacity of AI and data-driven abilities and putting a strong emphasis on respecting ethical standards, data privacy, and security, enterprises may uncover new opportunities, drive innovation, and make a good effect in the healthcare industry and beyond. Pharmaceutical businesses can model and analyse large quantities of genetic, molecular, and clinical data by utilizing AI and machine learning algorithms in data-driven research and development processes (Uzhakova and Fischer, 2024). The study had noted that through this framework, a thorough change management initiative was needed. Pre-assessments were carried out as part of this endeavour, and stakeholders were shown the draft framework in order to incorporate their input and improve the roadmap. This strategy encouraged stakeholder commitment and helped the change be accepted gradually.

In the pharmaceutical organisation context, a chance to move from reactive to predictive systems is presented by the incorporation of advanced analytics, AI and machine learning into supply chain operations. Predictive analytics methods are useful in pharmaceutical supply chains for demand forecasting, stock level anticipation, and early disruption detection. Predictive analytics uses real-time data and dynamic modelling to increase decision-making accuracy, in contrast to conventional approaches that depend on predetermined assumptions (Oluwole *et al.* 2024). Organizations can assess trade-offs between risk, service quality, and cost using data-driven frameworks.

Predictive modelling, patient recruitment optimization, data analysis, and other digital applications can streamline clinical development processes by using AI to detect possible problems, optimize trial designs, and enhance decision-making, which eventually increases efficacy and shortens development to clinical use timelines (Mariani *et al.* 2024). Pharmaceutical businesses continue to exercise caution when making significant digital expenditures and putting into practice a digitally driven R&D strategy can be difficult. This is why many pharmaceutical companies, according to study, are still investigating the best ways to integrate digital technologies into their operations, despite lacking a strong R&D strategy or the technical and financial resources of larger companies, for the purpose of increasing capacity for change management success.

4.3.4 Theme 4: Ethical Leadership and Responsible AI Governance

AI integration in healthcare research marks a critical shift for groundbreaking advancements in patient care management, diagnostics and treatment. This evolution emphasises the spectrum related to ethical challenges that require meticulous governance and scrutiny. These challenges revolve around confidentiality and privacy, as AI solutions need access to extensive data of patient, raising risks towards individual privacy. The challenge of informed consent is also becoming complex, as AI applications in healthcare research extend beyond the traditional consent frameworks, requiring updated procedures which transparently communicate uses of patient data. The study by Abujaber and Nashwan, (2024), emphasises four main ethical principles of medicine, which are further supported under actionable guidelines for operationalising these principles within the practical settings of research. This framework is visualised through a diagram that emphasises their multifaceted approach, while focusing on core ethical principles of respect for justice, autonomy, beneficence and non-maleficence as their core pillars.




Figure 4.3.4.1: Proposed ethical framework for AI in healthcare

(Source: Abujaber and Nashwan, 2024)

Integration of ML and AI in the healthcare system raises some significant ethical considerations which must be addressed to ensure equitable and responsible deployment. Complex interplay among clinical practices, ethical principles and technological innovation needs a thorough evaluation of the ethical implications of ML and AI in healthcare. Ethical considerations penetrate different aspects of development, utilisation and implementation of ML and AI in healthcare (Tilala *et al.* 2024). Starting from ensuring data privacy and safeguarding patient privacy to promoting transparency and mitigating algorithm biases, ethical principles are responsible for the adoption of AI in healthcare. Furthermore, the ethical implications of ML and AI are extended beyond individual patient care for broader social issues like healthcare responsibilities redistribution among stakeholders, healthcare disparities influences and access to healthcare services.

Some case studies by Jordan (2025) are,

Case Study 1: Ethical Implementation (Hypothetical)

AI Use in Clinical Trial Recruitment

1. Context: Pharma companies adopt AI to match patients to trials based on EHR data.
2. Approach: Ensures full consent of the patient, transparency about the role of AI, and bias audits.
3. Outcome: Rise of diversity during trials, improved trust in stakeholders and faster recruitment.
4. Lesson: Ethical AI adoption can foster outcomes while respecting the rights of individuals.

Case Study 2: Unethical Implementation (Real-World Inspired)

AI Bias in Drug Recommendation Systems

1. Context: The AI system disproportionately recommended the lower dose of medications for certain racial groups because of biased training data.
2. Outcome: Resulted in public backlash and ineffective treatments.
3. Lesson: Lack of explainability and bias mitigation led to reputational damage and ethical violations.

Case Study 3: Governance Success

AI-Powered Pharmacovigilance System

1. Context: The AI model used for detecting adverse drug events from EHRs and social media.
2. Governance: Followed guidelines of WHO, implemented continuous oversight for human and anonymised data per GDPR.
3. Outcome: Early detection of the adverse events with regulatory compliance.
4. Lesson: Strong governance frameworks make sure ethical and effective AI deployment.

4.3.5 Theme 5: Integrative Leadership Models for AI Implementation

Leading healthcare organisations toward AI transformation need multidimensional leadership. As, these types of healthcare companies need to engage leaders in strategic, technological, organisational and operational domains to facilitate the transformation of AI in their organisations.

Further, Sriharan *et al.* (2024), indicate that individuals in AI-related leadership roles are required to exhibit

- Technical capacity for understanding innovation and technological opportunities,
- Adaptive capacity for responding towards contextual changes,
- Interpersonal capacity that allows one to navigate the human aspects of the AI transformation process.

Furthermore, it is illuminating that leaders in the AI-related leadership roles must navigate the regulatory context, as the dynamic nature of change in technology and organisational context.




Figure 4.3.5.1: Multidimensional leadership framework for the transformation of AI

(Source: Sriharan *et al.* 2024)

For example, AI forecasts maintain some advanced features and prevent unexpected breakdowns in subsequent production processes. The proactive policy ensures complications and helps in fostering better management and planning of resources, long-term sustainability and industry leadership in the manufacturing dynamic of the pharmaceutical sector (Sriharan *et al.* 2024). Through investing in adopting AI technologies, Amgen is positioning itself as adaptable dynamic of a shift in the medical landscape. This progressive dynamic can also prove beneficial for their patients and buttress their leadership within industry standards. However, strategic leadership improves the performance of an organisational, fosters organisational learning, and enhances organisational transformation. Strategic leaderships are also indispensable for organisational

success, alongside with guiding a long-term, sustainable plan of action for some of the specific organisations. Leadership can apply to every firm's executive as a principle, irrespective of their management level; however, the dynamics of strategic leadership apply to the highest levels of leaders within the organisation.

For gen AI success, organisations must integrate across workflows to promote adoption need a change management. Indeed, McKinsey & Company (2024) has found that 70% of digital transformations are fail due to leaders ignoring the importance of managing change rather than technical issues. As with any type of digital transformation, leaders must apply an end-to-end lens and focus on the use of applications and cases which foster a sense of comprehensive business goals. Those leaders must develop a strategic road map which allows them to ensure that they are uplifting overall influences, other essential considerations and impact time. Gen AI tools are helping in deepening care providers, patients, pharmacists and insurers' relationships. However, the dynamic related to internal brand leaders can build on their closeness to healthcare providers, other partners and patients to foster real-time campaign strategies. The strategic leader needs to enhance change and quality of risk at the time of sensing new technologies.

4.4 Summary of Findings

The findings of the mixed data analysis indicate that any healthcare provider must have to anticipate upcoming trends, manage changes and carefully thought-out ensure organisational targets and long-term decisions that contribute to society and health sector growth. These leaders also allow leading organisations to handle unpredictable situations in markets, while sponsoring an environment where information is shared, people are adaptable, and ideas are generated. The organisation can also direct its R&D programs for global healthcare objectives, involving capabilities of situation readiness and new disease identification. However, graphic data support, AI-generated text and voice recordings, have potential for fast and accurate analysis as compared to other technologies or humans. The data of the primary result emphasises a workforce skewed toward younger professionals, which signals strong readiness for AI-driven transformation. Different respondents agree that leadership vision is highly recognised as a guiding force for integrating AI into the pharmaceutical sector.

In context to the factor of AI integration through the influence of leadership and organisational culture it has been observed that there is a strong inclination of positive and encouraging leadership

and innovative culture having a strong part in influencing adoption of technology innovation such as AI increasing organisation success and operation improvement. As observed in the primary findings it is noted that workforce and organisation take up positive adoption of AI integrated into change management in organisation for the purpose of improving pharmaceutical industry operations and functionality. The findings are also supported through the secondary data and thematic analysis that there is a capacity for AI to be innovating system research and development to organisation activities including risk management and predictive analysis of supply chain and drug discovery. The finding set supported AI implementation under several case studies that have presented that integrating AI as a tool for enhancing governance mechanisms supportive to building better opportunities of organisational growth.

The complex interplay between clinical practices, ethical principles and technological innovation requires an evaluation of the ethical implications of AI in healthcare. However, ethical considerations like consent, fairness, transparency and accountability in the process of decision-making by using AI are complicating their adoption process. Significant data privacy and ethical issues are raised by AI integration in the pharmaceutical industry. Overcoming these challenges needs a strategic investment, a robust validation framework and interdisciplinary collaboration for integrating AI technology in the pharmaceutical practices. The findings of the secondary data also emphasise that nowadays Gen AI tools are evolving for help in deepening relationships among patients, care providers, pharmacists and insurers as well. Pharmaceutical data comes from different sources and is frequently stored in heterogeneous formats, which makes it difficult for organisations to integrate AI systems seamlessly and hinders collaborative dynamics. AI may also forecast needs of maintenance through evaluating the sensor data to avoid expensive malfunctions and reduce downtime.

The integrated analysis of primary quantitative data and secondary thematic insights indicates that the modern healthcare and pharmaceutical environment demands a proactive leadership stance. Leaders must not only anticipate upcoming trends but also manage organizational change through long-term strategic decisions that balance institutional growth with societal health contributions.

Findings of this mixed method approach can be summarized in below logical groups :

Leadership as a Catalyst for Adaptive Environments

Strategic leaders in this sector are identified as key facilitators who enable organizations to navigate unpredictable market shifts. By fostering an environment characterized by transparent information sharing and cognitive adaptability, these leaders encourage the generation of innovative ideas.

The primary research results underscore a significant demographic shift, with a workforce skewed toward younger professionals. This demographic profile signals a high degree of "digital readiness" for AI-driven transformation. Respondents across the survey consistently identified Leadership Vision as the fundamental guiding force necessary for the successful integration of AI.

Operational Enhancements through AI Integration

The findings reveal a strong positive correlation between an innovative organizational culture and the successful adoption of AI technologies. Key operational improvements identified include:

- **Research and Development:** AI directs R&D toward global healthcare objectives, enhancing situational readiness and the identification of emerging diseases.
- **Supply Chain and Risk Management:** Secondary thematic analysis confirms AI's capacity for predictive analysis, reducing downtime by forecasting maintenance needs through sensor data evaluation.
- **Case Study Validation:** Success stories within the industry demonstrate that AI functions as a governance-enhancing tool, streamlining organizational functionality and accelerating drug discovery timelines.

Ethical Implications and Structural Hurdles

The complex interplay between clinical practice, ethics, and innovation requires a critical evaluation of AI's role in healthcare. While the potential for Generative AI (GenAI) to deepen relationships between patients, providers, and insurers is growing, several barriers remain:

- **The Ethical Paradox:** Issues surrounding informed consent, fairness, accountability, and algorithmic transparency complicate the adoption process.

- **Data Fragmentation:** Pharmaceutical data is often stored in heterogeneous formats across different sources, hindering seamless AI integration and collaborative dynamics.

Overcoming these hurdles necessitates robust validation frameworks, significant strategic investment, and interdisciplinary collaboration to ensure data privacy and ethical integrity.

4.5 Conclusion

This chapter has provided a comprehensive analysis of the primary quantitative data alongside qualitative thematic insights. The statistical results demonstrated high internal consistency (Cronbach's Alpha = 0.950), with a vast majority of the 200 participants expressing strong support for AI integration under visionary leadership.

The thematic analysis further reinforced these findings, positioning AI not merely as a technical upgrade but as a transformative influence on organizational success and leadership capabilities. While challenges regarding data silos and ethical governance persist, the study concludes that strategic leadership remains the primary determinant of whether a pharmaceutical firm can successfully transition into an AI-driven future.

CHAPTER V: DISCUSSION

5.1 Introduction

Chapter five emphasises the main findings of the study in relation to the theoretical framework and existing literature. This chapter focuses on evaluating the results from secondary qualitative and primary qualitative data with respect to the integration of AI in the pharmaceutical sector and its interrelation with the variables like governance mechanism, organisational readiness and strategic leadership. This discussion mainly focuses on analysing the dynamics related to organisational cultural influences, digital competence, and leadership orientation influences AI integration and its implementation in the pharmaceutical industry operations. Through supporting empirical results with the editing studies, this chapter offers the thesis a well-structured concept for identifying patterns, emphasising discrepancies and consistencies and offering understanding of industry practical implications. Meanwhile, the discourse addresses change management issues, integrates approaches of leadership, and addresses ethical considerations, which are important to sustain AI-driven changes. This chapter focuses on bridging the results section figures with the literature review section to present a better and comprehensive understanding of the objectives of the study.

5.2 Discussion of Results

5.2.1 Discussion of Primary Data Analysis

The primary data highlights that AI integration within the pharmaceutical industry is not merely a technical transition but a complex outcome influenced by **organizational readiness, leadership orientation, and workforce demographics** illustrate the critical theme analysed in the survey.

Demographic Drivers and Digital Fluency: Demographic profile indicates that some respondents are younger professionals who have less than 5 years of experience, which aligns with literature suggesting that early-career employees are receptive to adopting technological innovations because of higher adaptability and digital fluency. Demographic factors contribute to a positive perception for adoption of AI observed in the survey, with 81% of the respondent's recognising improvement in operational efficiency, regulatory compliance and research productivity. The findings also reveal that effective application of AI in medicine needs a combination of skills across various disciplines (Ahmad *et al.* 2021). The findings of the survey also indicate that employees at different hierarchical levels, ranging from staff to senior management, suggest widespread acceptance, not limited to the technical teams and recognise AI's strategic importance.

Leadership as the Strategic Pivot: Leadership orientation emerged as the most critical determinant of AI success. Respondents affirmed that effective implementation requires a leader who provides more than just software procurement; they must offer a strategic vision and foster an innovative culture. The findings also reveal that AI has transformative potential in the discovery of drugs, pharmaceutical manufacturing, and clinical trials is important. Leadership orientation appears as an important determinant of AI adoption, with major respondents affirming that leaders align with AI initiatives to offer a strategic vision, foster an innovative culture need a successful implementation. The literature also underlines the role of comprehensive organisational engagement in digital transformation initiatives. Similarly, literature needs to use digital leadership to maintain competitiveness and develop innovation in the fast digital transition (Tunaboğlu and Cerasi, 2025). Digital leadership encompasses strategic leadership, business portfolio and digital market skills for encompass intrapersonal and interpersonal competence to foster the process of decision-making, strategic mindset and drive activities for driving organisational digital transformation.

Cognitive Augmentation: While AI can perform cognitive tasks traditionally reserved for humans—such as problem-solving and linguistic analysis—primary participants noted that leadership decision-making is what integrates these AI insights into long-term strategic planning. Leaders foster a culture of fairness, accountability and transparency, and leveraging AI can enhance the decision-making process (Ucheagwu-Okoye, 2025). AI develop computer-controlled robots or digital computers that may perform cognitive and intellectual tasks as same as humans. As AI technologies evolve, there are different issues which are continuously arising. However, issues including informed consent, potential job displacement and data privacy have addressed with a proactive ethical approach.

Operational and Clinical Transformation The findings illustrate AI's transformative potential across the pharmaceutical value chain.

Drug Discovery and R&D: AI systems assist healthcare professionals in identifying patterns within vast medical datasets, predicting patient outcomes, and accelerating drug development timelines (Visan and Negut, 2024).

Manufacturing and Supply Chain: AI-driven reporting ensures data integrity and traceability, while predictive analytics mitigate risks from raw material procurement to the finished product.

Patient Engagement: The integration of AI-powered chatbots and virtual assistants allows for personalized patient care and real-world evidence analysis, evaluating a drug's long-term safety and efficacy (Priyanka et al., 2025).

The findings presented in this conversation show that participants agreed upon the fact that leaders show an active engagement in maintaining the continuous learning trend of AI, for building up-to-date maintenance of organisation with emerging digital innovations that are relevant to pharmaceutical operations. However, AI is also equipped for the development of digital computers with the capacity of cognitive human-like intelligence and autonomous executive intelligence. Such cognitive and intellectual processes involve languages, problem-solving, learning and decision-making approaches.

Major respondents are staff and team leads, suggesting data capture insight from mid-level and operational employees directly engaged with the workflow. However, by exploring large medical literature and data of patients, AI systems may assist the healthcare professionals in making informed decisions, predicting outcomes of patients and identifying patterns resulting in better outcomes of health and patient care (Visan and Negut, 2024). The field of AI in medicine has rapidly expanded and is already focusing on taking an influence in areas including monitoring remote patients, drug discovery and virtual health assistants. However, the findings of the study also reveal that the plan of treatment can be done with the help of AI. AI can accelerate drug development and improve access to treatments throughout the world (Nishan, 2025). Strategic leadership ensures that these technologies can be involved responsibly and equitably. Hence, the role of leadership for unlock the potential of the pharmaceutical industry's advanced technologies.

A large portion of the report clarifies that AI in the pharmaceutical sector has significantly improved research productivity, enhanced regulatory compliance, reduced development timelines and strengthened overall strategic competitiveness. However, it is supported by the research where Almeman (2024) mentioned in research that the development of the market of pharmaceutical business before the pandemic was marked by revolutionary changes that laid the foundation for the industry's ability to respond to the further global issues. Innovations within medication development, collaborative collaborations, digital health, regulatory frameworks, sustainability initiatives and market access strategies are collectively transforming this sector. Recently, AI has evolved and focuses on later conversion methodologies adopted in delivery, development and

identification of the potential therapeutics. This shift is mainly driven by the ability of AI, which allows for the enhancement of vast datasets. Hence, the exponential growth of data also fosters issues with the old concept of analysing data.

Ethical Stewardship and Governance: As AI technologies evolve, the research highlights a shift toward a proactive ethical approach. Participants agreed that leaders must actively engage in managing risks associated with data privacy, informed consent, and potential job displacement. The findings of the primary data illustrate that the leadership is actively shaping organisational culture to embrace AI. However, MAHABUB *et al.* (2025) mentioned that adaptation of new technology is the main aspect of strategic leadership in the AI era, and the other aspects are corporate culture stewardship, ethical behaviour and workforce adaptation. Furthermore, AI-driven reporting automates tasks for data analysis, ensuring traceability, data integrity and completeness throughout the whole developmental process, which simplifies reporting obligations and fosters regulatory compliance. The ability of AI-driven leadership to promote long-term, sustainable growth is its main characteristic. Mitigation of risk and risk assessment by using AI can also foster a proactive identification for potential risks with risk mitigation, regulatory adherence or initiate from raw material to finished product of a healthcare system. As it is already mentioned above, at various times the AI has played an important role in the healthcare sector to accelerate timelines of development of drugs or quality control.

Many of the participants had noted their belief in the fact that leadership conducted decision-making can emphasise high digital competency. Alongside AI insight integration for strategic planning, with maintenance of operational improvements and regulatory compliance frameworks. According to the research by Priyanka *et al.* (2025), predictive analytics integration as a form of digital injection for operations of strategic leadership has the potential to contribute to the endorsement of an innovative work culture. Implementation of smart systems can also help the leaders to initiate building motivation for organisational change. AI-based predictive analytics can empower physicians who are at high risk of adverse events, facilitate protective intervention and inform treatment decisions easily. Virtual assistants and AI-powered chatbots offer tailored information for personalised patient engagement. AI influences the extent of the benefit-risk assessment, and real-world evidence relies on real-world evidence analysis for evaluating a drug's efficacy and long-term safety.

Resource Allocation and Strategic Competitiveness Finally, the report clarifies that while the majority of participants believe their organizations possess sufficient financial and human resources for AI scalability, the role of strategic leadership is to ensure these resources are not wasted in isolated projects. The primary data indicates that leadership owns the success of AI adoption, ensuring it aligns with broader objectives instead of functioning as isolated projects. Hence, the long-term goal of AI automation leads to machines development can outperform humans in each aspect. As AI can also predict new uses of the existing drugs, which could foster the drug development process and cut down costs (Han *et al.* 2023). However, AI emphasises a large set of biological data for fostering the discovery of drugs and recognising potential drug targets. Simulation of AI implemented in the development of a drug for predicting interactions among biological and compound systems facilitates cost-effective and efficient clinical trials. Additionally, AI-driven tools may streamline formulation development, optimise supply chain management, lower regulatory compliance and manufacturing process. Information and a large database are indispensable for training and development of the AI algorithms.

The primary data findings were evaluated and presented to participants from the marginal segment for disagreement of the participants regarding the same. While a large segment of participants strongly agrees and supports the conception that human resources and financial resources are sufficient for successful AI integration and scalability. Under the case of the educational sector, strategic leadership was defined as that which focuses on strategies and behaviours that are associated with the entire procedure of commencement, appraisal, expansion, monitoring, and operation of strategic actions. Considering all diverse past, present, and future contexts, while maintaining accessibility for physical, financial and human resources (Carvalho *et al.* 2021). All pharmaceutical firms look for opportunities allow them to increase the efficiency of their business for the discovery and development of new products, achieving the necessary financial parameters and compliance with industry strict rules, among other things. However, supply chain disruptions in the pharmaceutical industry significantly impact customer satisfaction, potential profit and corporate reputation.

5.2.2 Discussion of Secondary Data Analysis

The secondary research underlines that the successful adoption of Artificial Intelligence (AI) within the pharmaceutical sector is not merely a technical achievement but a result of the multifaceted

interplay between leadership stewardship, organizational culture, and governance frameworks. Multifaceted influence of AI adoption in the pharmaceutical industry, emphasising that leadership, organisation and organisational dimension determine success in this dynamic. **Historical Evolution: From Predictive Modeling to Generative Intelligence:** The trajectory of AI in the industry has undergone a paradigm shift over the last four decades. The review of governance frameworks, case studies and thematic analysis indicates that the pharmaceutical industry has substantial transformation in the past decades. AI applications in the development of drugs in the time of 1980s and 1990s were most of them limit to computational models used for chemical structure prediction and molecular modelling (Garg *et al.* 2025). Since the 2010s, the widespread use of AI in the pharmaceutical sector has become more accessible due to developments in large datasets accessibility, big data and deep learning, as per the studies. The secondary findings indicate that for the discovery of medication in post-market surveillance, AI evolve as a game changer for the pharmaceutical product life cycle. Their ability for forecasting can be used for possible medication, improve their clinical trial dynamic and find hidden data patterns.

Benchmarking Industry Leaders: Strategic Case Studies: The secondary data also shed light on three different case studies, like *AstraZeneca*, *Pfizer*, *Novartis* and *Roche*.

AstraZeneca (2025): emphasises that the collaboration focuses on offering opportunities for the workforce and workers to use the tools of gen AI for practising on self-development basis. This organisation is integrating AI into its learning and development practices for a simplified way of working and innovative organisation talent and capacity.

(Pfizer, 2025) has focused on association with Regulation and Governance of AI to manage the AI governance model and mechanism for patient regulatory approach. The findings offer that organisations focused on managing reliability regarding risk-based dedication and stilling innovation in the form of privacy protection appropriation and scheduling data for the patients.

Novartis, (2025), focuses on managing global collaborative efforts and risk risk-based approach for risk assessment on the functional level and maintaining continuity of assessment programs.

Roche, (2025), developed a “lab in a loop” solution, with AI and ML mechanisms generating AI to drug discovery and other dynamics. This integration of AI and Machine Learning (ML) creates a recursive feedback system that accelerates the identification of viable drug candidates.

The ability of AI and data-driven methods to bring about transformation, along with a strong focus on ethical standards, data privacy, and security, can help businesses find new opportunities, foster innovation, and create positive impacts in healthcare and other fields. The findings of the secondary data indicate that, through using AI and machine learning, pharmaceutical companies can analyse large amounts of genetic, molecular, and clinical data during the research and development process (Uzhakova and Fischer, 2024).

Change Management and the Innovation Paradox: A critical insight from the secondary data is the high failure rate of digital transformations. As highlighted by McKinsey & Company (2024), nearly 70% of these initiatives fail due to a lack of leadership engagement in change management. The study highlighted that a comprehensive change management plan was necessary. As part of this effort, pre-assessments were conducted, and stakeholders were shown a draft of the framework to give their feedback and help shape the plan. This approach-built stakeholder support and made the change easier to accept over time.

In our case studies, we consistently found that innovation management is key to helping organisations adopt AI, successful firms employ Innovation Management, which rests on three pillars:

1. Supportive Policies: Incentivizing the workforce to adopt AI tools.
2. Quality Control: Balancing the inherent risks of innovation with strict regulatory adherence.
3. Linking Agents: Individuals who bridge the gap between technical AI potential and operational pharmaceutical needs.

Innovation management has three main parts: policies that encourage innovation, quality control throughout the innovation process, and the role of linking agents. Policies that support innovation are important because they help start-up efforts and directly encourage the use of AI. However, innovation itself can be risky. Because of this, companies need to balance their drive for innovation with policies that ensure quality and manage risks.

Ethical Stewardship and Social Responsibility: The use of machine learning and artificial intelligence in healthcare brings up important ethical issues that need to be carefully handled to

make sure these technologies are used fairly and responsibly. However, thematic analysis data indicate that ethical concerns are present throughout the development, use, and implementation of these technologies in the healthcare field (Tilala *et al.* 2024). There is a complex relationship between medical practices, ethical values, and new technology, which requires a detailed look at the ethical effects of ML and AI in healthcare. This includes protecting patient privacy, ensuring data security, promoting openness, and reducing any biases in algorithms. Ethical standards are key to the successful integration of AI in healthcare. Moreover, the ethical impact of ML and AI goes beyond individual patient treatment and affects wider social matters such as how healthcare responsibilities are shared among different groups, how healthcare inequalities are shaped, and how access to healthcare services is managed.

5.3 Conclusion

This chapter emphasises that integration of AI in the pharmaceutical sector is highly affected by ethical and strategic leadership, capacity of the organisation and readiness of the workforce. The primary data of the studies indicate that employees acknowledge AI positively, for enhancing productivity, competence, and operational efficiency, while leadership strategy and competence alignment have emerged as a key enabler. The secondary data also confirmed that multidimensional leadership, ethical guidelines and governance mechanisms are vital for measuring the acting principles during the adoption of AI. The literature supports the findings through exhibiting that successful implementation of AI and strategic leadership needs ethical oversight, change management, technological infrastructure and predictive analytics. Altogether, findings indicate that the pharmaceutical sector can achieve a sustainable digital transformation when AI capabilities, organisational culture and leadership vision are aligned coherently. This chapter indicates that the integration of AI in technological, strategic, ethical and organisational endeavours that underscores the interplay among governance, workforce engagement and innovative dynamics.

CHAPTER VI:

SUMMARY, IMPLICATIONS, AND RECOMMENDATIONS

6.1 Summary

The findings of the research and analysis included primary data and secondary data for the purpose of exploring quantitative and qualitative information for the purpose quantifying and generalizing findings in association to the understanding of strategic leadership and AI integration being inter-connectively associated towards information and development of a pharmaceutical industry. As per the finding it is observed that application of AI in medicine and pharmacology has been an onset development within the entirety of the pharmaceutical and healthcare industry. The findings presented that strategic leadership is a model for Digital leadership for the integration and advancement of digital transformation within the pharmaceutical industry as it contributed to the development of AI integration as a part of the digital innovation causing disruptive positive development.

The findings are also presented that leadership holds a strong influence on the development of adaptation and acceptance of AI integration with information industry alongside organisational readiness. The findings need understanding that AI is capable of advanced organisational activities such as drug discovery and operation, all functions such as management of market forecast and supply chain activities among several other decision-making procedures. The findings also support the fact that AI can contribute to the growth and development of the pharmaceutical industry of search and enhancement in their operationality and capacity in terms of scalability and success. AI has been observed to be presenting its implementation to have an influence in progressively expanding the opportunities of overall activities of leadership and findings that also presented that there is an opportunity for pharmaceutical firms for enhancing efficiency of business activities and organisational success through operational functions.

The implementation of AI as a digital innovation under the implementation of strategic leadership presents that decision making activity that ranges from organisation hierarchy to research and development activities necessitates building the importance of applying AI for the purpose of seizing the opportunity of using AI for development bases. The finding had presented through

several cases and instances that implementation of AI ranged from different applications such as big data and machine learning and use of data sets for deep analysis for the purpose of enhancing research and development activities alongside improving operationalities such as in supply chain management and organisation executive decision making.

The findings had also presented the issue of medical concerns faced by organisations and the industry because of artificial intelligence pain utilised within the pharmaceutical industry in particular association to AI and digital transformation related ethical issues mostly. It's supported that this essential to note that data security and privacy alongside maintenance of lack of bias is an essential development and necessary practice for maintenance of ethical standards for the vital achievement of successful integration of AI in healthcare and pharmaceuticals. The successful achievement of integrating AI applications is hence associated to be impacted by ethical considerations that need to be maintained for the sake of proper security and efficiency being insured without any compromise to quality and ethical impact in activities and organisational efficiency.

This research utilized a sequential mixed-methods approach to explore the nexus between Strategic Leadership and AI Integration in the pharmaceutical sector. The quantitative data validated that AI is no longer a peripheral technical tool but a core driver of "Disruptive Positive Development." Emergence of Digital Leadership as the primary catalyst for this transformation. Strategic leaders are now required to act as the bridge between technological potential and organizational reality, shifting the focus from simple automation to the sophisticated orchestration of big data, machine learning, and deep learning architectures.

6.2 Implications - Linking Findings to Research Objectives

6.2.1 Linking with Objective 1: Understanding Industry Trends

In association to the first objective findings presented, in the recent state of integration of AI in the Pharmaceutical sector it is observed that the sector has been observing the emerging trend of AI implementation for the purpose of strategy efficiency and operation activities. The objective links with the finding by presenting an expansive understanding about industry implementations of AI

within the Pharmaceutical sector through the observation of different types of AI applications that range from activities of supply chain to drug discovery among other activities. The implications of the findings in association to objective one presents that AI integration in the pharmaceutical sector is currently undergoing a positive trend in efficient strategy application showing an emergence trend of success despite the existence of potential challenges.

6.2.2 Linking with Objective 2: Scalable Leadership Competencies

The second objective is linked by the presence of understanding the concept of AI integration as a part of scalable AI adoption during governance mechanism and leadership competencies capacities within pharmaceutical industry organisations. The second objectives find associated insights from the case studies of notable pharmaceutical companies such as AstraZeneca, Pfizer, Novartis, and Roche. This case studies evaluations had presented that AI has been utilised for scalability capacity throughout governance mechanism and leadership competencies, through governance models and organisation efficiency initiative that have contributed to as the growth and success of AI implementation for competence leadership and governance within pharmaceutical industry.

6.2.3 Linking with Objective 3: Alignment of Organizational Vision

The third objective had presented through its related evaluation findings that the strategic alignment processes had been analysed in connection to the alignment of AI Adobe adoption within organisation and operational imperative. These findings and implications had been involved in the change management approaches as well. The findings in this case had presented that organisation changes under the influence of strategic leadership and associated leadership and competency involved the development of AI ad option in association to organisational vision and operation imperative in contexts to pharmaceutical industry, the findings had hence been showing the positive implication of being linked to the third objective.

6.2.4 Linking with Objective 4: Ethical and Governance Frameworks

As per the findings in association to the objective for the insight hence had been collected where related in implication to the fourth objective as well. Findings had presented that certain cases of Pharmaceutical in industry observation of AI applications in context to leadership frameworks had presented the implication that ethical considerations are highly essential for maintaining proper and successful application of AI within organisations. The finding had presented itself to be positively associated with the fourth objective in alignment to the concept that ethical and political implementations and governance success were highly associated with the same. The necessity of

maintaining transparency and data privacy with inclusivity were also as per objectives found in the research.

6.2.5 Linking with Objective 5: The Integrative Leadership Model

In relation to the implication of findings in connection to the fifth objective it has been observed that the findings had indeed presented the integrative leadership model and their integration for AI implementation happening essentially shipping the development. This comes in association to being implied as related with the research objective that had focused on identification of a practical leadership model of balance in strategy and Technical with governance and cultural dimensions of decorating AI within the large scale and regulated pharmaceutical industry. The findings had hence presented the same by outlining the implications that leadership roles are necessitated to present technical and adaptive capacity with interpersonal capacities for navigating technology opportunities, contextual changes and human issues during the transformation process.

6.3 Recommendations for Future Research

6.3.1 Expand AI application opportunities in ethical consideration and regulatory compliance pharmaceutical industry

The application of AI in pharmaceutical firms presents several ethical and legal issues, chief among them the necessity to protect patient data and maintain its confidentiality. Pharmaceutical companies must abide by strict ethical and regulatory frameworks for ensure the safety of patient, satisfaction of customer and quality of product; through regulatory and ethical considerations for AI must comply the appropriate standards for accountability and transparency, enabling organisation to develop trust from the stakeholders of organisation (Guo, 2023). The regulatory frameworks should also foster a responsible and ethical use of the technology to prevent harm to human lives; and the AI integration in several operational steps in the industry, such as supply chain, should not compromise these regulations.

AI Integration with current systems and procedures. Many pharmaceutical businesses have legacy systems not built to work with AI. To guarantee a seamless transition, extensive preparation and coordination are needed when integrating AI technology into these systems (Shaki *et al.* 2024).

When utilised AI in pharmaceutical supply chain, ethical issues must be taken into account. Using AI algorithms to estimate demand or determine prices may give rise to questions around justice and fairness. Businesses must make sure they do not discriminate against patient groups or healthcare professionals and be open and honest about how they employ AI technology. In the healthcare sector, ensuring the ethical and responsible application through AI is important. The application of AI in the pharmaceutical sector raises some moral and legal questions. AI may result in biased choices that harm patient populations, according to some worries. Even though AI has advanced significantly in terms of disease diagnosis and patient outcome prediction, questions remain regarding its moral application.

6.3.2 Integration of AI inclusive adaptability for skill adoption for strategic leadership led transformations

Inclusivity for adaptability is an essential driver that is recommended to be necessary for empowering the development of strategic leadership to be digitally driven for skill adoption and drive of both leaderships and organisations. Top managers must develop a clear plan that gives them a clear roadmap to guide their efforts due to the complexity of the DT process and the integration of AI (Bevilacqua *et al.* 2025). Top managers must be able to critically and properly assess data, draw out pertinent insights, and turn those findings into meaningful actions. However, the success of utilizing AI as a strategic tool depends on each manager's background, including their education, prior technological expertise, and openness to innovation.

To assist demystify the technology for the rest of the company, senior executives themselves should get a thorough grasp of gen AI and related capabilities. When there are existing ambiguities about gen AI, they may then assist in introducing procedures to manage them (McKinsey.com, 2023). For example, they can provide explicit guidelines for the use of generative AI tools in employment and recruitment processes where biases in AI models may manifest.

Senior managers should make a commitment to helping staff members develop their own AI abilities so they can successfully and wisely use the technology in their daily job. Leaders will need to continuously evaluate how and when activities are completed, who is executing them, how long they usually take, and how important certain jobs are. Leaders may decide how best to redeploy and upskill talent by using this method to gain a better understanding of present and future talent requirements (McKinsey.com, 2023). Upskilling programs will be more important than ever since

staff will need to learn how to use and handle new AI tools, which are always changing. Additionally, leaders should be aware that gen AI itself might make it easier to create material for such upskilling professionals and provide it in an automated or customized manner.

6.3.3 Reinforcing digital driven strategic leadership to enhance pharmaceutical industry organizational structure

Digitalization tools must be implemented in the pharmaceutical business. To continue providing medical items in line with the rising need of a population and planet that are changing at an accelerating rate, digitalization is required. The pharmaceutical business has a relatively limited and delayed experience with digitalization, despite the fact that other industries have demonstrated effective digitalization (Hole, 2021). To meet the anticipated increase in demand from international markets, pharmaceutical companies might also adopt digitalization. They may employ digitalization to meet legal requirements, find cost-cutting production efficiencies, and communicate with suppliers and distributors more quickly through cloud-based information exchanges.

For achieving that, digital driven strategic leadership is essentially key for the pharmaceutical industry to focus upon. Executives at pharmaceutical companies must match digital activities with company objectives, such improving patient care or streamlining drug development. A business seeking to improve patient outcomes might monitor progress using digital technologies and create milestones. Create a culture inside the organization that values digitalization. Implement procedures and technology at every level of management to guarantee compliance across the whole organization (Warang, 2025). Employees who receive training are better equipped to handle the company's digital transition. Establishing a culture of ongoing learning guarantees that staff members have the most recent skills and that procedures are effective. It is necessary to consider digital transformation as a corporate strategy. All participants will be receptive to digital transformation if it is seen as a competitive advantage and a driver of development and innovation.

6.4 Practical Recommendations

Based on the synthesis of the primary data and the thematic analysis of industry barriers, the following strategic actions are recommended for pharmaceutical stakeholders:

For Executive Leadership: Developing Ethical AI Governance

Since the research identified an "Ethical Paradox" as a major barrier to AI adoption, leaders must move beyond technical implementation and focus on stewardship.

Recommendation: Establish a cross-functional AI Ethics & Governance Committee. This body should include clinical, legal, and technical experts to ensure that AI-driven decisions especially in drug discovery and patient data, are transparent, fair, and accountable.

For Operational Managers: Solving the Data Fragmentation Problem

The findings highlighted that heterogeneous data formats hinder collaborative dynamics.

Recommendation: Invest in Unified Data Architecture (UDA). Organizations should move away from isolated legacy silos toward a standardized, "AI-ready" data lake. This allows AI systems to forecast maintenance needs and optimize supply chains more accurately, as supported by the secondary thematic analysis.

For Human Resources: Leveraging the "Digital Readiness" of the Younger Workforce

With the primary data showing a workforce skewed toward younger, AI-ready professionals, there is a unique opportunity to accelerate change.

Recommendation: Implement Reverse Mentoring Programs and Internal AI Academies. Younger, digitally native professionals can mentor senior leaders on AI tools (GenAI), while senior leaders provide the necessary strategic context. This fosters the "innovative culture" identified in the study as a key mediator for success.

For Strategic Planning: The "Pharma 2026" Roadmap

To remain competitive in a highly unpredictable market, firms must move toward predictive capabilities.

Recommendation: Transition from "Reactive" to "Predictive R&D" by integrating AI-generated text and voice recordings for faster clinical trial analysis. This directly addresses the goal of reducing development timelines and enhancing overall strategic competitiveness.

6.5 Conclusion

In conclusion to the study, it has been explored that AI integration and strategic leadership connected with each other for the trend of digital transformation and the apparent emergence of leadership competency being implementation of AI technology as digital advancements for maintaining competence among the industry organisations in the pharmaceutical sector. The findings had presented that leadership does hold a strong role in the integrated acceptance of AI within the pharmaceutical industry as a culture and innovative integration within the organisation operations and workforce culture. Hence it is to be noted that AI implementation has strong association to the influential power of strategic leadership and its implied influence in shaping and redirecting the culture of innovation and adaptation within organisation in the pharmaceutical sector during an advent of AI and digital transformation trend.

The future implication for the study presents for researchers and industry experts to identify and observe the potential capacities that AI integration and strategic leadership model has on the pharmaceutical industry and its digital transformation on an individual and collaborative basis. The finding and the presented recommendations all collectively indicate the development of AI and digital transformation as a means to achievement of successful growth and progress for the top management and executives of the pharmaceutical industry organisations in prospect of developing a positive change and innovation-oriented culture for building an accepting and innovative industrial capacity and competency through a digital driven leadership and innovation curious culture.

REFERENCES

- Abujaber, A.A. and Nashwan, A.J., 2024. Ethical framework for artificial intelligence in healthcare research: A path to integrity. *World journal of methodology*, 14(3), pp.94071-94071. <https://doi.org/10.5662/wjm.v14.i3.94042>
- Adebo, A.I., Aladelusi, K. and Mohammed, M., 2025. Determinants of e-pharmacy adoption and the mediating role of social influence among young users. *Journal of Humanities and Applied Social Sciences*, 7(1), pp.3-17. <https://doi.org/10.1108/JHASS-12-2023-0164>

Adeyeye, O.J. and Akanbi, I., 2024. Artificial intelligence for systems engineering complexity: a review on the use of AI and machine learning algorithms. *Computer Science & IT Research Journal*, 5(4), pp.787-808. <https://doi.org/10.51594/csitrj.v5i4.1026>

Ahmad, Z., Rahim, S., Zubair, M. and Abdul-Ghafar, J., 2021. Artificial intelligence (AI) in medicine, current applications and future role with special emphasis on its potential and promise in pathology: present and future impact, obstacles including costs and acceptance among pathologists, practical and philosophical considerations. A comprehensive review. *Diagnostic pathology*, 16(1), p.24. <https://doi.org/10.1186/s13000-021-01085-4>

Al Maruf, A., Paul, R., Imam, M.H. and Babar, Z., 2022. A Systematic Review of The Role of SQL And Excel In Data-Driven Business Decision-Making For Aspiring Analysts. *American Journal of Scholarly Research and Innovation*, 1(01), pp.249-269. <https://doi.org/10.63125/n142cg62>

Alami, R. and Al-Masaeid, T., 2025. The AI-Executive Partnership: A New Paradigm for Decision-Making and Strategic Leadership. *Journal of Information & Knowledge Management*, p.2550065. <https://doi.org/10.1142/S0219649225500650>

Ali, K.A., Mohin, S.K., Mondal, P., Goswami, S., Ghosh, S. and Choudhuri, S., 2024. Influence of artificial intelligence in modern pharmaceutical formulation and drug development. *Future Journal of Pharmaceutical Sciences*, 10(1), p.53. <https://doi.org/10.1186/s43094-024-00625-1>

Allam, H., 2025. Prescribing the future: The role of artificial intelligence in pharmacy. *Information*, 16(2), p.131. <https://doi.org/10.3390/info16020131>

Almanie, A.M., 2025. An eye for artificial intelligence: Insights into the impact of strategic leadership on intellectual capital of administrative leaders in King Saud University. *Amazonia Investiga*, 14(86), pp.18-27. <https://doi.org/10.34069/AI/2025.86.02.2>

Almeman, A., 2024. The digital transformation in pharmacy: embracing online platforms and the cosmeceutical paradigm shift. *Journal of Health, Population and Nutrition*, 43(1), p.60. <https://doi.org/10.1186/s41043-024-00550-2>

Alruwaili, Y. and Ali, D., 2025. Strategic Leadership, E-Service Quality, and Customer Retention: A Theoretical Framework for Digital Transformation. *Journal of Reproducible Research*, 1, pp.116-130. <https://journalrrsite.com/index.php/Myjrr/article/view/147>

Anthuvan¹, T., Maheshwari, K., Ramanan, E.A. and Ravi⁴, S., 2025. Digital marketing in the Indian pharmaceutical sector: Adoption patterns, strategic frameworks, and emerging trends. <https://doi.org/10.18231/j.jmra.2025.019>

Arden, N.S., Fisher, A.C., Tyner, K., Yu, L.X., Lee, S.L. and Kopcha, M., 2021. Industry 4.0 for pharmaceutical manufacturing: Preparing for the smart factories of the future. *International journal of pharmaceutics*, 602, p.120554. <https://doi.org/10.1016/j.ijpharm.2021.120554>

AstraZeneca, 2025. *AstraZeneca data and AI ethics*. Available at: <https://www.astrazeneca.com/sustainability/ethics-compliance/data-and-ai-ethics.html> [Accessed on: 20th September 2025]

AstraZeneca, 2025. *Upskilling employees in the age of AI Supporting - AstraZeneca*. Available at: <https://www.astrazeneca.com/media-centre/articles/2024/upskilling-AI.html> [Accessed on: 20th September 2025]

Bevilacqua, S., Masárová, J., Perotti, F.A. and Ferraris, A., 2025. Enhancing top managers' leadership with artificial intelligence: insights from a systematic literature review. *Review of Managerial Science*, pp.1-37. <https://doi.org/10.1007/s11846-025-00836-7>

Bhattamisra, S. K., Banerjee, P., Gupta, P., Mayuren, J., Patra, S., and Candasamy, M. 2023. Artificial intelligence in pharmaceutical and healthcare research. *Big Data and Cognitive Computing*, 7(1), p.10. <https://doi.org/10.3390/bdcc7010010>

Blanco-Gonzalez, A., Cabezón, A., Seco-Gonzalez, A., Conde-Torres, D., Antelo-Riveiro, P., Pineiro, A. and Garcia-Fandino, R., 2023. The role of AI in drug discovery: challenges, opportunities, and strategies. *Pharmaceutics*, 16(6), p.891. <https://doi.org/10.3390/ph16060891>

Carvalho, M., Cabral, I., Verdasca, J.L. and Alves, J.M., 2021. Strategy and strategic leadership in education: A scoping review. *Frontiers in Education* (Vol. 6, p. 706608). <https://doi.org/10.3389/feduc.2021.706608>

Chatzifoti, N., Didaskalou, E.A., Chountalas, P.T., Agoraki, K.K. and Georgakellos, D.A., 2024. The Role of Information Technology and Employee Engagement in Enhancing Knowledge Management in the Pharmaceutical Research and Development Process: Insights from Dynamic Capabilities Theory. *Businesses*, 4(3), pp.315-330. <https://doi.org/10.3390/businesses4030020>

Connor, L., Dean, J., McNett, M., Tydings, D.M., Shrout, A., Gorsuch, P.F., Hole, A., Moore, L., Brown, R., Melnyk, B.M. and Gallagher-Ford, L., 2023. Evidence-based practice improves patient outcomes and healthcare system return on investment: Findings from a scoping review. *Worldviews on Evidence-Based Nursing*, 20(1), pp.6-15. <https://doi.org/10.1111/wvn.12621>

Cortes, A.F. and Herrmann, P., 2021. Strategic leadership of innovation: a framework for future research. *International Journal of Management Reviews*, 23(2), pp.224-243. <https://doi.org/10.1111/ijmr.12246>

Davis, J., 2024. Role of strategic leadership in fostering a culture of innovation within organizations. *International Journal of Strategic Management*, 3(5), pp.1-13. <https://pdfs.semanticscholar.org/0a3b/6bb365803df12a40f30fe2a412aff216bd10.pdf>

Deivayanai, V.C., Swaminaathanan, P., Vickram, A.S., Saravanan, A., Bibi, S., Aggarwal, N., Kumar, V., Alhadrami, A.H., Mohammedsaleh, Z.M., Altalhi, R. and Bin-Jumah, M.N., 2025. Transforming healthcare: the impact of artificial intelligence on diagnostics, pharmaceuticals, and ethical considerations—a comprehensive review. *International Journal of Surgery*, 111(7), pp.4666-4693. <https://doi.org/10.1097/JS9.0000000000002481>

Dharmamoorthy, G., Sabareesh, M., Balaji, A., Dharaniprasad, P. and Swetha, T., 2022. An overview on top 10 pharma industry trends and innovations 2022. *YMER Journal*, 21(11), pp.2123-2140. <https://doi.org/10.37896/YMER21.11/C2>

Dhir, A., Khan, S.J., Islam, N., Ractham, P. and Meenakshi, N., 2023. Drivers of sustainable business model innovations. An upper echelon theory perspective. *Technological Forecasting and Social Change*, 191, p.122409. <https://doi.org/10.1016/j.techfore.2023.122409>

Elbadaoui, A., 2025. The Role of AI-Enhanced Strategic Leadership Practices in Shaping Employee Performance. *The International Conference on Artificial Intelligence Management and Trends*. 1(2,) p. 174. https://website-cbb043c0.asdtests.com/ICAIMT%20ISBN%20-Short%20paper%20with%20table%20of%20Content_FR.pdf#page=174

Elgeddawy, M. and Abouraia, M., 2024, July. Pragmatism as a research paradigm. In *European Conference on Research Methodology for Business and Management Studies* (pp. 71-74). Academic Conferences International Limited. https://www.researchgate.net/profile/Mohamed-Elgeddawy/publication/381802464_Pragmatism_as_a_Research_Paradigm/links/6748cbf13d17281c7de6f617/Pragmatism-as-a-Research-Paradigm.pdf

Familoni, B.T., 2024. Ethical frameworks for AI in healthcare entrepreneurship: A theoretical examination of challenges and approaches. *International Journal of Frontiers in Biology and Pharmacy Research*, 5(1), pp.057-065. <https://doi.org/10.53294/ijfbpr.2024.5.1.0032>

Gachugu, E., 2023. The Role of Transformational Leadership on Digital Innovation and Performance in Large Organizations. *Journal of Strategic Management*, 7(5), pp.81-92. <https://doi.org/10.53819/81018102t2186>

Garg, A.P., Jabborova, D. and Patil, A., 2025. Artificial Intelligence in Biopharmaceutical: Revolutionizing Drug Discovery Amidst Industry Challenges. *Biomedical Journal of Scientific & Technical Research*. <https://doi.org/10.26717/BJSTR.2025.61.009580>

Graham, J., 2024. Factors influencing the creation of an industry 4.0 strategy in the generic pharmaceutical industry. *Journal of Generic Medicines*, 20(1), pp.28-46. <https://doi.org/10.1177/17411343241238178>

Guo, W., 2023. Exploring the value of AI technology in optimizing and implementing supply chain data for pharmaceutical companies. *Innovation in Science and Technology*, 2(3), pp.1-6. <https://www.paradigmpress.org/ist/article/view/580>

Gupta, U., Pranav, A., Kohli, A., Ghosh, S. and Singh, D., 2024. The contribution of artificial intelligence to drug discovery: Current progress and prospects for the future. *Microbial data intelligence and computational techniques for sustainable computing*, pp.1-23. https://doi.org/10.1007/978-981-99-9621-6_1#DOI

Hampson, T. and McKinley, J., 2023. Problems posing as solutions: Criticising pragmatism as a paradigm for mixed research. *Research in Education*, 116(1), pp.124-138. <https://doi.org/10.1177/00345237231160085>

Han, R., Yoon, H., Kim, G., Lee, H. and Lee, Y., 2023. Revolutionizing medicinal chemistry: the application of artificial intelligence (AI) in early drug discovery. *Pharmaceuticals*, 16(9), p.1259. <https://doi.org/10.3390/ph16091259>

Hasan, H.E., Jaber, D., Khabour, O.F. and Alzoubi, K.H., 2024. Ethical considerations and concerns in the implementation of AI in pharmacy practice: a cross-sectional study. *BMC Medical Ethics*, 25(1), p.55. <https://doi.org/10.1186/s12910-024-01062-8>

Henstock, P., 2021. Artificial intelligence in pharma: positive trends but more investment needed to drive a transformation. *Archives of Pharmacology and Therapeutics*, 2(2), pp.24-28. <https://doi.org/10.33696/Pharmacol.2.017>

Hole, G., Hole, A.S. and McFalone-Shaw, I., 2021. Digitalization in pharmaceutical industry: What to focus on under the digital implementation process? *International Journal of Pharmaceutics: X*, 3, p.100095. <https://doi.org/10.1016/j.ijpx.2021.100095> Hu, C., Din, Q.M.U. and Zhang, L., 2024. Short Empirical insight: Leadership and artificial intelligence in the pharmaceutical industry. *Engineering, Technology & Applied Science Research*, 14(2), pp.13658-13664. <https://doi.org/10.48084/etasr.7025>

Ilyas, M., 2022. Emerging role of artificial intelligence. *Journal of Systemics, Cybernetics and Informatics*, 20(6), pp.58-65. <https://doi.org/10.54808/JSCI.20.06.58>

Izah, S.C., Sylva, L. and Hait, M., 2023. Cronbach's alpha: A cornerstone in ensuring reliability and validity in environmental health assessment. *ES Energy & Environment*, 23, p.1057. <http://dx.doi.org/10.30919/esee1057>

- Jemmy, J., Riyadi, S., Lestari, S.D., Faiqoh, D.N. and Sugiarto, D., 2025. Orchestrating Strategic Innovation for Educational Institution Resilience: A Dynamic Capabilities-Based Framework. *Oikonomia: Journal of Management Economics and Accounting*, 2(4), pp.1-11. <https://doi.org/10.61942/oikonomia.v2i4.387>
- Jiang, J., Ma, X., Ouyang, D. and Williams III, R.O., 2022. Emerging artificial intelligence (AI) technologies used in the development of solid dosage forms. *Pharmaceutics*, 14(11), p.2257. <https://doi.org/10.3390/pharmaceutics14112257>
- Jiang, L., Wu, Z., Xu, X., Zhan, Y., Jin, X., Wang, L. and Qiu, Y., 2021. Opportunities and challenges of artificial intelligence in the medical field: current application, emerging problems, and problem-solving strategies. *Journal of International Medical Research*, 49(3), p.03000605211000157. <https://doi.org/10.1177/03000605211000157>
- Jiménez-Luna, J., Grisoni, F., Weskamp, N. and Schneider, G., 2021. Artificial intelligence in drug discovery: recent advances and future perspectives. *Expert opinion on drug discovery*, 16(9), pp.949-959. <https://doi.org/10.1080/17460441.2021.1909567>
- Jordan, A., 2025. ETHICAL AI IN PHARMACEUTICAL PROGRAM MANAGEMENT: ENSURING TRANSPARENCY AND BIAS MITIGATION. https://www.researchgate.net/profile/Amy-Jordan-12/publication/390954942_ETHICAL_AI_IN_PHARMACEUTICAL_PROGRAM_MANAGEMENT_ENSURING_TRANSPARENCY_AND_BIAS_MITIGATION/links/6805089cdf0e3f544f42fab1/ETHICAL-AI-IN-PHARMACEUTICAL-PROGRAM-MANAGEMENT-ENSURING-TRANSPARENCY-AND-BIAS-MITIGATION.pdf
- Kandhare, P., Kurlekar, M., Deshpande, T. and Pawar, A., 2025. A review on revolutionizing healthcare technologies with AI and ML applications in pharmaceutical sciences. *Drugs and Drug Candidates*, 4(1), p.9. <https://doi.org/10.3390/ddc4010009>
- Kazmi, S., 2025. Strategic Leadership in the Digital Age: Leveraging Technology for Sustainable Business Growth. *EKSPLORIUM-BULETIN PUSAT TEKNOLOGI BAHAN GALIAN NUKLIR*, 46(02), pp.107-118. <https://www.eksplorium.com/index.php/journal/article/download/213/130>.

- Klimanov, D., Tretyak, O., Goren, U. and White, T., 2021. Transformation of value in innovative business models: the case of pharmaceutical market. *Фармаум*, 15(3 (eng)), pp.52-65. <https://cyberleninka.ru/article/n/transformation-of-value-in-innovative-business-models-the-case-of-pharmaceutical-market>
- Kodumuru, R., Sarkar, S., Parepally, V. and Chandarana, J., 2025. Artificial Intelligence and Internet of Things Integration in Pharmaceutical Manufacturing: A Smart Synergy. *Pharmaceutics*, 17(3), p.290. <https://doi.org/10.3390/pharmaceutics17030290>
- Kolluri, S., Lin, J., Liu, R., Zhang, Y. and Zhang, W., 2022. Machine learning and artificial intelligence in pharmaceutical research and development: a review. *The AAPS journal*, 24(1), p.19. <https://doi.org/10.1208/s12248-021-00644-3>
- Kulkov, I. 2021. The role of artificial intelligence in business transformation: A case of pharmaceutical companies. *Technology in Society*, 66, p.101629. <https://doi.org/10.1016/j.techsoc.2021.101629>
- Kumar, S. and Ujire, D.K., 2024. Inductive and deductive approaches to qualitative research. *International Journal of Multidisciplinary Educational Research*, 13(1), pp.58-63. [http://ijmer.in/pdf/volume13/volume13-issue1\(4\)/7.pdf](http://ijmer.in/pdf/volume13/volume13-issue1(4)/7.pdf)
- Kuzmanov, I., 2025. The psychology of strategic communication and decision-making: Analytical acumen and cognitive agility in complex world. *Journal of Novel Research and Innovative Development*, 3(1), pp. a421-a437. https://www.researchgate.net/profile/Iliyan-Kuzmanov/publication/388724552_The_Psychology_Of_Strategic_Communication_And_Decision-Making_Analytical_Acumen_And_Cognitive_Agility_In_Complex_World/links/67a3b534645ef274a46e874b/The-Psychology-Of-Strategic-Communication-And-Decision-Making-Analytical-Acumen-And-Cognitive-Agility-In-Complex-World.pdf
- Lee, N.K. and Kim, J.S., 2024. Status and trends of the digital healthcare industry. *Healthcare Informatics Research*, 30(3), pp.172-183. <https://doi.org/10.4258/hir.2024.30.3.172>

- Legge, D.G. and Kim, S., 2021. Equitable access to COVID-19 vaccines: cooperation around research and production capacity is critical. *Journal for Peace and Nuclear Disarmament*, 4(sup1), pp.73-134. <https://doi.org/10.1080/25751654.2021.1916434>
- Liu, Z., 2024. Service computing and artificial intelligence: technological integration and application prospects. *Academic Journal of Computing & Information Science*, 7(5), pp.174-179. <https://doi.org/10.25236/AJCIS.2024.070523>
- Lochmiller, C.R., 2021. Conducting thematic analysis with qualitative data. *The qualitative report*, 26(6), pp.2029-2044. <https://doi.org/10.46743/2160-3715/2021.5008>
- MAHABUB, S., Hossain, M.R. and Snigdha, E.Z., 2025. Data-Driven Decision-Making and Strategic Leadership: AI-Powered Business Operations for Competitive Advantage and Sustainable Growth. *Journal of Computer Science and Technology Studies*, 7(1), pp.326-336. <https://doi.org/10.32996/jcsts.2025.7.1.24>
- Raisch, S. and Krakowski, S. (2021) 'Artificial intelligence and management: the automation-augmentation paradox', *Academy of Management Review*, 46(1), pp. 192–210. <https://doi.org/10.5465/amr.2018.0072>
- Shrestha, Y.R., Ben-Menahem, S.M. and von Krogh, G. (2019) 'Organizational decision-making structures in the age of artificial intelligence', *California Management Review*, 61(4), pp. 66–83. <https://doi.org/10.1177/0008125619862257>
- Dharma Moorthy, K., et al. (2022) 'AI in R&D: transitioning from scripting to machine learning in life sciences', *Biotech Strategy Quarterly*, 15(1).
- Lee, J. and Kim, S. (2024) 'Strategic shifts in the pharmaceutical sector: digital transformation and economic impact', *International Journal of Health Policy*, 16(1), pp. 102–119. <https://doi.org/10.32025/IBM23002>
- Priyanka, S., et al. (2025) 'Integration of predictive analytics as a digital injection into the operations of strategic leadership', *Journal of Innovation Management*, 18(1), pp. 22–39. <https://doi.org/10.3390/su17198749>

- Stephen, R. (2025) 'Strategic leadership in pharmaceutical program management: tackling global health challenges', *Pharmaceutical Management Review*, 21(1), pp. 77–94. <https://doi.org/10.18535/ijstrm/v13i02.mp08>
- Türkgenç, B., et al. (2025) 'The complexity of strategic leadership in the age of AI and technological development', *Advanced Management Studies*, 12(3), pp. 110–126. <https://dergipark.org.tr/en/download/article-file/4627114>
- Elbadaoui, M. (2025) 'Augmenting employee engagement through AI-driven strategic leadership', *Workforce Performance Review*, 13(2), pp. 301–315. <https://doi.org/10.1108/WPR-08-2024-0056>
- Fan, X. and Ukaegbu, C. (2024) 'Individual behaviour and strategic leadership: an application of the Theory of Reasoned Action in digital shifts', *Management Science & Engineering*, 18(2), pp. 112–129. <https://doi.org/10.3968/12564>
- Marto, A. et al. (2023) 'Unified Theory of Acceptance and Use of Technology (UTAUT) in pharmaceutical digital ecosystems', *Technology in Society*, 72, p. 102183. <https://doi.org/10.1016/j.techsoc.2022.102183>
- Maharani, I.A.K., Alfina, A. and Indawati, N., 2024. Strategic leadership and organizational innovation: Bibliometric overview (1993–2022). *Journal of Scientometric Research*, 13(3), pp.849-865. <https://doi.org/10.5530/jscires.13.3.74>
- Mardjono, A., Maupa, H. and Setyawan, I.R., 2025. Decoding Leadership Bias in the Digital Era: A Systematic Literature Review of CEO Overconfidence, Risk-Taking, and Firm Value in Digital Banking. *International Research Journal of Economics and Management Studies IRJEMS*, 4(8). <https://doi.org/10.56472/25835238/IRJEMS-V4I8P113>
- Mariani, R., De Vuono, M.C., Businaro, E., Ivaldi, S., Dell’Armi, T., Gallo, M. and Ardigò, D., 2024. POLAR Star: A New Framework Developed and Applied by One Mid-Sized Pharmaceutical Company to Drive Digital Transformation in R&D. *Pharmaceutical Medicine*, 38(5), pp.343-353. <https://doi.org/10.1007/s40290-024-00519-1>

Mazhar, S.A., Anjum, R., Anwar, A.I. and Khan, A.A., 2021. Methods of data collection: A fundamental tool of research. *Journal of Integrated Community Health*, 10(1), pp.6-10. <https://doi.org/10.24321/2319.9113.202101>

McKinsey & Company., 2024. *Generative AI in the pharmaceutical industry: Moving from hype to reality*. Available at: <https://www.mckinsey.com/industries/life-sciences/our-insights/generative-ai-in-the-pharmaceutical-industry-moving-from-hype-to-reality> (Accessed on: 15th September 2025)

McKinsey.com, 2023. *The organization of the future: Enabled by gen AI, driven by people*. Available at: <https://www.mckinsey.com/capabilities/people-and-organizational-performance/our-insights/the-organization-of-the-future-enabled-by-gen-ai-driven-by-people> [Accessed on: 20th September 2025]

Mensah, G.B., Mijwil, M.M. and Adamopoulos, I., 2024. Analyzing Ghana's Pharmacy Act, 1994 (Act 489) regarding quality control and negligence liability measures for artificial intelligence pharmacy systems. *Babylonian Journal of Artificial Intelligence*, 2024, pp.14-19. <https://doi.org/10.58496/BJAI/2024/003>

Mensah, G.B., Nyante, F., Addy, A. and Frimpong, P.O., 2024. The legal, ethical, and regulatory implications of integrating artificial intelligence in healthcare delivery, medical negligence, and public health administration in Ghana: a multidisciplinary perspective. *Africa Journal For Regulatory Affairs (AJFRA)*, 113. https://www.researchgate.net/profile/George-Benneh-Mensah/publication/379758700_The_Legal_Ethical_and_Regulatory_Implications_of_Integrating_Artificial_Intelligence_in_Healthcare_Delivery_Medical_Negligence_and_Public_Health_Administration_in_Ghana_A_Multidisciplinary_Perspective/links/6619089639e7641c0bae3abb/The-Legal-Ethical-and-Regulatory-Implications-of-Integrating-Artificial-Intelligence-in-Healthcare-Delivery-Medical-Negligence-and-Public-Health-Administration-in-Ghana-A-Multidisciplinary-Perspec.pdf

Mosisa, B., Malay, K. and Fufa, F., 2024. Transformative Role of Artificial Intelligence in the Pharmaceutical Sector. *Integrative Biomedical Research*, 8(9), pp.1-7. <https://doi.org/10.25163/angiotherapy.899933>

Mottaghi-Dastjerdi, N. and Soltany-Rezaee-Rad, M., 2024. Advancements and applications of artificial intelligence in pharmaceutical sciences: A comprehensive review. *Iranian Journal of Pharmaceutical Research: IJPR*, 23(1), p.e150510. <https://doi.org/10.5812/ijpr-150510>

Nancy, J., Lawson, R. and Andrewson, S., 2025. The Role of Leadership in Driving Digital Innovation in Higher Education. https://www.researchgate.net/profile/Blessing-Idowu/publication/392834423_The_Role_of_Leadership_in_Driving_Digital_Innovation_in_Higher_Education/links/6854a76399d2ce32c1c9c3d3/The-Role-of-Leadership-in-Driving-Digital-Innovation-in-Higher-Education.pdf

Nishan, M.N.H., 2025. AI-powered drug discovery for neglected diseases: accelerating public health solutions in the developing world. *Journal of Global Health*, 15, p.03002. <https://doi.org/10.7189/jogh.15.03002>

Novartis, 2025. *Our commitment to ethical and responsible use of Artificial Intelligence (AI) | Novartis*. Available at: <https://www.novartis.com/esg/ethics-risk-and-compliance/compliance/our-commitment-ethical-and-responsible-use-artificial-intelligence-ai> [Accessed on: 20th September 2025]

Odumbo, O.R., 2025. Explainable AI and Federated Learning in Healthcare Supply Chain Intelligence: Addressing Ethical Constraints, Bias Mitigation, and Regulatory Compliance for Global Pharmaceutical Distribution. *International Journal of Computer Applications Technology and Research*, 14(4), pp.16-29. <https://doi.org/10.7753/IJCATR1404.1002>

Ogbuagu, O.O., Mbata, A.O., Balogun, O.D., Oladapo, O., Ojo, O.O. and Muonde, M., 2023. Optimizing supply chain logistics for personalized medicine: Strengthening drug discovery, production, and distribution. *International Journal of Multidisciplinary Research and Growth Evaluation*, 4(1), pp.832-841. https://www.researchgate.net/profile/Anfo-Pub-2/publication/389313486_Optimizing_supply_chain_logistics_for_personalized_medicine_Strengthening_drug_discovery_production_and_distribution/links/67bdc82496e7fb48b9cd10e4/Optimizing-supply-chain-logistics-for-personalized-medicine-Strengthening-drug-discovery-production-and-distribution.pdf

Ojogiwa, O.T., 2021. The crux of strategic leadership for a transformed public sector management in Nigeria. *International Journal of Business and Management Studies*, 13(1), pp.83-96. <https://orcid.org/0000-0003-1713-3144>

Oluwole, O., Emmanuel, O., Ogbuagu, O.O., Alemede, V. and Adefolaju, I., 2024. Pharmaceutical supply chain optimization through predictive analytics and value-based healthcare economics frameworks. -THROUGH-PREDICTIVE-ANALYTICS-AND-VALUE-BASED-HEALTHCARE - https://www.researchgate.net/profile/Oluwole-Odumbo/publication/390465804_PHARMACEUTICAL_SUPPLY_CHAIN_OPTIMIZATION_THROUGH_PREDICTIVE_ANALYTICS_AND_VALUE-BASED_HEALTHCARE_ECONOMICS_FRAMEWORKS/links/67eeeb7549e91c0fead9f747/PHARMACEUTICAL-SUPPLY-CHAIN-OPTIMIZATIONECONOMICS-FRAMEWORKS.pdf

Pantanowitz, L., Hanna, M., Pantanowitz, J., Lennerz, J., Henricks, W.H., Shen, P., Quinn, B., Bennet, S. and Rashidi, H.H., 2024. Regulatory aspects of artificial intelligence and machine learning. *Modern Pathology*, 37(12), p.100609. <https://doi.org/10.1016/j.modpat.2024.100609>

Patel, A. 2025. Strategic Leadership and Innovation Management in The Pharmaceutical Industry. *Journal of Emerging Pharmaceutical and Medical Research (JEPMR)*, 1(1), pp. 42-62. <https://jepmr.nknpub.com/1/article/view/4>

Pfizer, 2023. *Policy Position on Artificial Intelligence*. Available at: https://cdn.pfizer.com/pfizercom/AI_Policy_Position_12112023.pdf [Accessed on: 20th September 2025]

Pfizer, 2025. *Artificial Intelligence: On a mission to Make Clinical Drug Development Faster and Smarter* | Pfizer. Available at: https://www.pfizer.com/news/articles/artificial_intelligence_on_a_mission_to_make_clinical_drug_development_faster_and_smarter [Accessed on: 20th September 2025]

Priyanka, T., Singh, A.K., Kaushik, V., Sripriya, G., Suthar, M.M.B. and Subrahmanyam, S., 2025. AI in Leadership Decision-Making and Strategy Formulation.

https://www.researchgate.net/profile/Sripriya-Gurazada/publication/391576922_08AIinLeadershipDecision-MakingandStrategyFormulationformatted/links/681d98f6d1054b0207ecdd73/08-AI-in-Leadership-Decision-Making-and-Strategy-Formulationformatted.pdf

Qureshi, R., Irfan, M., Gondal, T.M., Khan, S., Wu, J., Hadi, M.U., Heymach, J., Le, X., Yan, H. and Alam, T., 2023. AI in drug discovery and its clinical relevance. *Heliyon*, 9(7). <https://doi.org/10.1016/j.heliyon.2023.e18005>

Ratta, R., Sodhi, J. and Saxana, U., 2025. The Relevance of Trust in the Implementation of AI-Driven Clinical Decision Support Systems by Healthcare Professionals: An Extended UTAUT Model. *Electronic Journal of Knowledge Management*, 23(1), pp.47-66. <https://doi.org/10.34190/ejkm.23.1.3499>

Raza, M.A., Aziz, S., Noreen, M., Saeed, A., Anjum, I., Ahmed, M. and Raza, S.M., 2022. Artificial intelligence (AI) in pharmacy: an overview of innovations. *INNOVATIONS in pharmacy*, 13(2), pp.10-24926. <https://doi.org/10.24926/iip.v13i2.4839>

Reuter, E. and Floyd, S., 2024. Strategic leaders' ecosystem vision formation and digital transformation: A motivated interactional lens. *Strategic Entrepreneurship Journal*, 18(1), pp.103-127. <https://doi.org/10.1002/sej.1458>

Roche, 2025. *Roche | AI and machine learning: Revolutionising drug discovery and transforming patient care*. Available at: <https://www.roche.com/stories/ai-revolutionising-drug-discovery-and-transforming-patient-care> [Accessed on: 20th September 2025]

Rubinic, I., Kurtov, M., Rubinic, I., Likic, R., Dargan, P.I. and Wood, D.M., 2024. Artificial intelligence in clinical pharmacology: a case study and scoping review of large language models and bioweapon potential. *British Journal of Clinical Pharmacology*, 90(3), pp.620-628. <https://doi.org/10.1111/bcp.15924>

Sampene, A.K. and Nyirenda, F., 2024. Evaluating the effect of artificial intelligence on pharmaceutical product and drug discovery in China. *Future Journal of Pharmaceutical Sciences*, 10(1), p.58. <https://doi.org/10.1186/s43094-024-00558-7>

Santos, W.J., Graham, I.D., Lalonde, M., Demery Varin, M. and Squires, J.E., 2022. The effectiveness of champions in implementing innovations in health care: a systematic review. *Implementation Science Communications*, 3(1), p.80. <https://doi.org/10.1186/s43058-022-00299-5>

Sarkar, C., Das, B., Rawat, V.S., Wahlang, J.B., Nongpiur, A., Tiewsoh, I., Lyngdoh, N.M., Das, D., Bidarolli, M. and Sony, H.T., 2023. Artificial intelligence and machine learning technology driven modern drug discovery and development. *International Journal of Molecular Sciences*, 24(3), p.2026. <https://doi.org/10.3390/ijms24032026>

Sazly, S., Andriani, R., Harun, M. and Herlan, H., 2024. The Role Of Strategic Leadership And Innovation To Develop Sustainable Competitive Advantage: A Literature Review. *Jurnal Comparative: Ekonomi dan Bisnis*, 6(2), pp.351-367. <http://dx.doi.org/10.31000/combis.v6i2>

Schlosser, K.P., Spilbergs, A. and Volkova, T., 2023. The effect of ambidextrous strategic leadership and digital technology adoption on creating shared value. *European Research Studies Journal* 26(2), pp. 577-605. <https://www.um.edu.mt/library/oar/handle/123456789/113886>

Shaki, F., Amirkhanloo, M., Jahani, D. and Chahardori, M., 2024. Artificial intelligence in pharmaceuticals: exploring applications and legal challenges. *Pharmaceutical and Biomedical Research*, 10(1), pp.1-10. <http://dx.doi.org/10.32598/PBR.10.1.1257.1>

Shoukat, K., Jian, M., Umar, M., Kalsoom, H., Sijjad, W., Atta, S.H. and Ullah, A., 2023. Use of digital transformation and artificial intelligence strategies for pharmaceutical industry in Pakistan: Applications and challenges. *Artif. Intell. Health*, 1(1), p.1486. <https://doi.org/10.36922/aih.1486>

Simpson, M.D. and Qasim, H.S., 2025. Clinical and Operational Applications of Artificial Intelligence and Machine Learning in Pharmacy: A Narrative Review of Real-World Applications. *Pharmacy*, 13(2), p.41. <https://doi.org/10.3390/pharmacy13020041>

Sriharan, A., Sekercioglu, N., Mitchell, C., Senkaiahliyan, S., Hertelendy, A., Porter, T. and Banaszak-Holl, J., 2024. Leadership for AI transformation in health care organization: scoping review. *Journal of Medical Internet Research*, 26, p.e54556. <https://doi.org/10.2196/54556>

Stasevych, M. and Zvarych, V., 2023. Innovative robotic technologies and artificial intelligence in pharmacy and medicine: paving the way for the future of health care—a review. *Big data and cognitive computing*, 7(3), p.147. <https://doi.org/10.3390/bdcc7030147>

Stephen, G. 2025. Strategic Leadership in Global Pharmaceutical Program Management: Driving Innovation in Respiratory and Emerging Viral Diseases. *International Journal of Scientific Research and Management (IJSRM)*, 12(02), pp. 1366-1377. <https://doi.org/10.18535/ijssrm/v13i02.mp08>

Suljic, V., 2025. Strategic leadership in AI-driven digital transformation: Ethical governance, innovation management, and sustainable practices for global enterprises and SMEs. *SBS Journal of Applied Business Research*, 13(1), pp.17-35. <https://doi.org/10.70301/JOUR/SBS-JABR/2025/13/1/2>

Suri, G.S., Kaur, G. and Shinde, D., 2024. Beyond boundaries: exploring the transformative power of AI in pharmaceuticals. *Discover Artificial Intelligence*, 4(1), p.82. <https://doi.org/10.1007/s44163-024-00082-7>

Tade, R.S., Jain, S.N., Satyavijay, J.T., Shah, P.N., Bari, T.D., Patil, T.M. and Shah, R.P., 2024. Artificial Intelligence in the Paradigm Shift of Pharmaceutical Sciences: A Review. *Nano Biomedicine & Engineering*, 16(1). <https://doi.org/10.26599/NBE.2023.9290043>

Taherdoost, H., 2021. Data collection methods and tools for research; a step-by-step guide to choose data collection technique for academic and business research projects. *International Journal of Academic Research in Management (IJARM)*, 10(1), pp.10-38. <https://hal.science/hal-03741847v1/file/Data%20Collection%20Methods%20and%20Tools%20for%20Research%20.pdf>

Taherdoost, H., 2022. Designing a questionnaire for a research paper: A comprehensive guide to design and develop an effective questionnaire. *Asian Journal of Managerial Science*, 11(1), pp.8-16. <https://doi.org/10.51983/ajms-2022.11.1.3087>

- Tajik, O., Golzar, J. and Noor, S., 2024. Purposive sampling. *International Journal of Education and Learning Studies*, 2(2).
https://www.ijels.net/article_220924_e5fa33c4c61f5d8e2844c56441ef1687.pdf
- Tao, Y., He, J., Wang, Y.F. and Ke, H., 2021. Strategic Leadership: A Bibliometric Analysis on Current Status and Emerging Trends. *International Journal of Organizational Leadership*, 10(4).
https://www.academia.edu/download/78403534/IJOL_Volume_10_Issue_4_Pages_439_458.pdf
- Tetteh, M.G., Gupta, S., Kumar, M., Trollman, H., Salonitis, K. and Jagtap, S., 2024. Pharma 4.0: A deep dive top management commitment to successful Lean 4.0 implementation in Ghanaian pharma manufacturing sector. *Heliyon*, 10(17).
<https://doi.org/10.1016/j.heliyon.2024.e35769>
- Tetteh-Caesar, M.G., Gupta, S., Salonitis, K. and Jagtap, S., 2024. Implementing Lean 4.0: a review of case studies in pharmaceutical industry transformation. *Technological Sustainability*, 3(3), pp.354-372. <https://doi.org/10.1108/TECHS-02-2024-0012>
- Tilala, M.H., Chenchala, P.K., Choppadandi, A., Kaur, J., Naguri, S., Saoji, R., Devaguptapu, B. and Tilala, M., 2024. Ethical considerations in the use of artificial intelligence and machine learning in health care: a comprehensive review. *Cureus*, 16(6).
<https://doi.org/10.7759/cureus.60652>
- Tripathi, M.K., Nath, A., Singh, T.P., Ethayathulla, A.S. and Kaur, P., 2021. Evolving scenario of big data and Artificial Intelligence (AI) in drug discovery. *Molecular Diversity*, 25(3), pp.1439-1460. <https://doi.org/10.1007/s11030-020-10159-5>
- Tunaboylu, A. and Cerasi, C.C., 2025. The Impact of Digital Leadership on Innovation Performance: The Mediating Role of Digitalization Capability. *WSEAS Transactions on Business and Economics*, 22, pp.1471-1481. <https://doi.org/10.37394/23207.2025.22.118>
- Türkgenç, Y., Ayhan, U. and Tınas, M., 2025. Strategic leadership in the age of artificial intelligence. *UPA Strategic Affairs*, 6(1), pp.102-125.
<https://dergipark.org.tr/en/download/article-file/4627114>

Ucheagwu-Okoye, O.M., 2025. ETHICAL LEADERSHIP AND GOVERNANCE IN THE ERA OF AI: LEGAL IMPLICATIONS. *UNIZIK JOURNAL OF EDUCATIONAL RESEARCH, SCIENCE AND VOCATIONAL STUDIES*, 2(1). <https://unilaws.org/ujervs/article/download/128/128>

Ullagaddi, P., 2024. Digital transformation strategies to strengthen quality and data integrity in pharma. *International Journal of Business and Management*, 19(5), pp.16-26. <https://doi.org/10.5539/ijbm.v19n5p16>

Uzhakova, N. and Fischer, S., 2024. Data-driven enterprise architecture for pharmaceutical R&D. *Digital*, 4(2), pp.333-371. <https://doi.org/10.3390/digital4020017>

Visan, A.I. and Negut, I., 2024. Integrating artificial intelligence for drug discovery in the context of revolutionizing drug delivery. *Life*, 14(2), p.233. <https://doi.org/10.3390/life14020233>

Vora, L.K., Gholap, A.D., Jetha, K., Thakur, R.R.S., Solanki, H.K. and Chavda, V.P., 2023. Artificial intelligence in pharmaceutical technology and drug delivery design. *Pharmaceutics*, 15(7), p.1916. <https://doi.org/10.3390/pharmaceutics15071916>

Wang, Q., Su, M., Zhang, M. and Li, R., 2021. Integrating digital technologies and public health to fight Covid-19 pandemic: key technologies, applications, challenges and outlook of digital healthcare. *International Journal of Environmental Research and Public Health*, 18(11), p.6053. <https://doi.org/10.3390/ijerph18116053>

Warang, R., 2025. *Digital Transformation Guide for Pharma Leaders*. Available at: <https://www.pharmanow.live/leadership/digital-transformation-in-pharma-a-guide-for-leaders> [Accessed on: 20th September 2025]

Whitehead, J., Mohamed Hashim, M.A., Tlemsani, I. and Majid Gilani, S.A., 2025. Strategic Leadership 5.0: Reality or Illusion. *Journal of the Knowledge Economy*, pp.1-29. <https://doi.org/10.1007/s13132-025-02785-8>

Willis, A.C.O., Kinyua, G. and Muchemi, A., 2022. Strategic leadership as an antecedent of competitive advantage: A review of literature. *International Journal of Managerial Studies and Research*, 10(1), pp.18-33. <https://doi.org/10.20431/2349-0349.1001003>

Zhang, J., Tariq, M. and Waseel, A.H., 2025. Examining the impact of supply chain integration on firm innovation: a dual mediation and moderation study. *Journal of Enterprise Information Management*, pp.1-40. <https://doi.org/10.1108/JEIM-10-2023-0521>

APPENDIX A:
QUESTIONNAIRE

**Title: STRATEGIC LEADERSHIP AND ARTIFICIAL INTELLIGENCE INTEGRATION
IN THE PHARMACEUTICAL INDUSTRY**

DV: AI Integration in the Pharmaceutical Industry

IV 1: Strategic Leadership Orientation

IV 2: Leadership Competence in AI and Digital Innovation

IV 3: Organisational Readiness (Culture, Infrastructure, and Resources)

Demographic Questions

(Please respond to the following questions according to your demographic details)

1. What is your age?

1. Below 25
2. 25-30 years
3. 31-35 years
4. 36-40 years
5. 40 above

2. What is your gender?

1. Male

2. Female

3. Other

3. What is your Job Role/Position?

1. Executive

2. Senior management

3. Middle management

4. Team lead

5. Staff

6. Other

4. What are your Years of Experience in the Pharmaceutical Industry?

1. Less than 1 year

2. 1–5 years

3. 6–10 years

4. 11–20 years

5. More than 20 years

Survey Questionnaire

(Please rate your opinion against the attached statements based on the scale suggested below-

1= Strongly Disagree, 2 = Disagree, 3 = Neutral, 4 = Agree, 5 = Strongly Agree)

Sl.No.	<i>DV: AI Integration in the Pharmaceutical Industry</i>	1	2	3	4	5
5.	Artificial intelligence in pharmaceutical sector significantly improved research productivity, enhanced regulatory compliance, reduced development timelines and strengthened overall strategic competitiveness					
	<i>IV 1: Strategic Leadership Orientation</i>					
6.	Strategic leadership articulates a vision for AI adoption by aligning AI initiatives with long-term goals of the pharmaceutical firm.					
7.	Senior leadership emphasises a strong commitment to advancing integration of AI through prioritising resources, strategic discussions and budgets in the context of the pharmaceutical industry.					
8.	Top management also fosters a culture of innovation by ensuring AI adoption is embedded as a priority for organisational strategic planning and direction.					
9.	Leadership regularly communicates about the importance of AI adoption, building confidence, awareness and alignment among employees of different departments in the pharmaceutical industry.					
10.	Executive leadership exhibit accountability for AI outcomes, linking AI implementation success with a broader organisational objective, competitiveness and performance indicators in the sector.					
	<i>IV 2: Leadership Competence in AI and Digital Innovation</i>					
11.	Leaders are possessing strong knowledge of AI applications, enabling informed decisions which enhance research, compliance, development and performance of the overall pharmaceutical industry.					
12.	Leadership illustrates the capability to emphasise AI solutions, selecting processes and tools that align with organisational objectives and pharmaceutical innovation.					
13.	Leaders are actively engaged in continuous learning about trends of AI, staying updated with the emerging digital innovations relevant to pharmaceutical operations and research.					
14.	Decision-making through leadership emphasises high digital competence, integrating AI insights in strategic planning, regulatory compliance frameworks and operational improvements.					

Sl.No.	<i>DV: AI Integration in the Pharmaceutical Industry</i>	1	2	3	4	5
5.	Artificial intelligence in pharmaceutical sector significantly improved research productivity, enhanced regulatory compliance, reduced development timelines and strengthened overall strategic competitiveness					
	<i>IV 1: Strategic Leadership Orientation</i>					
15.	Leadership encourage confidence in AI initiatives through demonstrating technical expertise, supporting successful implementation and guiding cross-functional teams across pharmaceutical processes.					
	<i>IV 3: Organisational Readiness</i>					
16.	Organisational culture encourages the adoption of AI, fostering collaboration, employee participation and openness to innovation in pharmaceutical initiatives towards digital transformation.					
17.	Data infrastructure within the organisation is developed, ensuring quality standards, reliable access, and integration for effective AI implementation.					
18.	Sufficient financial and human resources are consistently allocated, through enabling the successful adoption, sustainability and scalability of initiatives of AI in the pharmaceutical industry.					
19.	The cross-functional collaboration is actively supported, creating synergies in departments which can foster readiness for AI integration and change management in the organisation.					
20.	Employee training programs and initiatives of change management are implemented, enhancing organisational readiness and preparing staff for AI adoption for digital innovation.					